World Oral Care Formulation Patents Published in 2011
WORLD PATENTS IN ORAL CARE FORMULATIONS PUBLISHED IN 2011
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by using a refined search strategy in the claims section of all
patent applications. Salient search terms included oral care formulations and compositions for tooth cleaning and whitening; denture and dental prosthesis care; caries, calculus, stains
and plaque prevention, reduction or removal; dental adhesives, dental polymers, cement curing; polymer UV curing, cavity fillers, disinfectants, bleaching; oral hygiene and devices, etc.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN ORAL CARE PUBLISHED IN 2011



Publication No.: WO2011000053A1  Published: 06/Jan/2011

Title: MEDICINAL CARBOHYDRATES FOR TREATMENT OF RESPIRATORY CONDITIONS

Applicant/Assignee: AUSTRALIAN BIOMEDICAL COMPANY PTY LTD

Application No.: AU2010/000846   Filing Date: 02/Jul/2010

Abstract:The present invention relates to a method and compounds of Formula (1) and/or (2) or their pharmaceutically acceptable inorganic or organic salt thereof, and their compositions for treating respiratory conditions including post viral/bacterial infections, acute/chronic bronchitis, COPD, cystic fibrosis, and inflammatory conditions. It has been found by the applicants that the compounds of Formula (1) and/or (2) or their pharmaceutically acceptable inorganic or organic salt thereof could speed up the recovery of the viability of damaged respiratory tract cells by restoring sialylglyco- conjugates on their surface.

Priority: AU20090903123 Applic. Date: 2009-07-03

Inventor: JIN BETTY [AU]; JONES PAUL ARTHUR [AU]; SEAH EE LING [AU]; WU WEN YANG [AU]; JENKINS PETER JAMES [AU]


Publication No.: WO2011000104A1  Published: 06/Jan/2011

Title: FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES

Applicant/Assignee: APOTEX TECHNOLOGIES INC

Application No.: CA2010/001027   Filing Date: 05/Jul/2010

Abstract:Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.

Priority: US20090222979P Applic. Date: 2009-07-03

Inventor: TAM TIM FAT [CA]; LEUNG-TOUNG REGIS [CA]; WANG YINGSHENG [CA]; ZHAO YANQING [CA]; XIN TAO [CA]; SHAH BIRENKUMAR [CA]; N ZEMBA BLAISE [CA]; WODZINSKA JOLANTA MARIA [CA]; PREMYSLOVA MARINA [CA]


Publication No.: WO2011000149A1  Published: 06/Jan/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING EPHEDRAE FOR TREATING BRONCHITIS AND PREPARATION METHOD THEREFOR

Applicant/Assignee: HEBEI YILING MEDICINE RESEARCH INSTITUTE CO., LTD

Application No.: CN2009/072531   Filing Date: 30/Jun/2009

Abstract:A pharmaceutical composition for treating bronchitis and preparation method therefor. Said pharmaceutical composition consists of Herba ephedrae, gypsum, Fructus forsythiae, Radix scutellariae, Cortex mori, Semen armeniacae amarum, Radix peucedani and Rhizoma pinelliae. Said pharmaceutical composition is useful in relieving cough, eliminating phlegm, relieving asthma and resisting inflammation, so it has good curative effects on acute tracheobronchitis.

Priority:

Inventor: WU YILING [CN]; XU HONGHUI [CN]; SONG HONGGANG [CN]; LI WENLIE [CN]; LI XIAOYAN [CN]; WANG HONGTAO [CN]; ZHANG HUIXIN [CN]; AN JUNYONG [CN]; LI YUNPENG [CN]; WANG CHAO [CN]


Publication No.: WO2011000150A1  Published: 06/Jan/2011

Title: A MEDICINAL COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF

Applicant/Assignee: HEBEI YILING MEDICINE RESEARCH INSTITUTE CO., LTD

Application No.: CN2009/072537   Filing Date: 30/Jun/2009

Abstract:A medicinal composition, which is prepared by the following materials: Pericarpium Citri, Rhizoma Pinelliae, Radix Asteris, Flos Farfarae, Poria, Rhizoma Atractylodis Macrocephalae, Semen Armeniacae Amarum, Fructus Perillae, Semen Sinapis Albae, Radix Scutellariae, Ramulus Cinnamomi, Semen Raphani, Fructus Forsythiae, Herba Houttuyniae, and Radix Glycyrrhizae. The medicinal composition plays a role in eliminating sputum, relieving cough, relieving asthma, as well as anti-inflammatory, and has a good curative effect on bronchitis.

Priority:

Inventor: WU YILING [CN]; ZHANG YONGFENG [CN]; XU HONGHUI [CN]; LI XIAOYAN [CN]; JI XUELI [CN]; WU XIAOLI [CN]; WANG CHAO [CN]; LI YUNPENG [CN]; WANG MENG [CN]


Publication No.: WO2011001181A1  Published: 06/Jan/2011

Title: ANTIMICROBIAL MATERIAL

Applicant/Assignee: BRIGHTWAKE LIMITED

Application No.: GB2010/051088   Filing Date: 01/Jul/2010

Abstract:An antimicrobial material comprises propolis dispersed within a solid carrier. The antimicrobial material is preferably in the form of a film. The carrier may be a polymeric material.

Priority: GB20090011402 Applic. Date: 2009-07-01

Inventor: COTTON STEPHEN [GB]


Publication No.: WO2011002814A2  Published: 06/Jan/2011

Title: BIARYL OXYACETIC ACID COMPOUNDS

Applicant/Assignee: LIGAND PHARMACEUTICALS INC, SMITHKLINE BEECHAM CORPORATION

Application No.: US2010/040482   Filing Date: 29/Jun/2010

Abstract:Some embodiments of the present invention include novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. Some compounds provided include those of the general formula (I), and compounds of general formula (Ia).

Priority: US20090221899P Applic. Date: 2009-06-30

Inventor: MCGUINNESS BRIAN F [US]; HO KOC-KAN [US]; BABU SURESH [US]; DONG GUIZHEN [US]; DUO JINGQI [US]; LE THUY X H [US]; SAIONZ KURT W [US]; NEEB MICHAEL J [US]


Publication No.: WO2011003221A1  Published: 13/Jan/2011

Title: A MEDICINE COMPOSITION FOR TREATING BRONCHIAL ASTHMA AND PREPARATIVE METHOD THEREOF

Applicant/Assignee: HEBEI YILING MEDICINE RESEARCH INSTITUTE CO., LTD

Application No.: CN2009/000781   Filing Date: 09/Jul/2009

Abstract:A medicinal composition, which is prepared by the following traditional Chinese medicines: Herba Ephedrae, Semen Ginkgo, Cortex Mori, Radix Scutellariae, Semen Armeniacae Amarum, Rhizoma Pinelliae, Fructus Perillae, Flos Farfarae, Radix Paeoniae Rubra, Pheretima, Periostracum Cicadae, Radix Trichosanthis, Herba Houttuyniae and Fructus Forsythiae. The medicinal composition has a good curative effect on bronchial asthma.

Priority:

Inventor: WU YILING [CN]; LIU MINYAN [CN]; XU HONGHUI [CN]


Publication No.: WO2011003925A1  Published: 13/Jan/2011

Title: HUMANISED ANTIBODIES TO TOLL-LIKE RECEPTOR 2 AND USES THEREOF

Applicant/Assignee: OPSONA THERAPEUTICS LIMITED

Application No.: EP2010/059677   Filing Date: 06/Jul/2010

Abstract:A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.

Priority: IE20090000514 Applic. Date: 2009-07-06; US20090270239P Applic. Date: 2009-07-06

Inventor: DELLACASAGRANDE JEROME [IE]


Publication No.: WO2011004882A1  Published: 13/Jan/2011

Title: ACID PUMP ANTAGONIST FOR TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL GASTROINTESTINAL MOVEMENT

Applicant/Assignee: RAQUALIA PHARMA INC

Application No.: JP2010/061660   Filing Date: 09/Jul/2010

Abstract:Disclosed is use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof in the production of a medicinal agent for preventing or treating diseases associated with abnormal gastrointestinal movement. Also disclosed is a method for preventing or treating the diseases, which comprises administering the compound or a pharmaceutical composition containing the compound to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof may be used in combination with at least one second active substance. Further disclosed are a pharmaceutical composition and a kit both for use in the prevention or treatment of the diseases, each of which contains a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof.

Priority: JP20090163182 Applic. Date: 2009-07-09; JP20090188464 Applic. Date: 2009-08-17

Inventor: TAKAHASHI NOBUYUKI [JP]; KOIZUMI SHINICHI [JP]


Publication No.: WO2011005082A1  Published: 13/Jan/2011

Title: COMPOSITION FOR PROVIDING RELIEF OF UNDESIRED BODY ODOURS

Applicant/Assignee:

Application No.: NL2010/050421   Filing Date: 02/Jul/2010

Abstract:The present invention relates to a composition suitable for providing relief of undesired body odours caused by consumption of food and/or drink, comprising chlorella, parsley and a mouth refreshing agent. In particular, the food and/or drink comprises a plant, or part thereof, which belongs to the Allium genus. More in particular, the food and/or drink comprises onion, shallot, leek, bunching onion, chive, preferably garlic, any part thereof, or any combination thereof. The composition according to the invention comprises an amount of chlorella between 2 and 30, preferably between 4 and 25, more preferably between 5 and 20 percent by weight of the total composition.

Priority: NL20092003171 Applic. Date: 2009-07-09

Inventor: VAN HELSDINGEN CAREL CRISTIAAN [NL]; ARKE NIEK JOAN [NL]


Publication No.: WO2011005306A2  Published: 13/Jan/2011

Title: PRODUCTION OF AND USES FOR DECELLULARIZED LUNG TISSUE

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Application No.: US2010/001903   Filing Date: 06/Jul/2010

Abstract:The present invention provides a process of producing a decellularized extracellular matrix DC lung from native lung tissue using rapid freeze/thaw cycling to induce cellular damage and the constant circulation of a detergent or peracetic acid and enzymatic digestion with DNAase/RNAase within a continuously rotating bioreactor. Also, provided are methods to produce a functional engineered lung tissue on the DC lung using endogenous lung progenitor cells. In addition, a composition comprising the DC lung and the endogenous lung progenitor cells seeded therein or thereon and an implantable composition comprising the functional engineered lung tissue which are useful in methods of treating a lung to restore at least some function thereto.

Priority: US20090270348P Applic. Date: 2009-07-07

Inventor: CORTIELLA JOAQUIN [US]; NICHOLS JOAN E [US]; NILES JEAN A [US]


Publication No.: WO2011005645A1  Published: 13/Jan/2011

Title: POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-{[4-(TRIFLUOROMETHYL)BENZOYL]AMINO}BENZYL)PYRIMIDIN-5-YL]

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: US2010/040733   Filing Date: 01/Jul/2010

Abstract:Provided is a crystalline form of the ethylenediamine salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acetic acid, processes for its preparation, pharmaceutical compositions comprising it, and methods of its use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

Priority: US20090223165P Applic. Date: 2009-07-06

Inventor: KIM SOOJIN [US]


Publication No.: WO2011005832A1  Published: 13/Jan/2011

Title: STABLE CRYSTALLINE POLYMORPHS OF THE DIPOTASSIUM SALT OF (S) -2- {4- [2- (2, 4-DIAMIN0-QUINAZ0LIN-6-YL) -ETHYL] -BENZOYLAMINO} -4-METHYLEN?-PENTA NEDIOIC ACID

Applicant/Assignee: CHELSEA THERAPEUTICS, INC

Application No.: US2010/041171   Filing Date: 07/Jul/2010

Abstract:The present invention provides stable crystalline polymorphic forms of antifolate compounds, particularly (5)-2-{4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]- benzoylamino}-4-methylene-pentanedioic acid, dipotassium salt, and methods of preparation thereof. The polymorphs may be in the form of hydrates. The invention further provides pharmaceutical compositions comprising the polymorphs and methods of treatment using the polymorphs. The polymorphs are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis, and the polymorphs may be administered alone in or combination with on or more further active agents.

Priority: US20090223888P Applic. Date: 2009-07-08

Inventor: PIMPLASKAR HARISH K [US]; LEBEDEV MIKHAIL [SE]; HORVATH KAROL [SE]


Publication No.: WO2011007091A1  Published: 20/Jan/2011

Title: DERIVATIVES OF 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS UROTENSIN-II RECEPTOR ANTAGONISTS

Applicant/Assignee: SANOFI-AVENTIS

Application No.: FR2010/051468   Filing Date: 13/Jul/2010

Abstract:The present invention relates to compounds of formula (I), where: A is a (C-1-C4)alkyl group

W is a halogen atom

E is a CR3 member where R3 is a halogen atom or a hydrogen atom, or E is a nitrogen atom

B is a -NR1 R2 group where Ri is a hydrogen atom or a (C-1-C4)alkyl and R2 is a (C1-C4)alkyl group

V is a hydrogen atom, a halogen atom, or a (C1-C4)alkyl group

Z is an oxygen atom or a -CH2- group

or to the acid or base addition salt thereof. The invention also relates to a method for preparing same and to the therapeutic use thereof.

Priority: FR20090054937 Applic. Date: 2009-07-16

Inventor: ALTENBURGER JEAN-MICHEL [FR]; FOSSEY VALERIE [FR]; MANETTE GERALDINE [FR]; PETIT FREDERIC [FR]


Publication No.: WO2011007174A2  Published: 20/Jan/2011

Title: COMPOSITION AND METHOD

Applicant/Assignee: INNOSPEC LIMITED

Application No.: GB2010/051156   Filing Date: 14/Jul/2010

Abstract:A stable flowable aqueous composition comprising at least two component surfactants, each component surfactant having a maximum solubility in water at which a saturated solution forms, wherein the total concentration of all surfactants present in the composition is greater than would be obtained by combining equivalent amounts of saturated solutions of the component surfactants

wherein at least one component surfactant includes a compound of formula (I): wherein R1 represents a C4-36 alkyl group

each of R2, R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group and wherein at least one of R2, R3, R4 and R5 is not hydrogen and M+ represents a cation.

Priority: GB20090012468 Applic. Date: 2009-07-17

Inventor: COTRELL PHILIP [US]; SYED SAMAD [US]


Publication No.: WO2011007551A1  Published: 20/Jan/2011

Title: SUGAR ALCOHOL-CONTAINING ANTIBACTERIAL AGENT FOR INHIBITING PROLIFERATION OF PERIODONTAL DISEASE-CAUSING BACTERIA

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/004530   Filing Date: 13/Jul/2010

Abstract:Disclosed is an antibacterial agent having ameliorating and prophylactic effect on periodontal diseases and dental caries, which is characterized by the inhibitory effect of a sugar alcohol on proliferation of periodontal disease-causing bacteria and dental caries-causing bacteria. Specifically disclosed is an antibacterial agent for inhibiting proliferation of periodontal disease-causing bacteria, which contains a sugar alcohol, in particular lactitol or maltitol, as an active ingredient.

Priority: JP20090165554 Applic. Date: 2009-07-14

Inventor: KODAMA YUSHI [JP]; HIGUCHI HIROAKI [JP]; NARISE ATSUSHI [JP]; SAKURAI KOJI [JP]


Publication No.: WO2011007794A1  Published: 20/Jan/2011

Title: ZEOLITE AND SERICITE-CONTAINING COMPOSITION FOR MEDICAL OR MEDICAL ASSISTING USES

Applicant/Assignee: RAPAS CORPORATION

Application No.: JP2010/061879   Filing Date: 14/Jul/2010

Abstract:The present invention is directed to improve the usefulness of zeolite and sericite in various medical fields. To achieve this purpose, a composition for medical or medical assisting uses, which contains zeolite and sericite, is provided based on, as the most important characteristic, the finding that zeolite and sericite can exert a synergistic effect when used in combination. It is confirmed that the aforesaid composition containing zeolite and sericite exerts an advantageous synergistic effect in the following cases. When externally applied, the aforesaid composition is particularly efficacious in, for example, treating skin itching, sore and pain caused by burn injury, skin diseases, miliaria, etc., atopic dermatitis, cut, scratch, nail slipping, inflammatory diseases, sunburn inflammation, muscle fragmentation, muscular pain, contusion, bruise, sprain, athlete's foot, urticaria and cancerous pain, as a substitute for ice in cooling, as an additive to hair dyes and perming agents for preventing itching and sore, and so on. When orally administered, the aforesaid composition is particularly efficacious in, for example, healing bronchitis, asthma, stomach ulcer, duodenal ulcer, gastritis, stomatitis, chronic gastritis, periodontal disease, chronic liver disease, pollen allergy, oral dysodia, cancer, etc., overcoming fatigue and exhaustion, and so on.

Priority: JP20090168531 Applic. Date: 2009-07-17; JP20090235118 Applic. Date: 2009-10-09; JP20090270208 Applic. Date: 2009-11-27

Inventor: ISHIDUKA HIROKO [JP]


Publication No.: WO2011007885A1  Published: 20/Jan/2011

Title: PROTEOGLYCAN-CONTAINING MATERIAL

Applicant/Assignee: SUNSTAR INC, HIROSAKI UNIVERSITY

Application No.: JP2010/062125   Filing Date: 16/Jul/2010

Abstract:Disclosed is a novel proteoglycan-containing material, which has novel use applications and/or an excellent effect. Specifically disclosed is a proteoglycan-containing material which is produced from a fish cartilage and contains an acidic sugar component having a molecular weight of 2000 kDa or more. The proteoglycan-containing material has effects advantageous for skin moisturization and anti-aging, such as an excellent effect of proliferating skin fibroblasts, an excellent effect of enhancing and improving the skin barrier function, an excellent effect of enhancing and improving skin collagen production capability and an excellent effect of inhibiting the thickening of dermises.

Priority: JP20090168123 Applic. Date: 2009-07-16

Inventor: GOTO MASASHI [JP]; YAMAMOTO KAZUSHI [JP]; KATOU YOUJI [JP]; KATAGATA YOHTARO [JP]; ITOU SEIKO [JP]


Publication No.: WO2011008086A1  Published: 20/Jan/2011

Title: MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM

Applicant/Assignee: N.V. NUTRICIA

Application No.: NL2010/050446   Filing Date: 12/Jul/2010

Abstract:Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

Priority: EP20090165543 Applic. Date: 2009-07-15; US20090255950P Applic. Date: 2009-10-29

Inventor: STAHL BERND [DE]; NAUTA ALMA JILDOU [NL]; GARSSEN JOHAN [NL]; SAMAIN ERIC [FR]; DROUILLARD SOPHIE [FR]


Publication No.: WO2011008132A1  Published: 20/Jan/2011

Title: LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS

Applicant/Assignee: IVY PHARM JSC

Application No.: RU2010/000391   Filing Date: 12/Jul/2010

Abstract:Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo

R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12alkoxy, C1-12alkylamino, C1-12alkoxycarbonyl, C1-12alkylamido, arylamido, wherein the alkylene groupings in the given substituents can in turn be substituted by one or more of the following groups: hydroxy, oxy, carboxy, amino or amido

R3-R10, independently of each other, signify hydrogen

or NHR3R4 and NHR5R6, taken together, and/or NHR7R8 and NHR9R10, taken together, are a ligand (or ligands) containing one or several donor aliphatic or aromatic atoms of nitrogen and being in cis position on the metal atoms (M). The claimed compound can be used in a preparation containing a coordination compound and free molecules of an aliphatic thiol (or derivatives thereof), which are not bound to the coordination compound. The coordination compound and the free molecules of an aliphatic thiol (or derivatives thereof) in the preparation can be in either cationic or anionic form or in the form of neutral particles. The proposed substances are capable of making the action of drugs more effective by increasing the affinity of the target to the drug and/or providing for therapeutically optimal concentrations of the drug in the microenvironment of the target and/or reducing the toxicity of drugs.

Priority: RU20090126459 Applic. Date: 2009-07-13

Inventor: BALAZOVSKY MARK BORISOVICH [RU]; ANTONOV VIKTOR GEORGIEVICH [RU]; BELYAEV ALEXANDR NIKOLAEVICH [RU]; EREMIN ALEXEI VLADIMIROVICH [RU]


Publication No.: WO2011008475A1  Published: 20/Jan/2011

Title: OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/040014   Filing Date: 25/Jun/2010

Abstract:The invention provides compounds represented by the formula (I), each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: wherein: A, m, n, p, a, X, Y and Z are defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis and pulmonary edema.

Priority: US20090221687P Applic. Date: 2009-06-30

Inventor: FANG WENKUI K [US]; CHOW KEN [US]


Publication No.: WO2011008492A2  Published: 20/Jan/2011

Title: SILICA-BASED PARTICLE COMPOSITION

Applicant/Assignee: NALCO COMPANY

Application No.: US2010/040189   Filing Date: 28/Jun/2010

Abstract:The present invention relates to a method for forming a silica-based particle or composite consisting of a silica-based material, an active, with or without a surface modification, and the related composition. The silica-based particle is illustrated by the formula (SiO2)x(OH)yRzSt, whereby R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, and water soluble agents and, optionally, a surface modifier, S, which may be either organic, polymeric, or inorganic. Examples of a surface modifying material are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers. As such, the particle can be used in a variety of applications including any of a variety of high temperature, at acidic, neutral, or basic pH, or pressure environments.

The composites have applications as diverse as papermaking, water treatment, chemical tracing, personal care, microbiological control, and delivery of polymers, for example. With regard to papermaking, the particle provides retention and drainage performance while delivering whitener, or OBA, other functional additives and serves an additive tracker.

Priority: US2009-495109 Applic. Date: 2009-06-30

Inventor: KEISER BRUCE A [US]; KEIZER TIMOTHY S [US]; ADAIR JAMES H [US]


Publication No.: WO2011008636A1  Published: 20/Jan/2011

Title: 3-OXY-HYDROMORPHONE DERIVATIVES

Applicant/Assignee: MALLINCKRODT INC

Application No.: US2010/041448   Filing Date: 09/Jul/2010

Abstract:The present invention provides 3-oxy-hydromorphone derivatives, and in particular, 3-ester, 3-carbonate, and 3-sulfonate derivatives of hydromorphone.

Priority: US20090225581P Applic. Date: 2009-07-15

Inventor: CANTRELL GARY L [US]; HALVACHS ROBERT E [US]; MOSER FRANK W [US]; BERBERICH DAVID W [US]; WANG PETER X [US]


Publication No.: WO2011008809A1  Published: 20/Jan/2011

Title: CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND

Applicant/Assignee: THERAVANCE, INC

Application No.: US2010/041903   Filing Date: 14/Jul/2010

Abstract:The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid l-(2-{[4-(4-carbamoylpiperidin-l-yImethyl)benzoyl]methylamino}ethyl)piperidin-4- yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases

processes and intermediates for preparing the crystalline freebases

and methods of using the crystalline freebases to treat a pulmonary disorder.

Priority: US20090225803P Applic. Date: 2009-07-15

Inventor: WOOLLAM GRAHAME [GB]


Publication No.: WO2011009119A2  Published: 20/Jan/2011

Title: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING FIBROTIC DISORDERS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: US2010/042432   Filing Date: 19/Jul/2010

Abstract:The present invention relates to biomarkers, therapeutic targets, and therapeutic agents for treating and diagnosing fibrotic disorders. In particular, the present invention relates to diagnosis, drug screening, and therapeutic targeting of NOX4 biomarkers of pulmonary fibrosis and other fibrotic diseases and conditions.

Priority: US20090226508P Applic. Date: 2009-07-17

Inventor: THANNICKAL VICTOR J [US]; HECKER LOUISE [US]


Publication No.: WO2011009867A2  Published: 27/Jan/2011

Title: NOVEL COMPOSITION

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/060492   Filing Date: 20/Jul/2010

Abstract:An oral care composition comprising a dispersion of responsive or non-responsive microgel particles, and at least one orally acceptable carrier or excipient for treating dentine hypersensitivity. Microgel particles comprise a polymeric network comprising monomeric units interconnected with one another through a crosslinking agent in which the polymeric network can be obtained by polymerization in a dispersed medium of a suitable monomer e.g. a vinyl monomer, and a crosslinking agent.

Priority: GB20090012768 Applic. Date: 2009-07-22

Inventor: EDWARDS MARK IEUAN [GB]; GRACIA LOUISE [GB]; MAJCEN NATASA [GB]; SNOWDEN MARTIN [GB]


Publication No.: WO2011010691A1  Published: 27/Jan/2011

Title: POLYION COMPLEX COMPRISING PHD2 EXPRESSION INHIBITING SUBSTANCE

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/062344   Filing Date: 22/Jul/2010

Abstract:Disclosed is a safer and more sustainable gene delivery system or the like, which is effective for treatment of ischemic diseases and the like. Specifically disclosed is a pharmaceutical composition which contains, as an active ingredient, a polyanionic substance that inhibits the expression of PHD2, and which contains a polyion complex of the polyanionic substance and a polycationically charged polymer.

Priority: JP20090171562 Applic. Date: 2009-07-22

Inventor: KATAOKA KAZUNORI [JP]; WU SHOURONG [JP]; NISHIYAMA NOBUHIRO [JP]; ITAKA KEIJI [JP]; KOYAMA HIROYUKI [JP]; HASHIMOTO TAKUYA [JP]; TEI YUICHI [JP]


Publication No.: WO2011010706A1  Published: 27/Jan/2011

Title: FGF21 CIS-ELEMENT BINDING SUBSTANCE

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED, GALAXY PHARMA INC

Application No.: JP2010/062383   Filing Date: 22/Jul/2010

Abstract:Provided is a substance, in particular an oligonucleotide including a base sequence complementary to at least a portion of an AU-rich element, capable of binding to at least a portion of the cis-element of the mRNA of FGF21 and thereby inhibiting binding of cis-element binding factor to the cis-element. Also provided is a drug, in particular an agent for the prevention and treatment of obesity and other lifestyle-related diseases, which includes the substance, and in particular the oligonucleotide.

Priority: JP20090172584 Applic. Date: 2009-07-23

Inventor: ADACHI SHUNGO [JP]; NISHI KAZUNORI [JP]; UMEMOTO TADASHI [JP]; NOGAMI MASAHIRO [JP]; NAKAO SHOICHI [JP]


Publication No.: WO2011012421A1  Published: 03/Feb/2011

Title: A DENTIFRICE COMPOSITION COMPRISING POLYETHYLENEGLYCOL AND A COOLING AGENT

Applicant/Assignee: UNILEVER NV, UNILEVER PLC, HINDUSTAN UNILEVER LIMITED

Application No.: EP2010/059855   Filing Date: 09/Jul/2010

Abstract:The invention relates to a dentifrice composition comprising: (i) 40 to 60 weight% Polyethyleneglycol or a derivative thereof

and, (ii) 0.01 to 2 weight% N-substituted p-menthane carboxamide. Preferred N-substituted p-menthane carboxamide is selected from N-(4- cyanomethylphenyl)p-menthanecarboxamide, N-(4-sulfamoylphenyl)p-menthanecarboxamide, N-(4-cyanophenyl)p-menthanecarboxamide, N-(4-acetylphenyl)p menthanecarboxamide, N-(4-hydroxymethylphenyl)p menthanecarboxamide, or N-(3-hydroxy-4-methoxyphenyl) p menthanecarboxamide. The invention is based on the finding that the bitter taste associated with dentifrice compositions which contain Polyethyleneglycol can be effectively masked when the dentifrice contains a N-substituted p-menthane Carboxamide.

Priority: IN2009MU01729 Applic. Date: 2009-07-29

Inventor: AGARWAL RUPESH KUMAR [IN]; GREEN ALISON KATHARINE [GB]; GOLDING STEPHEN [GB]; SINHA GEETANJALI [IN]; THORNTHWAITE DAVID WILLIAM [GB]


Publication No.: WO2011012592A1  Published: 03/Feb/2011

Title: DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2010/060830   Filing Date: 27/Jul/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Priority: US20090229818P Applic. Date: 2009-07-30

Inventor: BROTHERTON-PLEISS CHRISTINE E [US]; CAROON JOAN MARIE [US]; LOPEZ-TAPIA FRANCISCO JAVIER [US]; WALKER KEITH ADRIAN MURRAY [US]


Publication No.: WO2011012896A2  Published: 03/Feb/2011

Title: COMPOUNDS - 801

Applicant/Assignee: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNGERY) LIMITED

Application No.: GB2010/051242   Filing Date: 29/Jul/2010

Abstract:Spirocyclic amide derivatives of formula (I) wherein ArCH2CH2NH- represents a ss-adrenoceptor binding group, processes for their preparation, pharmaceutical compositions containing them, a process for preparing such pharmaceutical compositions, their use in therapy, and intermediates for use in their preparation.

Priority: GB20090013342 Applic. Date: 2009-07-31

Inventor: ALCARAZ LILIAN [GB]; BAILEY ANDREW [GB]; KINDON NICHOLAS [GB]


Publication No.: WO2011012897A1  Published: 03/Feb/2011

Title: NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA

Applicant/Assignee: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNGERY) LIMITED

Application No.: GB2010/051243   Filing Date: 29/Jul/2010

Abstract:The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is (R)-7-(2-(2-fluoro-5-((4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethylamino)-1-hydroxyethyl)-4- hydroxybenzo[d]thiazol-2(3H)-one or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist

an antioxidant

a CCR1 antagonist

a chemokine antagonist (not CCR1)

a corticosteroid

a CRTh2 antagonist

a DP1 antagonist

an Histone Deacetylase activator

an IKK2 kinase inhibitor

a COX inhibitor

a lipoxygenase inhibitor

a leukotriene receptor antagonist

an MPO inhibitor

a PDE4 inhibitor

a PPAR? agonist

a protease inhibitor

a p38 inhibitor, a Statin

a thromboxane antagonist

a vasodilator

or, an ENAC blocker (Epithelial Sodium-channel blocker)

and its use in the treatment of respiratory disease.

Priority: GB20090013345 Applic. Date: 2009-07-31

Inventor: ALCARAZ LILIAN [GB]; KINDON NICHOLAS [GB]; LISTER ANDREW [GB]


Publication No.: WO2011013494A1  Published: 03/Feb/2011

Title: AQUEOUS COMPOSITION

Applicant/Assignee: ARCH CHEMICALS JAPAN, INC

Application No.: JP2010/061578   Filing Date: 08/Jul/2010

Abstract:Disclosed is an aqueous composition which is prevented from the occurrence of remarkable white turbidity and precipitation even when a polyvalent anionic compound and a polycationic antibacterial agent are contained as components. The aqueous composition additionally contains a phosphoric acid ester of a polyoxyethylene alkyl ether and/or a salt thereof. It is more preferred to add a phosphoric acid ester of a polyoxyethylene alkyl ether or a salt thereof which has a linear alkyl group having a predetermined number or more of carbon atoms and contains a polyoxyethylene in a predetermined repeating number or more. It is also more preferred to add the phosphoric acid ester of the polyoxyethylene alkyl ether or the salt thereof at a predetermined ratio or more relative to the amount of the polycationic antibacterial agent.

Priority: JP20090177172 Applic. Date: 2009-07-30

Inventor: YONEDA RYU [JP]; NEW MAYUMI [JP]; SAKATA KAZUHIKO [JP]


Publication No.: WO2011013729A1  Published: 03/Feb/2011

Title: FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Applicant/Assignee: ONCOTHERAPY SCIENCE, INC

Application No.: JP2010/062747   Filing Date: 29/Jul/2010

Abstract:Provided are a compound represented by general formula (I) and having a TTK inhibitory action and a medicine containing the compound. In formula (I), (X, Y, V, W) is (-N=, =CR1-, =N-, -CR7=), (-CR2=, =N-, =N-, -CR7=), etc.

A is an (un)substituted aromatic hydrocarbon ring, etc.

L is a single bond, -C(=O)-NRA-, etc.

Z is a group represented by the formula -NR3R4 or a group represented by the formula -OR5

R1 to R3, R6, and R7 each is a hydrogen atom, etc.

R4 and R5 each is an (un)substituted alkyl, etc.

and R8 is an (un)substituted cycloalkyl, etc.

Priority: JP20090178452 Applic. Date: 2009-07-30; JP20100121045 Applic. Date: 2010-05-26

Inventor: KUSAKABE KEN-ICHI [JP]; YOSHIDA HIROSHI [JP]; NOZU KOHEI [JP]; HASHIZUME HIROSHI [JP]; TADANO GENTA [JP]; SATO JUN [JP]; TAMURA YUUSUKE [JP]; MITSUOKA YASUNORI [JP]


Publication No.: WO2011013752A1  Published: 03/Feb/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/062804   Filing Date: 29/Jul/2010

Abstract:Disclosed is a compound having a histamine H4 receptor-regulating activity. Specifically disclosed is a compound represented by formula (I) [wherein ring A represents a ring represented by formula (a-1), (a-2) or (a-3) (wherein R1 represents a substituted or unsubstituted alkyl group, or the like

W represents -O-, or the like

n represents an integer of 0 to 6

X represents -N(R7)- or -O-

R7 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

Y represents -C(R8)= or -N=

and R8 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like), or the like

Z represents =O, =S, or the like

and ring B represents a ring represented by formula (b-1), (b-2), (b-3) or (b-4) (wherein R10 independently represents a substituted or unsubstituted alkyl group, a halogen atom, a hydroxy group, a substituted or unsubstituted alkyloxy group, or a substituted or unsubstituted amino group

and R11, R12a and R12b independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

and p represents an integer of 0 to 4), or the like] or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt thereof.

Priority: JP20090178508 Applic. Date: 2009-07-31

Inventor: TACHIBANA YUUKI [JP]; MIYAGAWA MASAYOSHI [JP]; MASUDA TSUTOMU [JP]; HASEGAWA TSUYOSHI [JP]


Publication No.: WO2011013785A1  Published: 03/Feb/2011

Title: NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME

Applicant/Assignee: JAPAN TOBACCO INC

Application No.: JP2010/062873   Filing Date: 30/Jul/2010

Abstract:Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after organ transplantation, autoimmune diseases, allergic diseases and chronic myeloproliferative diseases by using these compounds as the active ingredient. In general formula [I], Ra's are the same or different and represent (1) a C1-6 alkyl group, etc.

n1 represents an integer of 0 to 4

Rb's are the same or different and represent (1) a C1-6 alkyl group, etc.

n2 represents an integer of 0 to 4

m1 represents an integer of 0 to 3

m2 represents an integer of 1 to 4

Xa=Xb represents (1) CH=CH, etc.

X represents (1) a nitrogen atom, etc.

and Rc represents (1) a hydrogen atom, etc.

Priority: JP20090179502 Applic. Date: 2009-07-31; US20090274137P Applic. Date: 2009-08-13

Inventor: NOJI SATORU [JP]; SHIOZAKI MAKOTO [JP]; MIURA TOMOYA [JP]; HARA YOSHINORI [JP]; YAMANAKA HIROSHI [JP]; MAEDA KATSUYA [JP]; HORI AKIMI [JP]; INOUE MASAFUMI [JP]; HASE YASUNORI [JP]


Publication No.: WO2011014122A1  Published: 03/Feb/2011

Title: SYSTEM AND METHOD FOR EXTRACTING VITAMIN E FROM FATTY ACID DISTILLATES

Applicant/Assignee: THE THAILAND RESEARCH FUND, CHIANG MAI UNIVERSITY, CHUMPORN PALM OIL INDUSTRY PUBLIC COMPANY LIMITED, AXIS IP HOLDING PTE LTD

Application No.: SG2009/000491   Filing Date: 23/Dec/2009

Abstract:Various systems and processes for extracting Vitamin E from a fatty acid distillate (FAD) having a Vitamin E component are disclosed. The process includes preparing a mixture of a FAD and a non-polar solvent (e.g., hexane). The mixture can be sequentially cooled to a series of pre-determined temperatures. As the mixture is sequentially cooled to each of the pre-determined temperatures within the series of pre-determined temperatures, non-Vitamin E components present in the FAD can form solid fractions within the mixture at the various pre-determined temperature stages. The process further includes removing the solid fractions from the mixture at each of the pre-determined temperature stages. After completion of a number of cooling and separation stages or cycles, the non- polar solvent can be removed from the remaining mixture to recover a Vitamin E extract.

Priority: TH20090003454 Applic. Date: 2009-07-30

Inventor: RAVIYAN PATCHARIN [TH]; SOINAK KRIENGKAI [TH]


Publication No.: WO2011014261A1  Published: 03/Feb/2011

Title: FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: US2010/002141   Filing Date: 02/Aug/2010

Abstract:Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, Ra, Ra', Rb, Rb', Rc, and Rc'are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Priority: US20090213946P Applic. Date: 2009-07-31

Inventor: FREEMAN BRUCE A [US]; SCHOPFER FRANCISCO J [US]


Publication No.: WO2011014401A2  Published: 03/Feb/2011

Title: ORAL CARE ARTICLES AND METHODS

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/042865   Filing Date: 22/Jul/2010

Abstract:An oral care article in the form of a flexible porous dissolvable solid structure, comprising: from about 1% to about 70% surfactant

from about 10% to about 70% water soluble polymer, from about 0% to about 25% plasticizer

and wherein said article comprises an oral care component and has a density of from about 0.03 g/cm3 to about 0.5 g/cm3.

Priority: US20090229794P Applic. Date: 2009-07-30

Inventor: BAIG ARIF [US]; GLENN ROBERT WAYNE JR [US]


Publication No.: WO2011014415A1  Published: 03/Feb/2011

Title: HIGH CLEANING DENTIFRICE COMPOSITIONS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/043007   Filing Date: 23/Jul/2010

Abstract:A dentifrice composition containing minor amounts of relatively small particle size high cleaning abrasives, without oral care actives. The dentifrice may be encapsulated and optionally, positioned on the head of a toothbrush. Use of the dentifrice provides a small amount of high cleaning abrasive to the teeth, and has stain removal efficacy. In one aspect, a dentifrice composition comprising an orally acceptable carrier and 1 to 10 wt% abrasive, such that the total amount of abrasive delivered per application is 2 mg to 8 mg, the abrasive having a weight mean particle size in the range of 3 to 7 [mu]m, with at least 90% of the particles by weight having a size below 16 [mu]m, and wherein the composition does not contain an oral care active.

Priority: US20090230321P Applic. Date: 2009-07-31

Inventor: BROWN JAMES R [US]; ONTUMI DENNIS K [US]; ROBINSON RICHARD S [US]


Publication No.: WO2011014515A1  Published: 03/Feb/2011

Title: 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS

Applicant/Assignee: IRM LLC

Application No.: US2010/043417   Filing Date: 27/Jul/2010

Abstract:Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

Priority: US20090229975P Applic. Date: 2009-07-30

Inventor: CHE JIANWEI [US]; CHEN BEI [US]; DING QIANG [US]; HAO XUESHI [US]; HE XIAOHUI [US]; JIANG SONGCHUN [US]; JIN QIHUI [US]; JIN YUNHO [US]; LIU HONG [US]; LIU YAHUA [US]; OKRAM BARUN [US]; UNO TETSUO [US]; WU XU [US]; YANG KUNYONG [US]; ZHU XUEFENG [US]


Publication No.: WO2011015289A1  Published: 10/Feb/2011

Title: 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL] AMINO]ETHYL]-2(1H)-QUINOLINONE HEMI-FUMARATE

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: EP2010/004490   Filing Date: 22/Jul/2010

Abstract:The invention relates to 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1 R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone hemi- fumarate salt. The invention also relates to processes for its preparation, pharmaceutical compositions thereof, and to its use as a medicament.

Priority: EP20090167207 Applic. Date: 2009-08-04

Inventor: PIVETTI FAUSTO [IT]; LUTERO EMILIO [IT]


Publication No.: WO2011015630A1  Published: 10/Feb/2011

Title: COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

Applicant/Assignee: SCIPHARM SARL

Application No.: EP2010/061428   Filing Date: 05/Aug/2010

Abstract:The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.

Priority: EP20090167491 Applic. Date: 2009-08-07

Inventor: FREISSMUTH MICHAEL [AT]; KOENIG XAVER [AT]; GLOECKEL CHRISTINA [AT]


Publication No.: WO2011015882A2  Published: 10/Feb/2011

Title: NOVEL ANHYDRATE

Applicant/Assignee: GENERICS [UK] LIMITED, MYLAN INDIA PRIVATE LIMITED

Application No.: GB2010/051310   Filing Date: 06/Aug/2010

Abstract:Novel Anhydrate The present invention relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.

Priority: IN2009KO01048 Applic. Date: 2009-08-07

Inventor: GORE VINAYAK GOVIND [IN]; MANOJKUMAR BINDU [IN]; SHINDE DATTATRAYA [IN]; KOKANE DATTATREY [IN]


Publication No.: WO2011015883A1  Published: 10/Feb/2011

Title: DICHLOROMETHANE SOLVATE OF TIOTROPIUM BROMIDE AND ITS USE

Applicant/Assignee: GENERICS [UK] LIMITED, MYLAN INDIA PRIVATE LIMITED

Application No.: GB2010/051311   Filing Date: 06/Aug/2010

Abstract:The present invention relates to a novel solvate of tiotropiumbromide, a process to prepare this solvate and the use of this and other solvates in processes for the preparation of anhydrous tiotropium bromide. The present invention also relates to pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.

Priority: IN2009KO01046 Applic. Date: 2009-08-07

Inventor: GORE VINAYAK GOVIND [IN]; MANOJKUMAR BINDU [IN]; SHINDE DATTATRAYA [IN]; KOKANE DATTATREY [IN]


Publication No.: WO2011016395A1  Published: 10/Feb/2011

Title: PREPARATION FOR ORAL CAVITY

Applicant/Assignee: NIPPON SHIKA YAKUHIN CO., LTD

Application No.: JP2010/062880   Filing Date: 30/Jul/2010

Abstract:Disclosed is a preparation for oral cavity that is appropriately usable as a prophylactic agent for dental caries, a therapeutic agent for dental caries in early stage, a prophylactic and/or therapeutic agent for dentinal hypersensitivity, a drug to be administered to the back layer of a tooth surface under cavity preparation, etc., which shows an excellent effect of blocking the dentinal tubules, is capable of improving the acid resistance of the teeth and recalcifying the teeth, ensures a short-time treatment with an easy operation, and has a high safety and good esthetic properties.

Specifically disclosed is a preparation for oral cavity such as a prophylactic agent for dental caries and/or a therapeutic agent for dental caries in early stage, a prophylactic and/or therapeutic agent for dentinal hypersensitivity, a drug to be administered to the back layer of a tooth surface under cavity preparation, etc., comprising a liquid (A), in which fluoroaminosilicate glass micrograins are dispersed, and an aqueous inorganic phosphoric acid solution (B).

Priority: JP20090183093 Applic. Date: 2009-08-06

Inventor: TSUNEKAWA MASAYOSHI [JP]; YOKOTA KAZUYOSHI [JP]


Publication No.: WO2011016459A1  Published: 10/Feb/2011

Title: THIENOOXAZEPINE DERIVATIVE

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: JP2010/063120   Filing Date: 03/Aug/2010

Abstract:Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)

Priority: JP20090181360 Applic. Date: 2009-08-04

Inventor: MATSUMOTO TAKAHIRO [JP]; NOMURA IZUMI [JP]


Publication No.: WO2011016472A1  Published: 10/Feb/2011

Title: PYRIDINE AND PYRIMIDINE DERIVATIVES HAVING TTK-INHIBITING ACTIVITY

Applicant/Assignee: ONCOTHERAPY SCIENCE, INC

Application No.: JP2010/063153   Filing Date: 04/Aug/2010

Abstract:Disclosed are: an effective inhibitor of TTK protein kinase

and an effective medicinal agent. Specifically disclosed are: a compound

and inventions relating to the compound (e.g., a pharmaceutical composition, a TTK inhibitor, and others). Novel compounds are discovered, each of which can inhibit the activity of TTK kinase and has specific properties particularly useful for the formulation of a medicinal agent that can treat the diseases. Therefore, the compounds are useful for diseases for which the inhibition of the activity of TTK kinase is believed to be effective.

Priority: JP20090183833 Applic. Date: 2009-08-06; JP20100121046 Applic. Date: 2010-05-26

Inventor: KUSAKABE KEN-ICHI [JP]; YAMAGUCHI NAOKO [JP]; MITSUOKA YASUNORI [JP]


Publication No.: WO2011016534A1  Published: 10/Feb/2011

Title: PLASMA PROTEIN HAVING ANTITUSSIVE EFFECT

Applicant/Assignee: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

Application No.: JP2010/063329   Filing Date: 05/Aug/2010

Abstract:Disclosed is activated blood coagulation factor XI which can act as an antitussive drug for cough induced by the stimulation of the tracheal bifurcation, such as chronic cough. Specifically disclosed is a pharmaceutical composition for preventing cough, treating cough and/or ameliorating the symptoms of cough, which comprises: a polypeptide chain that comprises a full-length amino acid sequence constituting activated blood coagulation factor XI (also referred to as "FXIa", hereinbelow), an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in the preceding amino acid sequence, a partial sequence of any one of the aforementioned amino acid sequences, or an amino acid sequence containing any one of the aforementioned amino acid sequences as a part thereof, as an active ingredient

and a pharmacologically acceptable carrier.

Priority: JP20090182945 Applic. Date: 2009-08-06

Inventor: KAMEI SHINTARO [JP]; SHINDOME ASAMI [JP]; HAMAMOTO TAKAYOSHI [JP]; MAEDA HIROAKI [JP]; HIRASHIMA MASAKI [JP]; OKUDA SACHIO [JP]; UMEHASHI MISAKO [JP]; OGAWA SACHIE [JP]; MAEDA MEGUMI [JP]; AKAIKE NORIO [JP]; TAKAHAMA KAZUO [JP]; WADA RYOKO [JP]


Publication No.: WO2011016863A2  Published: 10/Feb/2011

Title: METHODS AND USES OF CYTOCHROME P450 INHIBITORS

Applicant/Assignee: ANGION BIOMEDICA CORP

Application No.: US2010/002175   Filing Date: 05/Aug/2010

Abstract:Methods are provided for treating or preventing chronic obstructive pulmonary diseases such as emphysema, and fibrotic diseases including heart, liver, kidney and vascular diseases, by administering to a subject a pharmaceutical composition comprising a compound that inhibits cytochrome P450RA or CYP26.

Priority: US20090273629P Applic. Date: 2009-08-05

Inventor: OEHLEN LAMBERTUS J W M [US]; PANICKER BIJOY [US]


Publication No.: WO2011016982A2  Published: 10/Feb/2011

Title: ORAL CARE COMPOSITIONS WHICH COMPRISE STANNOUS AND POTASSIUM

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/042436   Filing Date: 19/Jul/2010

Abstract:The present invention relates to a single phase oral care composition comprising: a. a stannous salt delivering a stannous ion

b. a potassium salt delivering a potassium ion wherein the potassium salt is selected from potassium nitrate, potassium gluconate, potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, and mixtures thereof

c. a chelant

d. a fluoride ion source

and e. less than 0.01% of an alkyl sulphate or an alkyl ethoxylate sulphate

wherein the oral care composition provides a soluble fluoride ion level of greater than 50% of the total fluoride ion. The composition of the invention has been found to allow prolonged contact between stannous ion and nitrate ion in a single dentifrice without toxic effects or insoluble products. The invention further provides for the maintenance of an efficacious fluoride ion level.

Priority: EP20090166510 Applic. Date: 2009-07-27

Inventor: STRAND ROSS [GB]


Publication No.: WO2011016983A2  Published: 10/Feb/2011

Title: ORAL CARE COMPOSITIONS WHICH COMPRISE STANNOUS AND POTASSIUM

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/042437   Filing Date: 19/Jul/2010

Abstract:The present invention relates to a single phase oral care composition comprising: a. a stannous salt delivering a stannous ion

b. a potassium salt delivering a potassium ion

c. a chelant

d. a fluoride ion source

e. less than 0.01% of an alkyl sulphate or an alkyl ethoxylate sulphate

and f. a surfactant selected from a cationic, an amphoteric surfactant, a nonionic surfactant or mixtures thereof

wherein the oral care composition provides a soluble fluoride ion level of greater than 50% of the total fluoride ion. The composition of the invention has been found to allow prolonged contact between stannous ion and nitrate ion in a single dentifrice without toxic effects or insoluble products. The invention further provides for the maintenance of an efficacious fluoride ion level.

Priority: EP20090166510 Applic. Date: 2009-07-27

Inventor: STRAND ROSS [GB]


Publication No.: WO2011016984A2  Published: 10/Feb/2011

Title: ORAL CARE COMPOSITIONS WHICH COMPRISE STANNOUS, POTASSIUM AND MONOFLUOROPHOSPHATE

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/042438   Filing Date: 19/Jul/2010

Abstract:The present invention relates to a single phase oral care composition comprising: a. a stannous salt b. a potassium salt c. a chelant d. monofluorophosphate (MFP). The composition of the invention has been found to allow prolonged contact between stannous ion and nitrate ion in a single dentifrice without toxic effects or insoluble products. The invention further provides for the maintenance of an efficacious fluoride ion level.

Priority: EP20090166511 Applic. Date: 2009-07-27

Inventor: STRAND ROSS [GB]


Publication No.: WO2011017201A2  Published: 10/Feb/2011

Title: DP2 ANTAGONIST AND USES THEREOF

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/043783   Filing Date: 29/Jul/2010

Abstract:Described herein is the DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.

Priority: US20090231660P Applic. Date: 2009-08-05

Inventor: STEARNS BRIAN ANDREW [US]; KING CHRISTOPHER DAVID [US]; BRITTAIN JASON EDWARD [US]; HOLME KEVIN ROSS [US]


Publication No.: WO2011017350A2  Published: 10/Feb/2011

Title: COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/044284   Filing Date: 03/Aug/2010

Abstract:Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Priority: US20090231282P Applic. Date: 2009-08-04

Inventor: HUTCHINSON JOHN HOWARD [US]; SEIDERS THOMAS JON [US]; WANG BOWEI [US]


Publication No.: WO2011017633A2  Published: 10/Feb/2011

Title: TOOTHPASTE COMPOSITION

Applicant/Assignee: FMC CORPORATION

Application No.: US2010/044742   Filing Date: 06/Aug/2010

Abstract:The present invention is directed to a toothpaste composition comprising a binder, an abrasive, a foaming agent, water, and polyethylene glycol, wherein the binder comprises semi-refined carrageenan. The toothpaste composition has improved shelf life.

Priority: IN2009DE01644 Applic. Date: 2009-08-07; IN2009DE01643 Applic. Date: 2009-08-07

Inventor: RANDIVE VINAYAK B [IN]; GADKARI VIJAY K [IN]


Publication No.: WO2011017636A2  Published: 10/Feb/2011

Title: CARRAGEENAN PRODUCTS AND METHOD FOR THEIR PRODUCTION AND USE

Applicant/Assignee: FMC CORPORATION

Application No.: US2010/044745   Filing Date: 06/Aug/2010

Abstract:The present invention is directed to a carrageenan product comprising a semi-refined, alkali treated iota carrageenan wherein the semi-refined, alkali treated iota carrageenan has: (i) a viscosity of 18 cP to 83 cP, (ii) a particle size of at least 90% passing through a #100 US sieve mesh and at least 20% passing through a #230 US sieve mesh, and (iii) a fraction of sodium cations of at least 35%, wherein the fraction of sodium cations is determined by the weight of sodium cations divided by the sum of the weight of sodium cations and potassium cations. This invention is also directed to toothpaste compositions comprising the carrageenan product of the invention.

Priority: IN2009DE01644 Applic. Date: 2009-08-07; IN2009DE01643 Applic. Date: 2009-08-07

Inventor: SEWALL CHRISTOPHER J [US]; RANDIVE VINAYAK B [IN]; GADKARI VIJAY K [IN]


Publication No.: WO2011018501A2  Published: 17/Feb/2011

Title: COMPOSITION INCLUDING AN UNSAPONIFIABLE FRACTION

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: EP2010/061764   Filing Date: 12/Aug/2010

Abstract:The present invention relates to a composition, notably cosmetic, nutraceutical, dermatological, pharmaceutical or dietary, including at least one unsaponif iable extract, a drug including one such composition, the use of one such composition, a treatment method consisting in administering one such composition and a method comprising the administration of one such composition.

Priority: FR20090055643 Applic. Date: 2009-08-12; US20090235728P Applic. Date: 2009-08-21

Inventor: MSIKA PHILIPPE [FR]; DAGUET DAVID [FR]


Publication No.: WO2011018510A1  Published: 17/Feb/2011

Title: NEW MACROLIDES AND THEIR USE

Applicant/Assignee: BASILEA PHARMACEUTICA AG

Application No.: EP2010/061822   Filing Date: 13/Aug/2010

Abstract:The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

Priority: EP20090167830 Applic. Date: 2009-08-13

Inventor: KELLENBERGER JOHANNES LAURENZ [CH]; DREIER JUERG [CH]


Publication No.: WO2011019342A2  Published: 17/Feb/2011

Title: ORAL CARE COMPOSITION

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2009/053500   Filing Date: 12/Aug/2009

Abstract:Disclosed are oral care compositions and the use of such oral care compositions for treating conditions caused by biofilm formation. Also disclosed are methods for inhibiting biofilm formation and/or degrading biofilm. The oral care composition includes a sesquiterpenoid and an antimicrobial agent, in which the sesquiterpenoid and the antimicrobial agent are present in an amount effective to inhibit and/or degrade a biofilm in the oral cavity.

Priority:

Inventor: SCHAEFFER-KORBYLO LYNDSAY [US]; MORGAN ANDRE MICHELLE [US]; MIKSA DAVIDE [US]; DU-THUMM LAURENCE [US]; PRENCIPE MICHAEL [US]; SZEWCZYK GREGORY [US]; ARVANITIDOU EVANGELIA S [US]


Publication No.: WO2011019681A1  Published: 17/Feb/2011

Title: SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/044954   Filing Date: 10/Aug/2010

Abstract:Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation.

Priority: US20090232997P Applic. Date: 2009-08-11

Inventor: NGUYEN PHONG X [US]; HEIDELBAUGH TODD M [US]; CHOW KEN [US]; GARST MICHAEL E [US]


Publication No.: WO2011020206A1  Published: 24/Feb/2011

Title: ANTISEPTIC PHARMACEUTICAL COMPOSITION FOR ORAL HYGIENE AND THE TREATMENT OF ORAL DISEASES OF MICROBIAL ORIGIN

Applicant/Assignee:

Application No.: CL2010/000030   Filing Date: 19/Aug/2010

Abstract:The invention relates to a polyantiseptic antimicrobial pharmaceutical composition for oral use, for the hygiene and treatment of oral diseases of bacterial, mycotic or viral etiology, for over-the-counter sale, without contraindications. Said composition does not contain phenolic or chlorophenolic compounds, and consists of a mixture of hydrogen peroxide, eugenol, natural camphor, zinc sulphate, sodium fluoride, xylitol, cetylpyridinium chloride and excipients. Said formulation is used to deodorise, disinfect, astringe and soothe inflammation of the oral area, avoids the neoformation of bacterial plaque, prevents tooth cavities, inhibits the formation of dental tartar, improves the resistance of teeth to cavities, and treats and prevents oral aphthous ulcers. It is also used to irrigate and treat periodontal bags, fistulae, abcesses, alveolitis, necrosis and pulp gangrene, to help to avoid oral diseases during orthodontic treatments, post-surgery of the mouth and in patients wearing fixed and detachable prostheses, and to relieve, cure or prevent oral diseases in patients undergoing radiotherapy or chemotherapy, hospitalised patients and terminally ill patients. Said composition is also a medicament for protecting the oral health of systemic patients, patients suffering from nutritional, endocrine, haematological, cardiovascular and psychosomatic disorders in addition to physically or mentally weakened patients or patients with genetic or hereditary alterations.

Priority: CL20090001747 Applic. Date: 2009-08-20

Inventor: GALVAN GONZALEZ TOMAS BERNARDO [CL]


Publication No.: WO2011020684A2  Published: 24/Feb/2011

Title: DELIVERY SYSTEM

Applicant/Assignee: UNILEVER PLC, UNILEVER N.V, HINDUSTAN UNILEVER LIMITED

Application No.: EP2010/060951   Filing Date: 28/Jul/2010

Abstract:A delivery system comprising friable agglomerates, said friable agglomerates comprising oil, wax having a melting point of at least 50 DEG C, and active ingredient, characterized in that the friable agglomerates have air pockets within them and a method of manufacture of such a delivery system.

Priority: EP20090168145 Applic. Date: 2009-08-19

Inventor: GROVES BRIAN JOSEPH [GB]


Publication No.: WO2011020829A1  Published: 24/Feb/2011

Title: WATER-SOLUBLE POLYSACCHARIDE ETHERS AND THE USE THEREOF

Applicant/Assignee: PHARMPUR GMBH

Application No.: EP2010/061971   Filing Date: 17/Aug/2010

Abstract:The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Priority: DE200910037514 Applic. Date: 2009-08-17

Inventor: MENZ DIRK HENNING [DE]; RITTER HELMUT [DE]; MUELLER BERND [DE]


Publication No.: WO2011020913A2  Published: 24/Feb/2011

Title: CYCLODEPSIPEPTIDE ANTIVIRAL COMPOUNDS

Applicant/Assignee: PHARMA MAR, S.A

Application No.: EP2010/062174   Filing Date: 20/Aug/2010

Abstract:A compound of general formula (I), wherein X, Y, n, p, q, and R1-R17 take various meanings, for use in the treatment of HIV infections, AIDS and ARC.

Priority: EP20090382148 Applic. Date: 2009-08-21

Inventor: ALCAMI PERTEJO JOSE [ES]; BEDOYA DEL OLMO LUIS MIGUEL [ES]; CUEVAS MARCHANTE MARIA DEL CARMEN [ES]


Publication No.: WO2011021203A2  Published: 24/Feb/2011

Title: DESFERRIOXAMINE-METAL COMPLEXES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM LTD, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTLTD

Application No.: IL2010/000681   Filing Date: 19/Aug/2010

Abstract:The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.

Priority: US20090235062P Applic. Date: 2009-08-19; US20100298596P Applic. Date: 2010-01-27; US20100347617P Applic. Date: 2010-05-24

Inventor: CHEVION MORDECHAI [IL]; VINOKUR VLADIMIR [IL]; BERENSHTEIN EDUARD [IL]; ELIASHAR RON [IL]; BULVIK BARUCH [IL]


Publication No.: WO2011021645A1  Published: 24/Feb/2011

Title: BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/063945   Filing Date: 18/Aug/2010

Abstract:Provided is a bicyclic urea derivative that inhibits soluble epoxide hydrolase (sEH), said bicyclic urea derivative represented by formula (I), or a pharmacologically permitted salt thereof. In the formula, R1 represents a C3-9 cycloalkyl group that may be substituted, a C6-10 aryl group that may be substituted, or the like

R2a and R2b each independently represent a hydrogen atom or the like

m is 0, 1, or the like

and ring A is a ring represented by formula (a) or the like (in which R3a, R3b, and R3c each independently represent a hydrogen atom or the like and may be identical or different, and n is 0 or the like).

Priority: JP20090190185 Applic. Date: 2009-08-19

Inventor: SONE TOSHIHIKO [JP]; NAKAJIMA TOMOKO [JP]; TAKAI KENTARO [JP]


Publication No.: WO2011021678A1  Published: 24/Feb/2011

Title: FUSED HETEROCYCLIC COMPOUND

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: JP2010/064042   Filing Date: 20/Aug/2010

Abstract:Disclosed are: a fused heterocyclic compound having excellent medical activities including a p38 MAPK-inhibiting activity and a TNF-a production-inhibiting activity

a medicinal agent comprising the compound

and others. Specifically disclosed is a compound represented by formula (I) [wherein one of Y1 and Y2 represents an N atom and the other represents CH

one of X1 and X2 represents CH and the other represents C-L-R2

L represents a bond, -NH-, -CH2- or -CO-

R1 represents an optionally substituted phenyl group, an optionally substituted heterocyclic group, an optionally substituted C1-6 alkyl group, an optionally substituted C3-6 cycloalkyl group, or an optionally substituted indanyl group

and R2 represents an optionally substituted aryl group, or an optionally substituted bicyclic heteroaryl group] or a salt thereof. The compound is useful as a p38 MAPK inhibitor and/or a TNF-a production inhibitor.

Priority: JP20090192602 Applic. Date: 2009-08-21

Inventor: MIWATASHI SEIJI [JP]; KAIEDA AKIRA [US]; TAKAHASHI MASASHI [US]; INUI HIROMI [JP]; OKAMOTO REI [JP]


Publication No.: WO2011021833A2  Published: 24/Feb/2011

Title: COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION

Applicant/Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE

Application No.: KR2010/005420   Filing Date: 17/Aug/2010

Abstract:The present invention relates to a composition containing substance P for preventing or treating inflammation. The composition containing substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in blood, which are associated with inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.

Priority: KR20090075881 Applic. Date: 2009-08-17

Inventor: SON YOUNG SOOK [KR]; HONG HYUN SOOK [KR]; KIM DO YEON [KR]; LEE EUN KYUNG [KR]


Publication No.: WO2011022075A1  Published: 24/Feb/2011

Title: USE OF AEROSOLIZED ANTIBIOTICS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Applicant/Assignee: MPEX PHARMACEUTICALS, INC

Application No.: US2010/002307   Filing Date: 19/Aug/2010

Abstract:The present invention relates to methods and compositions for treating obstructive pulmonary disorders. In particular, compositions and methods described herein relate to the use of an aerosolized antibiotic for treating obstructive pulmonary disorders including chronic obstructive pulmonary disorder (COPD) and chronic bronchitis (CB).

Priority: US20090240749P Applic. Date: 2009-09-09; US20090235319P Applic. Date: 2009-08-19; US20090249228P Applic. Date: 2009-10-06

Inventor: DUDLEY MICHAEL N [US]; BERKLEY NEIL [US]; GRIFFITH DAVID C [US]; LOUTIT JEFFERY S [US]; MORGAN ELIZABETH E [US]; BOSTIAN KEITH A [US]; SETHI SANJAY [US]


Publication No.: WO2011022449A1  Published: 24/Feb/2011

Title: DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES

Applicant/Assignee: SANOFI-AVENTIS

Application No.: US2010/045828   Filing Date: 18/Aug/2010

Abstract:The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of Claim 1. The present invention is directed also to the preparation of a compound of formula I.

Priority: US20090235482P Applic. Date: 2009-08-20; FR20100050258 Applic. Date: 2010-01-15

Inventor: CHOI-SLEDESKI YONG-MI [US]; GARDNER CHARLES J [US]; LIANG GUYAN [US]; POLI GREGORY B [US]; SHUM PATRICK WAI-KWOK [US]; STOKLOSA GREGORY T [US]; ZHAO ZHICHENG [US]


Publication No.: WO2011023573A1  Published: 03/Mar/2011

Title: ANTIMICROBIAL AMINO-SALICYLIC ACID DERIVATIVES

Applicant/Assignee: BASF SE

Application No.: EP2010/061804   Filing Date: 13/Aug/2010

Abstract:Disclosed is a novel method for achieving an antimicrobial, preservative and/or microorganism adhesion inhibiting effect, for the protection within an article and/or material or on the surface of an article and/or material. The novel method comprises application of a salicylic compound of the formula (I) wherein one of A and A is a residue of the formula (I'): -NH-CO-R1 while the other is hydrogen

R1 is C1-C22alkyl, C3-C12cycloalkyl, C3-C12cycloalkyl interrupted by O and/or NR5, C4-C12aryl, C5-C18arylalkyl

R2 is OR3 or NHR4

R3 and R4 are selected from H, C1-C22alkyl, C3-C12cycloalkyl, C3-C12cycloalkyl interrupted by O and/or NR5, C4-C12aryl, C5-C18arylalkyl

R5 is H or C1-C8alkyl

wherein each aryl moiety is unsubstituted or substituted by C1-C4alkyl, C1-C4alkoxy, C1-C4acyl, C1-C4acyloxy, C1-C4acylamino, CF3, OH, amino, halogen

or an adduct or salt thereof

to said article and/or material.

Priority: EP20090168669 Applic. Date: 2009-08-26

Inventor: HOELZL WERNER [FR]; PURSCHWITZ JANINA [DE]


Publication No.: WO2011023693A1  Published: 03/Mar/2011

Title: METHYLPYRROLOPYRIMIDINECARBOXAMIDES

Applicant/Assignee: NYCOMED GMBH

Application No.: EP2010/062329   Filing Date: 24/Aug/2010

Abstract:The compounds of formula (I) wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, and the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

Priority: EP20090168685 Applic. Date: 2009-08-26

Inventor: STADLWIESER JOSEF [DE]; SCHMIDT BEATE [DE]; BERNSMANN HEIKO [DE]; DUNKERN TORSTEN [DE]; BENEDIKTUS EWALD [DE]; PAHL ANDREAS [DE]; HUSSONG RAGNA [DE]; NIMZ OLAF [DE]; MUELLER MATTHIAS [DE]; VIERTELHAUS MARTIN [DE]


Publication No.: WO2011023812A1  Published: 03/Mar/2011

Title: MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES1) INHIBITORS

Applicant/Assignee: NOVASAID AB

Application No.: EP2010/062596   Filing Date: 27/Aug/2010

Abstract:A compound of formula (I): as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from inflammatory diseases, nociceptive pain, auto-immune disease, breathing disorders, fever, cancer, inflammation related anorexia, Alzheimer's disease and cardiovascular diseases.

Priority: EP20090168830 Applic. Date: 2009-08-27

Inventor: WANNBERG JOHAN [SE]; ALTERMAN MATHIAS [SE]; MALM JOHAN [SE]; STENBERG PATRIC [SE]; WESTMAN JACOB [SE]; WALLBERG HANS [SE]


Publication No.: WO2011024056A2  Published: 03/Mar/2011

Title: AN IMPROVED PROCESS FOR THE PREPARATION OF BOSENTAN

Applicant/Assignee: AUROBINDO PHARMA LIMITED

Application No.: IB2010/002090   Filing Date: 27/Aug/2010

Abstract:The present application provides purification of Bosentan crude by making its crystalline potassium salt, which is further converted to Bosentan (I) with bis-sulfonamide (VIII) and deshydroxyethyl (IX) impurities to less than 0.2% by HPLC analysis.

Priority: IN2009CH02065 Applic. Date: 2009-08-27; IN2010CH02132 Applic. Date: 2010-07-28

Inventor: BRAJESH KUMAR SINHA [IN]; KONDURU RAJASEKHARA RAJU [IN]; BUDIDET SHANKAR REDDY [IN]; VADDI PANDU RANGARAO [IN]; AMINUL ISLAM [IN]; MEENAKSHISUNDERAM SIVAKUMARAN [IN]


Publication No.: WO2011024874A1  Published: 03/Mar/2011

Title: BASE ADDITION SALTS

Applicant/Assignee: NIPPON SHINYAKU CO., LTD

Application No.: JP2010/064416   Filing Date: 25/Aug/2010

Abstract:Provided is novel base addition salts of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide (hereinafter referred to as "compound (A)"). As an example of the aforesaid base addition salts, a base addition salt composed of compound (A) and a base selected from the group consisting of (a) to (d) can be cited: (a) t-butylamine

(b) potassium

(c) sodium

and (d) dimethylaminoethanol.

Priority: JP20090196079 Applic. Date: 2009-08-26; JP20090196080 Applic. Date: 2009-08-26; JP20090196081 Applic. Date: 2009-08-26; JP20090196082 Applic. Date: 2009-08-26

Inventor: VICTOR M DIAZ PEREZ [GB]; JENNIFER HILL [GB]


Publication No.: WO2011024918A1  Published: 03/Mar/2011

Title: ANTIANGIOGENIC AGENT AND METHOD FOR INHIBITION OF ANGIOGENESIS

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: JP2010/064523   Filing Date: 26/Aug/2010

Abstract:Disclosed are: an antiangiogenic agent having a higher therapeutic effect than those of conventional antiangiogenic agents

and a method for inhibiting angiogenesis, which utilizes the antiangiogenic agent. The antiangiogenic agent comprises at least one type of miRNA selected from the group consisting of miRNA, pre-miRNA and pri-miRNA each having an miRNA activity on VE-cadherin.

Priority: JP20090195848 Applic. Date: 2009-08-26

Inventor: TAKAKURA NOBUYUKI [JP]; KIDOYA HIROYASU [JP]; MURAMATSU FUMITAKA [JP]


Publication No.: WO2011024955A1  Published: 03/Mar/2011

Title: NUCLEIC ACID CAPABLE OF BINDING TO TGF-?II-TYPE RECEPTOR, AND USE THEREOF

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/064612   Filing Date: 27/Aug/2010

Abstract:Disclosed is a substance which can be used for the elucidation of the physiological functions of TGF-ss and a TGF-ssII-type receptor and the analysis of mechanism of development of TGF-ss-induced diseases and the diagnosis and treatment of TGF-ss-induced diseases. Specifically disclosed are: an aptamer which is characterized by being capable of binding to a TGF-ssII-type receptor and being capable of inhibiting the binding between TGF-ss and a TGF-ssII-type receptor

a method for detecting a TGF-ssII-type receptor, which is characterized by using the aptamer

a medicinal agent comprising the aptamer

and others.

Priority: JP20090198813 Applic. Date: 2009-08-28

Inventor: NAKAMURA YOSHIKAZU [JP]; YAMAMURA YASUKO [JP]


Publication No.: WO2011024973A1  Published: 03/Mar/2011

Title: THERAPEUTIC AGENT FOR RHINITIS

Applicant/Assignee: IGISU CO., LTD

Application No.: JP2010/064644   Filing Date: 27/Aug/2010

Abstract:Disclosed is a therapeutic agent for rhinitis, which has a significant rhinitis-ameliorating effect on rhinitis, particularly allergic rhinitis, can exert a medicinal efficacy thereof rapidly, has fast-acting properties, can exert the medicinal efficacy thereof for a prolonged period, has no topical adverse side effect, and has excellent effectiveness and safety. Specifically disclosed is a therapeutic agent for rhinitis, particularly a therapeutic agent for allergic rhinitis, which comprises a C-type natriuretic peptide (CNP) or a B-type natriuretic peptide (BNP) as an active ingredient.

Priority: JP20090197488 Applic. Date: 2009-08-27

Inventor: ENDO KYOKO [JP]


Publication No.: WO2011024987A1  Published: 03/Mar/2011

Title: AROMATIC FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/064665   Filing Date: 30/Aug/2010

Abstract:Disclosed is a compound having an activity of modulating a histamine-H4 receptor. Specifically disclosed is a compound represented by formula (I) [wherein Ra and Rb independently represent a hydrogen atom, a substituted or unsubstituted alkyl group, or the like

X represents -O- or -S(O)p-

p represents an integer of 0 to 2

Y represents =O or =S

R1 represents a halogen atom, a substituted or unsubstituted alkyl group, or the like

n represents an integer of 0 to 4

and R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or the like], a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt.

Priority: JP20090200094 Applic. Date: 2009-08-31

Inventor: TACHIBANA YUUKI [JP]; MASUDA TSUTOMU [JP]


Publication No.: WO2011025128A2  Published: 03/Mar/2011

Title: METHOD FOR TREATING TH17 INFLAMMATORY DISEASE THROUGH INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS AND PHARMACEUTICAL COMPOSITION THEREFOR

Applicant/Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION

Application No.: KR2010/003182   Filing Date: 20/May/2010

Abstract:The present invention relates to a method for treating or preventing Th17 inflammatory disease mediated with IL-6 or IL-17 by administration of medication which inhibits vascular endothelial growth factor receptors, and a pharmaceutical composition therefor.

Priority: KR20090080922 Applic. Date: 2009-08-31

Inventor: KIM YOON KEUN [KR]; GHO YONG SONG [KR]; KIM YU SUN [KR]


Publication No.: WO2011027551A1  Published: 10/Mar/2011

Title: HYDROGEN SULFIDE-PRODUCING ENZYME INHIBITOR

Applicant/Assignee: LOTTE CO., LTD

Application No.: JP2010/005384   Filing Date: 01/Sep/2010

Abstract:The aim is to suppress the production of hydrogen sulfide, more specifically, to provide a hydrogen sulfide-producing enzyme inhibitor. The present inventors achieved the present invention by discovering, as a result of dedicated research, that catechin is provided with inhibitory activity towards hydrogen sulfide-producing enzymes. Specifically disclosed is a hydrogen sulfide-producing enzyme inhibitor that uses catechin as an active component.

Priority: JP20090203689 Applic. Date: 2009-09-03

Inventor: KIKUCHI SANAE [JP]; NARISE ATSUSHI [JP]; SAKURAI KOJI [JP]


Publication No.: WO2011027729A1  Published: 10/Mar/2011

Title: HYDROXYPROPYL CELLULOSE PARTICLES

Applicant/Assignee: NIPPON SODA CO., LTD

Application No.: JP2010/064690   Filing Date: 30/Aug/2010

Abstract:Hydroxypropyl cellulose particles containing particles each having a particle size of larger than 150 [mu]m and not larger than 355 [mu]m in an amount of 50 to 100 wt%.

Priority: JP20090202246 Applic. Date: 2009-09-02

Inventor: MASUE YUSUKE [JP]


Publication No.: WO2011027807A1  Published: 10/Mar/2011

Title: IMMUNITY INDUCER

Applicant/Assignee: TORAY INDUSTRIES, INC

Application No.: JP2010/064993   Filing Date: 02/Sep/2010

Abstract:Disclosed is an immunity inducer comprising, as an active ingredient, a recombinant vector which comprises at least one polypeptide selected from the polypeptides (a) to (c) mentioned below and having an immunity-inducing activity or a polynucleotide encoding the at least one polypeptide and which can express the polypeptide in vivo: (a) a polypeptide which comprises at least seven contiguous amino acid residues contained in an amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12 or SEQ ID NO:44 shown in the Sequence Listing

(b) a polypeptide which has a 90% or more sequence identity with the polypeptide (a) and comprises at least seven amino acid residues

and (c) a polypeptide which contains the polypeptide (a) or (b) as a partial sequence thereof. The immunity inducer is useful as a therapeutic and/or prophylactic agent for cancer or the like.

Priority: JP20090203489 Applic. Date: 2009-09-03

Inventor: KURIHARA AKIRA [JP]; OKANO FUMIYOSHI [JP]


Publication No.: WO2011027888A1  Published: 10/Mar/2011

Title: DIAMIDE-PHENYL DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/065259   Filing Date: 06/Sep/2010

Abstract:Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a pharmaceutically acceptable salt of the compound. (In the formula, A represents a group represented by formula (a) (wherein Ra1, Ra2 and Ra3 each independently represents a hydrogen atom or the like) or the like

R1 represents a C1-6 alkyl group (which is substituted by a C1-4 alkoxy group (which may be substituted by a C1-4 alkoxy group), a C1-4 alkylsulfonyl group or the like) or the like

and R2 represents an optionally substituted C1-6 alkyl group or an optionally substituted C3-6 cycloalkyl group.)

Priority: JP20090205721 Applic. Date: 2009-09-07

Inventor: TANAKA DAISUKE [JP]


Publication No.: WO2011027916A1  Published: 10/Mar/2011

Title: THERAPEUTIC AGENT FOR ALLERGIC DISEASES

Applicant/Assignee: NIHON UNIVERSITY

Application No.: JP2010/065689   Filing Date: 07/Sep/2010

Abstract:Disclosed are: an inhibitor of the IgE-dependent activation of mast cells

a method for inhibiting the the IgE-dependent activation of mast cells

a pharmaceutical composition for treating and/or preventing allergic diseases

a method for treating and/or preventing allergic diseases

a phosphorylated peptide which can be used for the inhibitors and the methods

and others. The inhibitor of the IgE-dependent activation of mast cells is characterized by comprising a peptide (a) or (b), a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide which comprises the amino acid sequence represented by formula (I): KVPEDRV-Y1-EELNI-Y2-SAT-Y3-SELEDPG

and (b) a peptide which is produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence represented by formula (I) and which has an inhibitory activity on the IgE-dependent activation of mast cells.

Priority: JP20090206324 Applic. Date: 2009-09-07

Inventor: OKAYAMA YOSHIMICHI [JP]; RA CHISEI [JP]


Publication No.: WO2011028651A1  Published: 10/Mar/2011

Title: INHIBITORS OF HUMAN 15-LIPOXYGENASE-1

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/047095   Filing Date: 30/Aug/2010

Abstract:Disclosed are inhibitors of human 15 lipoxygenase 1, for example, of formula (I), wherein R1, R2, R3, R4, X, Y, and Z are as defined herein, that are useful in treating a 15-lipoxygenase mediated disease or disorder, e.g., prostate cancer. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating prostate cancer in a mammal.

Priority: US20090238972P Applic. Date: 2009-09-01; US20100315788P Applic. Date: 2010-03-19

Inventor: MALONEY DAVID J [US]; HOLMAN THEODORE [US]; BANTUKALLU GANESHA RAI [US]; SIMEONOV ANTON [US]; JADHAV AJIT [US]; KENYON VICTOR [US]


Publication No.: WO2011028743A1  Published: 10/Mar/2011

Title: PHARMACEUTICAL FORMULATIONS FOR INDIBULIN

Applicant/Assignee: ZIOPHARM ONCOLOGY, INC

Application No.: US2010/047436   Filing Date: 01/Sep/2010

Abstract:In certain embodiments, the invention relates to pharmaceutical formulations of an indolyl-3-glyoxylic acid derivative or a pharmaceutically acceptable salt thereof, such as indibulin. Methods of preparing such formulations and methods of treatment using these formulations are also described.

Priority: US20090239254P Applic. Date: 2009-09-02

Inventor: AMEDIO JOHN C JR [US]


Publication No.: WO2011029059A1  Published: 10/Mar/2011

Title: USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS

Applicant/Assignee: MPEX PHARMACEUTICALS, INC

Application No.: US2010/047903   Filing Date: 03/Sep/2010

Abstract:The invention relates to methods for treating cystic fibrosis comprising administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. The invention relates in particular to administering the aerosol solution to a human wherein said human has a pulmonary infection comprising P. aeruginosa.

Priority: US20090249231P Applic. Date: 2009-10-06; US20090240092P Applic. Date: 2009-09-04

Inventor: LOUTIT JEFFEREY S [US]; MORGAN ELIZABETH E [US]; DUDLEY MICHAEL N [US]; GRIFFITH DAVID C [US]; LOMOVSKAYA OLGA [US]


Publication No.: WO2011029218A1  Published: 17/Mar/2011

Title: USE OF MONTMORILLONITE IN MANUFACTURE OF MEDICAMENTS

Applicant/Assignee: JINAN KANGZHONG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD

Application No.: CN2009/001187   Filing Date: 26/Oct/2009

Abstract:The present invention provides the use of montmorillonite in manufacture of medicaments for preventing or treating cold. Said cold comprises common cold and influenza. The pharmaceutical dosage forms of montmorillonite comprise nose drops, spray and aerosol.

Priority: CN20091018651 Applic. Date: 2009-09-09

Inventor: LI SHIBIAO [CN]; XU CUIPING [CN]; ZHANG MEIXUE [CN]; ZHANG JING [CN]; XU DONGFENG [CN]


Publication No.: WO2011029525A1  Published: 17/Mar/2011

Title: A THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: EP2010/005159   Filing Date: 24/Aug/2010

Abstract:The invention concerns the use of an exogenous pulmonary surfactant in combination with antioxidant enzymes for the prevention of bronchopulmonary dysplasia (BPD). The use of the invention decreases the markers of pulmonary oxidative stress.

Priority: EP20090169719 Applic. Date: 2009-09-08

Inventor: DANI CARLO [IT]


Publication No.: WO2011030116A1  Published: 17/Mar/2011

Title: USE OF STEROID COMPOUNDS FOR INFLAMMATORY AND AUTOIMMUNE DISORDERS

Applicant/Assignee: BIONATURE E.A. LTD, TOWLER, PHILIP, DEAN

Application No.: GB2010/001727   Filing Date: 13/Sep/2010

Abstract:This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammatory conditions, including, but not limited to asthma, lung inflammation, retinal inflammatory conditions, autoimmune diseases such as rheumatoid arthritis, diabetes type I, systemic lupus erythematosus, ulcerative colitis and inflammatory bowel diseases and myopathies, as well as multiple sclerosis. The active compounds are represented by Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, B, X, Y and Z are defined in the description of the invention.

Priority: GB20090016020 Applic. Date: 2009-09-11; GB20100009342 Applic. Date: 2010-06-03

Inventor: PANOUTSAKOPOULOU VASILIKI [GR]; ANGELAKOPOULOU MARIA [GR]; CALOGEROPOULOU THEODORA [GR]; GRAVANIS ACHILLEAS [GR]; LAZARIDIS LAKOVOS [GR]; NEOPHYTOU CONSTANTINOS [CY]


Publication No.: WO2011030163A1  Published: 17/Mar/2011

Title: USE OF GUAIFENESIN FOR INHIBITING MUCIN SECRETION

Applicant/Assignee: RECKITT BENCKISER LLC, RECKITT & COLMAN (OVERSEAS) LIMITED

Application No.: GB2010/051525   Filing Date: 13/Sep/2010

Abstract:A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.

Priority: US2009-558517 Applic. Date: 2009-09-12; GB20100002039 Applic. Date: 2010-02-09

Inventor: ALBRECHT HELMUT [US]; KIM K CHUL [US]; SEAGRAVE JEANCLARE [US]; RUBIN BRUCE K [US]; SOLOMON GAIL [US]


Publication No.: WO2011030864A1  Published: 17/Mar/2011

Title: ANILINE COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065649   Filing Date: 10/Sep/2010

Abstract:Provided are novel aniline compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity

or salts thereof.

Priority: JP20090210790 Applic. Date: 2009-09-11

Inventor: IWAMURA RYO; MURAKAMI YOKO; HAGIHARA MASAHIKO; OKANARI EIJI


Publication No.: WO2011030865A1  Published: 17/Mar/2011

Title: SUBSTITUTED ZENZYL COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065650   Filing Date: 10/Sep/2010

Abstract:Provided are novel substituted benzyl compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity

or salts thereof.

Priority: JP20090210791 Applic. Date: 2009-09-11

Inventor: IWAMURA RYO; SHIBAKAWA NOBUHIKO; HAGIHARA MASAHIKO; OKANARI EIJI


Publication No.: WO2011030868A1  Published: 17/Mar/2011

Title: SUBSTITUTED CARBONYL COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065654   Filing Date: 10/Sep/2010

Abstract:Novel substituted carbonyl compounds represented by general formula (I) or salts thereof, which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity and which are useful in the treatment of respiratory diseases. In general formula (I), R1 is -OR5, -O(CH2CH2O)mR6 or -NR7R8 (wherein R5 is C7-22 alkyl or the like

R6 is H or benzyl

m is 1 to 4

and R7 and R8 are each H, C1-12 alkyl, or the like)

R2 and R3 are each H or C1-6 alkyl

Y is a (substituted) bicyclic heteroaromatic ring, -Q1-Q2, or the like (wherein Q1 is arylene or the like

and Q2 is a (substituted) 5- or 6-memebred heterocycle, or the like)

and Z is (substituted) aryl or a (substituted) 5- or 6-memeberd heteroaromatic ring.

Priority: JP20090210792 Applic. Date: 2009-09-11

Inventor: HAGIHARA MASAHIKO; IWAMURA RYO; SHIBAKAWA NOBUHIKO; YONEDA KENJI; OKANARI EIJI; NAKANISHI TAKAYUKI


Publication No.: WO2011030871A1  Published: 17/Mar/2011

Title: N-SUBSTITUTED HETEROARYL COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065657   Filing Date: 10/Sep/2010

Abstract:Provided are novel N-substituted heteroaryl compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity. In general formula (I), R1 is H or (halogeno) C1-6 alkyl

R2 and R3 are each H or C1-6 alkyl

Y is a (substituted) bicyclic heteroaromatic ring, -Q1-Q2, or the like (wherein Q1 is arylene or the like

and Q2 is a (substituted) 5- or 6-membered heterocycle, or the like)

and Z is a nitrogenous 5- or 6-membered aromatic ring or a nitrogenous bicyclic aromatic ring, the N atom of each aromatic ring being either quaternized with C1-6 alkyl or converted into oxide.

Priority: JP20090210787 Applic. Date: 2009-09-11

Inventor: HAGIHARA MASAHIKO; SHIBAKAWA NOBUHIKO; OKANARI EIJI


Publication No.: WO2011030872A1  Published: 17/Mar/2011

Title: SULFONAMIDE COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065658   Filing Date: 10/Sep/2010

Abstract:Provided are novel sulfonamide compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity

or salts thereof.

Priority: JP20090210788 Applic. Date: 2009-09-11

Inventor: IWAMURA RYO; KATSUBE TETSUSHI; OKANARI EIJI; SHIGETOMI MANABU; TOKUNAGA YASUNORI


Publication No.: WO2011030873A1  Published: 17/Mar/2011

Title: BENZYL COMPOUNDS

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/065659   Filing Date: 10/Sep/2010

Abstract:Provided are novel benzyl compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity

or salts thereof.

Priority: JP20090210789 Applic. Date: 2009-09-11

Inventor: IWAMURA RYO; SHIBAKAWA NOBUHIKO; HAGIHARA MASAHIKO; OKANARI EIJI


Publication No.: WO2011031713A2  Published: 17/Mar/2011

Title: METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN

Applicant/Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVI, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC

Application No.: US2010/048068   Filing Date: 08/Sep/2010

Abstract:Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-I) and NAD.

The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine- specific mono-ADP-ribosyltransferase (for example, ARTl) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine- containing polypeptide. Methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a modified polypeptide (such as HNP-I) including at least one ornithine residue in place of an arginine residue are also disclosed.

Priority: US20090241311P Applic. Date: 2009-09-10

Inventor: MOSS JOEL [US]; STEVENS LINDA [US]; LEVINE RODNEY L [US]


Publication No.: WO2011031875A2  Published: 17/Mar/2011

Title: CELL-BASED COMPOSITIONS AND USES THEREOF

Applicant/Assignee: FATE THERAPEUTICS, INC

Application No.: US2010/048290   Filing Date: 09/Sep/2010

Abstract:The present invention provides compositions and methods of using the compositions to increase the efficacy of cell-based therapies. Particularly, the present invention provides in vivo and ex vivo methods of directing cell-based compositions to sites in vivo to provide cell replacement and/or regenerative therapy.

Priority: US20090241711P Applic. Date: 2009-09-11

Inventor: MENDLEIN JOHN D [US]


Publication No.: WO2011032233A1  Published: 24/Mar/2011

Title: NOVEL OMEGA CONOTOXIN PEPTIDES

Applicant/Assignee: THE UNIVERSITY OF QUEENSLAND

Application No.: AU2010/001228   Filing Date: 21/Sep/2010

Abstract:This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine

Xaa2 is selected from arginine and lysine

Xaa5 is selected from aspartic acid and glutamic acid

and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.

Priority: AU20090904560 Applic. Date: 2009-09-21

Inventor: LEWIS RICHARD JAMES [AU]


Publication No.: WO2011033040A2  Published: 24/Mar/2011

Title: ANTIBACTERIAL PARTICLES AND THEIR SYNTHESIS

Applicant/Assignee: CENTRUM FUER ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBH

Application No.: EP2010/063646   Filing Date: 16/Sep/2010

Abstract:The field of the invention relates to a method for the manufacture of an antibacterial nanoparticle and its use. The present disclosure provides a method for the synthesis of antibacterial nanoparticles based on ZnO doped with copper or magnesium, and investigation of their antibacterial activity on Escherichia CoIi (E.Coli) DH5a as a representative of gram-negative bacteria and Staphylococcus Carnosus (S. Carnosus) as a representative of gram-positive bacteria.

Priority: GB20090016202 Applic. Date: 2009-09-16

Inventor: ALEKSANDROVIC VESNA [DE]; SCHLUNDT CHARIS RABEA [DE]; WERNER KATJA [DE]; WOOST MARIE [DE]


Publication No.: WO2011033055A1  Published: 24/Mar/2011

Title: FUSED TRIAZOLE AMINES AS P2X7 MODULATORS

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2010/063686   Filing Date: 17/Sep/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, and R3 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Priority: US20090244322P Applic. Date: 2009-09-21

Inventor: BROTHERTON-PLEISS CHRISTINE [US]; HARRIS III RALPH NEW [US]; LOE BRADLEY E [US]; LOPEZ-TAPIA FRANCISCO JAVIER [US]; REGE PANKAJ D [US]; REPKE DAVID BRUCE [US]; STABLER RUSSELL STEPHEN [US]; WALKER KEITH ADRIAN MURRAY [US]


Publication No.: WO2011034078A1  Published: 24/Mar/2011

Title: GLYCINE COMPOUND

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: JP2010/065918   Filing Date: 15/Sep/2010

Abstract:Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compounds having VAP-1 inhibitory activity, it was discovered that the aforesaid compound or a salt thereof shows an excellent VAP-1 inhibitory activity and, therefore, is useful in preventing and/or treating a VAP-1 associated disease, in particular, diabetic nephropathy or diabetic macular edema. The present invention has been thus completed. Also disclosed is a medicinal composition, in particular a medicinal composition for preventing and/or treating a VAP-1 associated disease, which comprises the aforesaid compound or a salt thereof and an excipient.

Priority: JP20090214991 Applic. Date: 2009-09-16

Inventor: YOSHIHARA KOUSEI [JP]; SUZUKI DAISUKE [JP]; YAMAKI SUSUMU [JP]; KOGA YUJI [JP]; SEKI NORIO [JP]; FUJIYASU JIRO [JP]; NEYA MASAHIRO [JP]


Publication No.: WO2011034215A1  Published: 24/Mar/2011

Title: COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY

Applicant/Assignee: TAISHO PHARMACEUTICAL CO., LTD

Application No.: JP2010/066637   Filing Date: 17/Sep/2010

Abstract:The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: (I) wherein R is a hydrogen atom or a C1-10 alkyl group

R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group or a substituent having the structure represented by the following formula Ia or Ib: (Ia) (Ib) where R3 is a C1-6 alkyl group

R4 is a C1-6 alkyl group, a C3-8 cycloalkyl group, or a benzyl group

and R2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:(Ic) (Id)

Priority: JP20090215093 Applic. Date: 2009-09-17; JP20100103546 Applic. Date: 2010-04-28

Inventor: AMADA HIDEAKI [JP]; MATSUDA DAISUKE [JP]; BOHNO AYAKO [JP]


Publication No.: WO2011034580A2  Published: 24/Mar/2011

Title: SMALL PEPTIDE MODULATORS OF POTASSIUM CHANNEL TRAFFICKING

Applicant/Assignee: UNIVERSITY OF HOUSTON

Application No.: US2010/002513   Filing Date: 16/Sep/2010

Abstract:Provided herein are peptide modulators of ion channels. Specifically, the peptide modulators comprise the amino acid sequence VEDEC wherein V is valine, E is glutamate, D is aspartate, C is cysteine. In certain embodiments, the modulator is attached to the C- terminal end of SIoI protein isoform. The present invention also claims conjugations of the first valine that make the peptide modulator more membrane permeable, such as myristoyl moieties and arginine-rich cell penetrating peptides. The present invention contemplates use of the peptide modulators in the treatment of diseases/malfunctions such as epilepsy, chronic pain, migraine, asthma, chronic obstructive pulmonary disease, urinary incontinence, hypertension, erectile dysfunction, irritable bowel syndrome, renal disorders of electrolyte imbalance, and possibly in certain kinds of cancer.

Priority: US20090277011P Applic. Date: 2009-09-18

Inventor: DRYER STUART E [US]


Publication No.: WO2011034896A2  Published: 24/Mar/2011

Title: SMALL MOLECULE INHIBITORS OF THE ALPHA4-PAXILLIN INTERACTION

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/048897   Filing Date: 15/Sep/2010

Abstract:The present invention is directed to novel compounds that are able to inhibit the interaction of paxillin or its paralogues, including leupaxin or Hic-5f with alpha.4 integrin or its binding partners that regulate signaling events downstream of the paxillin (approx.) ,alpha.4 interaction, The present invention further relates to methods for therapeutic use of such compounds and pharmaceutical compositions of such compounds for the treatment of a disease or condition.

Priority: US20090243638P Applic. Date: 2009-09-18

Inventor: GINSBERG MARK [US]; KUMMER CHRISTIANE [US]


Publication No.: WO2011035855A1  Published: 31/Mar/2011

Title: PYRIDINYL-IMIDAZOLONE DERIVATIVES FOR INHIBITING PI3 KINASES

Applicant/Assignee: MERCK PATENT GMBH

Application No.: EP2010/005459   Filing Date: 06/Sep/2010

Abstract:The invention relates to compounds of the formula (I), wherein X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings specified in claim 1, are PI3K inhibitors and can be used inter alia to treat autoimmune diseases, inflammations, cardiovascular diseases, neurodegenerative diseases, and tumors.

Priority: DE200910043260 Applic. Date: 2009-09-28

Inventor: EMDE ULRICH [DE]; BUCHSTALLER HANS-PETER [DE]; KLEIN MARKUS [DE]; ESDAR CHRISTINA [DE]; BOMKE JOERG [DE]


Publication No.: WO2011036130A1  Published: 31/Mar/2011

Title: INDOLE DERIVATIVES AS CRAC MODULATORS

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2010/063838   Filing Date: 21/Sep/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Priority: US20090245521P Applic. Date: 2009-09-24; US20100378062P Applic. Date: 2010-08-30

Inventor: ALAM MUZAFFAR [US]; DU BOIS DAISY JOE [US]; HAWLEY RONALD CHARLES [US]; KENNEDY-SMITH JOSHUA [US]; MINATTI ANA ELENA [US]; PALMER WYLIE SOLANG [US]; SILVA TANIA [US]; WILHELM ROBERT STEPHEN [US]


Publication No.: WO2011036461A1  Published: 31/Mar/2011

Title: FUSED IMIDAZO [3, 2 - D] PYRAZINES AS PI3 KINASE INHIBITORS

Applicant/Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)

Application No.: GB2010/001804   Filing Date: 24/Sep/2010

Abstract:There is provided compounds of formula (I), wherein A1, A2, A3, A4, n, the dotted lines, B1, B1a, B2, B2a, B3, B3a, B4, B4a, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Priority: EP20090380153 Applic. Date: 2009-09-24

Inventor: PASTOR FERNANDEZ JOAQUIN [ES]; MARTINEZ GONZALEZ SONIA [ES]; ALVAREZ ESCOBAR ROSA MARIA [ES]; RODRIGUEZ ARISTEGUI SONSOLES [ES]; GONZALES CANTALAPIEDRA ESTHER [ES]; HERNANDEZ HIGUERAS ANA ISABEL [ES]; VARELA BUSTO CARMEN [ES]


Publication No.: WO2011036651A1  Published: 31/Mar/2011

Title: PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Applicant/Assignee: GENKYOTEX SA

Application No.: IB2010/054329   Filing Date: 27/Sep/2010

Abstract:The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Priority: EP20090171466 Applic. Date: 2009-09-28

Inventor: PAGE PATRICK [FR]; GAGGINI FRANCESCA [CH]; LALEU BENOIT [FR]


Publication No.: WO2011036895A1  Published: 31/Mar/2011

Title: MALEIC ACID SALT AND CRYSTAL THEREOF

Applicant/Assignee: KYORIN PHARMACEUTICAL CO., LTD

Application No.: JP2010/005786   Filing Date: 27/Sep/2010

Abstract:Disclosed is a benz[d][1,3]oxazine derivative having excellent stability when used as an active ingredient for a medicinal agent, and also having excellent solubility and crystallinity. Specifically disclosed is 2-[2-((S)-3- dimethylaminopyrrolidin-1-yl)pyridine-3-yl]-5-ethyl-7- methoxy-4H-benz[d][1,3]oxazin-4-one maleate.

Priority: JP20090220296 Applic. Date: 2009-09-25

Inventor: TSUBUKI TAKESHI [JP]; SAGAWA TETSUYA [JP]; FUNADA KEIKO [JP]; ARAYA ICHIRO [JP]


Publication No.: WO2011037550A2  Published: 31/Mar/2011

Title: DRY POWDER COMBINATION OF TIOTROPIUM

Applicant/Assignee:

Application No.: TR2010/000184   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a pharmaceutical composition containing tiotropium formulated with an effective amount of a cromolyn derivative used for the treatment of respiratory disease by inhalation route.

Priority: TR20090007237 Applic. Date: 2009-09-23

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2011038081A1  Published: 31/Mar/2011

Title: BIODEGRADABLE FOAMS WITH IMPROVED DIMENSIONAL STABILITY

Applicant/Assignee: ARKEMA INC

Application No.: US2010/049945   Filing Date: 23/Sep/2010

Abstract:The invention provides a blowing agent composition and method of making the same comprising mixing carbon dioxide and a co-blowing agent or a blowing agent selected from the group consisting of hydrofluorocarbons, hydrochlorofluorocarbons, hydrofluoroethers, hydrofluoroolefins, hydrochlorofluoroolefins, hydrobromofluoroolefins, hydrofluoroketones, hydrochloroolefins, fluoroiodocarbons, alkyl esters, water, and mixtures thereof. Also provided is a method of making a low density foam using the blowing agent composition, and a biodegradable or biorenewable foam formed from a foamable biodegradable or biorenewable resin composition and the blowing agent composition.

Priority: US20090245743P Applic. Date: 2009-09-25

Inventor: VAN HORN BRETT L [US]; YACKABONIS WILLIAM E [US]


Publication No.: WO2011038086A2  Published: 31/Mar/2011

Title: INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/049954   Filing Date: 23/Sep/2010

Abstract:Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

Priority: US20090245198P Applic. Date: 2009-09-23

Inventor: STEARNS BRIAN ANDREW [US]; ROPPE JEFFREY ROGER [US]; PARR TIMOTHY ANDREW [US]; STOCK NICHOLAS SIMON [US]; VOLKOTS DEBORAH [US]; HUTCHINSON JOHN HOWARD [US]


Publication No.: WO2011038097A2  Published: 31/Mar/2011

Title: INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/049967   Filing Date: 23/Sep/2010

Abstract:Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

Priority: US20090245206P Applic. Date: 2009-09-23

Inventor: ROPPE JEFFREY ROGER [US]; PARR TIMOTHY [US]; STEARNS BRIAN ANDREW [US]


Publication No.: WO2011038471A1  Published: 07/Apr/2011

Title: PHARMACEUTICAL COMPOSITION AND USE THEREOF

Applicant/Assignee: HEBRON FARMACEUTICA PESQUISA, DESENVOLV. E INOVACAO TECNOLOGICA LTDA, INSTITUTO DE TECNOLOGIA E PESQUISA - ITP

Application No.: BR2010/000285   Filing Date: 01/Sep/2010

Abstract:The technical subject matter of the present invention relates to a pharmaceutical composition that contains, as the active principle, substances obtained by extraction and purification of essential oils from a plant of the Alpinia genus. More specifically, this composition can be used for the treatment of hypertonia in cases of pyramidal syndrome, lung treatments involving pulmonary bronchodilation, and elimination of expression wrinkles. A second embodiment is the use of the pharmaceutical composition to prepare a medicament for treating such cases of hypertonia and in aesthetic treatment.

Priority: BR2009PI04010 Applic. Date: 2009-10-01

Inventor: FILHO LAURO XAVIER [BR]; CANDIDO EDNA ARAGAO FARIAS [BR]


Publication No.: WO2011038579A1  Published: 07/Apr/2011

Title: COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Applicant/Assignee: ZHEJIANG BETA PHARMA INC

Application No.: CN2010/001541   Filing Date: 30/Sep/2010

Abstract:The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Flt3, PDGFR, PDGFR, c-KIT, VEGFR1, VEGFR2, VEGFR3, c- RAF, AbI, Bcr-Abl, Aurora- A, AxI, BMX, CHK2, CSR0, Fes, FGFRi, FGFR3, IKKa, IR, JNK2a2, Lck, Met, MKK6, MST2, p70S6K, PKA, PKD2, ROCK-II, Ros, Rskl, SAPK2a, SAPK2ss, SAPK3 SAPK4, Syk, Tie2, TrkA and/or TrkB Kinases.

Priority: CN20091177355 Applic. Date: 2009-09-30

Inventor: KANG XINSHAN [CN]; FINE RICHARD M [CN]; KLEBANSKY BORRIS [CN]; LONG WEI [CN]; MA CUNBO [CN]; LI HAIJUN [CN]; WANG YANPING [CN]; HU YUNYAN [CN]; WANG YINXIANG [CN]


Publication No.: WO2011038754A1  Published: 07/Apr/2011

Title: ORAL CARE COMPOSITIONS CONTAINING HUMAN RECOMBINANT INTERLEUKIN-1

Applicant/Assignee: UNITED TECHNOLOGIES UT AG

Application No.: EP2009/062639   Filing Date: 29/Sep/2009

Abstract:The present invention relates to oral care compositions comprising human recombinant interleukin-1 and methods thereof for keeping oral cavity in a good condition, reducing oral malodor, and/or preventing or treating periodontal diseases. Preferably, the human recombinant interleukin-1 is human recombinant interleukin-1 alpha or beta.

Priority:

Inventor: PETROPAVLOV IGOR ARTUROVICH [CH]; POMYTKIN IGOR ANATOLIEVICH [RU]


Publication No.: WO2011040201A1  Published: 07/Apr/2011

Title: DENTURE DETERGENT

Applicant/Assignee: KOBAYASHI PHARMACEUTICAL CO., LTD

Application No.: JP2010/065505   Filing Date: 09/Sep/2010

Abstract:Provided is a denture detergent which inhibits a metallic component of a denture from rusting. The denture detergent comprises (1) a hydrogen persulfate, (2) a perborate and/or a percarbonate, and (3) a benzotriazole compound.

Priority: JP20090229079 Applic. Date: 2009-09-30

Inventor: TAKUMI SINYA [JP]; UNO AKIRA [JP]; HARATANI MASAHIRO [JP]


Publication No.: WO2011041145A2  Published: 07/Apr/2011

Title: METHOD AND SYSTEM FOR ACCESSING PATIENT DATA

Applicant/Assignee: NOVARTIS AG

Application No.: US2010/049438   Filing Date: 20/Sep/2010

Abstract:Data concerning patients that have received treatment by a drug is stored and accessed to it is provided. One or more storage elements are provided that contain data concerning patients that have received the drug. The data includes data from clinical trials and data from patients prescribed the drug by a physician. A processor is programmed to search the storage elements for data on patients meeting a specified profile and to create a dataset. The dataset includes information on the patients having the specified profile, including a response of the patients to treatment using the drug.

Priority: US20090246706P Applic. Date: 2009-09-29; US20090261470P Applic. Date: 2009-11-16

Inventor: ANDERSON CHRISTOPHER N [CH]; CREMER MALIKA [CH]


Publication No.: WO2011041146A2  Published: 07/Apr/2011

Title: DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

Applicant/Assignee: NOVARTIS AG

Application No.: US2010/049441   Filing Date: 20/Sep/2010

Abstract:S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Priority: US20090246706P Applic. Date: 2009-09-29; US20090258329P Applic. Date: 2009-11-05; US20100307992P Applic. Date: 2010-02-25; US20100352029P Applic. Date: 2010-06-07

Inventor: BOULTON CRAIG [GB]; BURTIN PASCALE [CH]; DAVID OLIVIER [CH]; DE VERA ANA [CH]; DUMORTIER THOMAS [CH]; HUNT IRENE [CH]; SCHMOUDER ROBERT [US]


Publication No.: WO2011041461A2  Published: 07/Apr/2011

Title: POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/050786   Filing Date: 29/Sep/2010

Abstract:Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Priority: US20090247877P Applic. Date: 2009-10-01

Inventor: CLARK RYAN [US]; STEARNS BRIAN ANDREW [US]; ZHAO LUCY [US]; SEIDERS THOMAS JON [US]; VOLKOTS DEBORAH [US]; ARRUDA JEANNIE M [US]; ZALATAN DAVID NATHAN [US]


Publication No.: WO2011041462A2  Published: 07/Apr/2011

Title: POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/050787   Filing Date: 29/Sep/2010

Abstract:Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Priority: US20090247877P Applic. Date: 2009-10-01

Inventor: CLARK RYAN [US]; STEARNS BRIAN ANDREW [US]; SCOTT JILL MELISSA [US]; COATE HEATHER RENEE [US]; ZHAO LUCY [US]; SEIDERS THOMAS JON [US]; VOLKOTS DEBORAH [US]; ARRUDA JEANNIE M [US]; STOCK NICHOLAS SIMON [US]; TRUONG YEN PHAM [US]; ZALATAN DAVID NATHAN [US]


Publication No.: WO2011041639A2  Published: 07/Apr/2011

Title: HETEROATOM CONTAINING SUBSTITUTED FATTY ACIDS

Applicant/Assignee:

Application No.: US2010/051059   Filing Date: 01/Oct/2010

Abstract:Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

Priority: US20090248049P Applic. Date: 2009-10-02

Inventor: MILLER RAYMOND A [US]


Publication No.: WO2011041694A2  Published: 07/Apr/2011

Title: COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/051150   Filing Date: 01/Oct/2010

Abstract:Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Priority: US20090247861P Applic. Date: 2009-10-01

Inventor: SEIDERS THOMAS JON [US]; ZHAO LUCY [US]; ARRUDA JEANNIE M [US]; WANG BOWEI [US]; STEARNS BRIAN ANDREW [US]; TRUONG YEN PHAM [US]; SCOTT JILL MELISSA [US]; HUTCHINSON JOHN HOWARD [US]; CLARK RYAN [US]; COATE HEATHER RENEE [US]; STOCK NICHOLAS SIMON [US]; VOLKOTS DEBORAH [US]


Publication No.: WO2011041729A2  Published: 07/Apr/2011

Title: COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/051199   Filing Date: 01/Oct/2010

Abstract:Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Priority: US20090247861P Applic. Date: 2009-10-01

Inventor: SEIDERS THOMAS JON [US]; ZHAO LUCY [US]; ARRUDA JEANNIE M [US]; STEARNS BRIAN ANDREW [US]; TRUONG YEN PHAM [US]; SCOTT JILL MELISSA [US]; HUTCHINSON JOHN HOWARD [US]; STOCK NICHOLAS SIMON [US]; VOLKOTS DEBORAH [US]


Publication No.: WO2011041897A1  Published: 14/Apr/2011

Title: COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTIC AGENTS

Applicant/Assignee: ANGIOCHEM INC

Application No.: CA2010/001596   Filing Date: 05/Oct/2010

Abstract:The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a compostion capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.

Priority: US20090249152P Applic. Date: 2009-10-06

Inventor: CASTAIGNE JEAN-PAUL [CA]; DEMEULE MICHEL [CA]; CHE CHRISTIAN [CA]; REGINA ANTHONY [CA]


Publication No.: WO2011042469A1  Published: 14/Apr/2011

Title: USE OF A COMPOUND BASED ON EREMOPHILANOLIDES

Applicant/Assignee:

Application No.: EP2010/064929   Filing Date: 06/Oct/2010

Abstract:The invention relates to a compound based on eremophilanolides, wherein the compound has a plant extract from the furanopetasin variety, said extract being free of pyrrolizidine alkaloids, and/or a plant extract that contains furanoeremophilane compounds from the furanopetasin variety, said compounds being converted into the corresponding eremophilanolides by means of oxidation. The compound is pharmacologically effective and does not exhibit a hepatotoxic potential in contrast to the petasites extract from the petasin variety and furan variety, said extract being free of pyrrolizidine alkaloids.

Priority: DE200910048595 Applic. Date: 2009-10-07

Inventor: RITTINGHAUSEN REINER [DE]


Publication No.: WO2011042897A1  Published: 14/Apr/2011

Title: LIQUID PRECURSOR COMPOSITIONS AND USES THEREOF FOR A PH-DEPENDANT SUSTAINED RELEASE TREATMENT OF ORAL DISORDERS

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM, LTD

Application No.: IL2010/000808   Filing Date: 05/Oct/2010

Abstract:The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.

Priority: US20090248544P Applic. Date: 2009-10-05

Inventor: FRIEDMAN MICHAEL [IL]; STEINBERG DORON [IL]; GATI IRITH [IL]


Publication No.: WO2011043359A1  Published: 14/Apr/2011

Title: PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Applicant/Assignee: KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/067511   Filing Date: 06/Oct/2010

Abstract:Disclosed is a pharmaceutical product or the like, which contains an aromatic heterocyclic compound represented by formula (I) or the like as an active ingredient. (In the formula, Q1 represents a CR2 group (wherein R2 represents a hydrogen atom or the like) or the like

Q2 represents a CR3 group (wherein R3 represents a hydrogen atom or the like) or the like

Q3 represents a nitrogen atom or the like

R1 represents a -C(=O)OR16 group (wherein R16 represents a hydrogen atom or the like) or the like

R5 represents a hydrogen atom or the like

R6 represents an optionally substituted cycloalkyl group or the like

X and Y may be the same or different and each represents a CH group wherein H may be substituted by a substituent, or the like

and Z represents a nitrogen atom or the like.)

Priority: JP20090232201 Applic. Date: 2009-10-06; JP20100118474 Applic. Date: 2010-05-24

Inventor: TAKADA CHIE; SAEKI KOJI; KAWASAKI HIROKAZU; TAGAYA MIHO; KOMAI MASATO; IKEMURA TOSHIHIDE; YAMAGUCHI SHINPEI; IIDA KYOICHIRO


Publication No.: WO2011043371A1  Published: 14/Apr/2011

Title: OXAZOLE COMPOUND

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: JP2010/067541   Filing Date: 06/Oct/2010

Abstract:Disclosed is a novel and excellent prophylactic and/or therapeutic method for diseases associated with interleukin-1 receptor-associated kinase-4 (IRAK-4), which is based on an interleukin-1 receptor-associated kinase-4 (IRAK-4) inhibitory effect. Specifically disclosed is an oxazole carboxylic acid amide derivative which is characterized in that an oxazole that is substituted with a heteroaryl group at the 2-position is bonded to a heteroaryl ring via a carboxamide. The oxazole carboxylic acid amide derivative has a strong inhibitory effect on IRAK-4, and can serve as a prophylactic and/or therapeutic agent for diseases associated with IRAK-4 such as inflammatory diseases and autoimmune diseases.

Priority: JP20090233048 Applic. Date: 2009-10-07

Inventor: INAMI HIROSHI [JP]; MIZUTANI TSUYOSHI [JP]; MAEDA JUNKO [JP]; USUDA HIROYUKI [JP]; NAGASHIMA SHINYA [JP]; ITO TOMONORI [JP]; AOYAMA NAOHIRO [JP]; KONTANI TORU [JP]; HAYASHIDA HISASHI [JP]; TERASAWA TAKESHI [JP]; SEO RYUSHI [JP]; AKAMATSU MASAHIKO [JP]; ISHIKAWA TAKESHI [JP]; HAYASHI KAZUMI [JP]


Publication No.: WO2011043397A1  Published: 14/Apr/2011

Title: ANTI-INFLUENZA VIRUS AGENT

Applicant/Assignee: SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, TAKASAGO INTERNATIONAL CORPORATION

Application No.: JP2010/067576   Filing Date: 06/Oct/2010

Abstract:Disclosed is a novel antiviral agent which is useful for prevention and treatment of influenza. Specifically disclosed is an anti-influenza virus agent which contains patchouli alcohol and/or a patchouli essential oil extract as an active ingredient.

Priority: JP20090235617 Applic. Date: 2009-10-09

Inventor: YAMADA HARUKI [JP]; KIYOHARA HIROAKI [JP]; NAGAI TAKAYUKI [JP]; OHMIYA TADAMASA [JP]; HIRAMOTO TADAHIRO [JP]


Publication No.: WO2011043453A1  Published: 14/Apr/2011

Title: ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR

Applicant/Assignee: NIPPON CHEMIPHAR CO., LTD

Application No.: JP2010/067715   Filing Date: 08/Oct/2010

Abstract:Disclosed are: a compound represented by general formula (I) or a pharmacologically acceptable salt thereof

and an activator for a peroxisome proliferator activated receptor (PPAR), which contains the compound or salt as an active ingredient. (In the formula, R1 and R3 each represents a hydrogen atom, a halogen atom, an alkyl group having 1-8 carbon atoms, an alkyl group which is substituted by a halogen atom and has 1-8 carbon atoms, or the like

R2 represents a hydrogen atom, an alkyl group having 1-8 carbon atoms or the like

R4, R5, R6 and R7 each represents a hydrogen atom, an alkyl group having 1-8 carbon atoms or the like

X represents a nitrogen atom or the like

Y represents an oxygen atom or the like

Z represents an oxygen atom, a sulfur atom, a bonding hand or the like

p represents 1 or 2

m represents an integer of 1-4

and n represents an integer of 0-4.)

Priority: JP20090234600 Applic. Date: 2009-10-08

Inventor: SAKUMA SHOGO [JP]; KOBAYASHI KUNIO [JP]


Publication No.: WO2011045471A1  Published: 21/Apr/2011

Title: COMPOSITIONS AND METHODS AND USES RELATED THERETO

Applicant/Assignee: VALIO LTD

Application No.: FI2010/050792   Filing Date: 13/Oct/2010

Abstract:The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to a composition comprising probiotics consisting of Lactobacillus rhamnosus LC70 alone or Lactobacillus rhamnosus GG and Lactobacillus rhamnosus LC705.Also the invention relates to the com- position for use as a medicament. Furthermore, the present invention relates to uses of Lactobacillus rhamnosus LC705 alone or together with Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection and for intensifying resistance against viruses causing respiratory infections in a subject. Furthermore, the present invention describes uses of Lactobacillus rhamnosus GG for the manufacture of a composition for the treatment and/or prevention of a respiratory infection in an adult and for intensifying resistance against viruses causing respiratory infections in an adult subject. Still, the present invention relates to uses of Lactobacillus rhamnosus for the manufacture of a composition for reducing, delaying or inhibiting influenza virus replication and for increasing antiviral cytokine(s) in a subject to be or being infected with a respiratory infection. Still, the present invention relates to methods of treating or preventing a respiratory infection in a subject or in an adult subject, intensifying resistance against viruses causing respiratory infections in a subject or in an adult subject, reducing, delaying or inhibiting influenza virus replication in a subject and increasing antiviral cytokine(s) in a subject to be or being infected with a respiratory infection.

Priority: FI20090006058 Applic. Date: 2009-10-13

Inventor: KEKKONEN RIINA [FI]; MIETTINEN MINJA [FI]


Publication No.: WO2011045557A1  Published: 21/Apr/2011

Title: COMPOSITIONS OF BOTANICAL EXTRACTS AND THEIR USE

Applicant/Assignee: UNION OF AGRICULTURAL COOPERATIVES OF RETHYMNO, TOWLER, PHILIP DEAN

Application No.: GB2010/001836   Filing Date: 29/Sep/2010

Abstract:The invention relates to compositions of extracts of the following plants: (a) Coridothymus capitatus

(b) Origanum dictamnus

and (c) at least one of Salvia fruticosa or Salvia pomifera. The compositions may additionally comprise one or more pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The said extracts are obtainable by hydro-alcoholic extraction and/or by hydro-distillation of the plant leaves. The compositions of the invention extracts are useful for treating, preventing or ameliorating the symptoms of microbial or viral infections of the upper respiratory tract, including, but not limited to, influenza viruses, notably type A/HI Nl species, rhinovirus, coronavirus and human respiratory syncytial virus.

Priority: GB20090017086 Applic. Date: 2009-09-29

Inventor: CASTANAS ELIAS [GR]; PIRINTSOS STERGIOS [GR]; LIONIS CHRISTOS [GR]


Publication No.: WO2011045593A1  Published: 21/Apr/2011

Title: NOVEL MACROCYLES AND METHODS FOR THEIR PRODUCTION

Applicant/Assignee: BIOTICA TECHNOLOGY LIMITED

Application No.: GB2010/051713   Filing Date: 12/Oct/2010

Abstract:There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R3 are as described in the description, said compounds being useful as anti-inflammatory agents with reduced systemic effects.

Priority: GB20090017816 Applic. Date: 2009-10-12

Inventor: MOSS STEVEN JAMES [GB]; GREGORY MATTHEW ALAN [GB]; ZHANG MING-QIANG [CN]


Publication No.: WO2011045594A1  Published: 21/Apr/2011

Title: NOVEL MACROCYCLES AND METHODS FOR THEIR PRODUCTION

Applicant/Assignee: BIOTICA TECHNOLOGY LIMITED

Application No.: GB2010/051714   Filing Date: 12/Oct/2010

Abstract:There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R4 and X are as described in the description, said compounds being useful as anti-inflammatory agents with reduced system effect.

Priority: GB20090017817 Applic. Date: 2009-10-12

Inventor: MOSS STEVEN JAMES [GB]; GREGORY MATTHEW ALAN [GB]; ZHANG MING-QIANG [CN]


Publication No.: WO2011045740A2  Published: 21/Apr/2011

Title: METHODS OF PHOTOPROTECTING A MATERIAL AGAINST SOLAR UV RADIATION USING PHOTONIC PARTICLES

Applicant/Assignee: L'OREAL

Application No.: IB2010/054609   Filing Date: 12/Oct/2010

Abstract:The present invention provides a method of photoprotecting a material against solar UV radiation, consisting in treating said material using a composition comprising a dispersion of photonic particles with a mean size in the range 1 [mu]m to 500 [mu]m, each comprising a diffracting arrangement of monodisperse nanoparticles or voids, the diffraction spectrum of said arrangement including a first order reflection peak in the wavelength range 250 nm to 400 nm, or consisting in integrating said dispersion of photonic particles into said material. In particular, the present invention provides methods of photoprotecting materials such as paints, inks, coatings, materials manufactured from polymers, or fibrous materials such as textiles, papers, or organic or mineral glasses.

Priority: FR20090057134 Applic. Date: 2009-10-12; US20090256152P Applic. Date: 2009-10-29; FR20100051141 Applic. Date: 2010-02-17; US20100306319P Applic. Date: 2010-02-19

Inventor: SIMONNET JEAN-THIERRY [FR]; LUCET-LEVANNIER KARINE [FR]


Publication No.: WO2011045741A2  Published: 21/Apr/2011

Title: PHOTONIC PARTICLES

Applicant/Assignee: L'OREAL

Application No.: IB2010/054610   Filing Date: 12/Oct/2010

Abstract:The present invention provides photonic particles (1) with a mean size in the range 1 [mu]m to 500 [mu]m, in particular in the range 1 [mu]m to 300 [mu]m, comprising a diffracting arrangement of hollow nanoparticles (10), as well as compositions containing a dispersion of said particles. The present invention also provides a method of photo protecting human keratins material against solar UV radiation. The present invention also provides methods of photo protecting industrial materials such as paints, inks, coatings, materials manufactured from polymers, or fibrous materials such as textiles, papers, or organic or mineral glasses.

Priority: FR20090057133 Applic. Date: 2009-10-12; US20090257094P Applic. Date: 2009-11-02; FR20100051144 Applic. Date: 2010-02-17; US20100306329P Applic. Date: 2010-02-19

Inventor: SIMONNET JEAN-THIERRY [FR]; LUCET-LEVANNIER KARINE [FR]


Publication No.: WO2011046179A1  Published: 21/Apr/2011

Title: COMPOSITION FOR ORAL CAVITY

Applicant/Assignee: SUNSTAR INC

Application No.: JP2010/068070   Filing Date: 14/Oct/2010

Abstract:Disclosed is a composition for the oral cavity, which has high stain removal efficiency relative to the polishing power. Specifically disclosed is a composition for the oral cavity, which contains fused silica and a tooth polishing agent. The composition for the oral cavity has high stain removal power relative to the polishing power. In other words, the composition for the oral cavity has a high (stain removal power)/(polishing power) value. Consequently, by using the composition for the oral cavity, stain can be efficiently removed from a tooth without unnecessarily damaging the tooth.

Priority: JP20090237785 Applic. Date: 2009-10-14; JP20100099954 Applic. Date: 2010-04-23

Inventor: SAKAMOTO HIROSHI [JP]


Publication No.: WO2011046200A1  Published: 21/Apr/2011

Title: ANTIINFLAMMATORY AGENT COMPRISING DIFFERENTIATION-INDUCING FACTOR OR ANALOG THEREOF

Applicant/Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Application No.: JP2010/068157   Filing Date: 15/Oct/2010

Abstract:Provided is a composition to be used as drugs, foods or cosmetics efficacious for treating inflammation and/or tumor, which has a novel mechanism of action and shows fewer side effects. The composition comprises a clinically effective amount of a compound belonging to the DIF family or a salt thereof that is acceptable for using in drugs, foods or cosmetics, together with an excipient or carrier that is acceptable for using in drugs, foods or cosmetics.

Priority: JP20090238935 Applic. Date: 2009-10-16

Inventor: TAKAHASHI FUMI [JP]; SASAGURI TOSHIYUKI [JP]


Publication No.: WO2011046997A1  Published: 21/Apr/2011

Title: CGRP RECEPTOR ANTAGONISTS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: US2010/052433   Filing Date: 13/Oct/2010

Abstract:The disclosure generally relates to the novel compounds of formula (I), including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

Priority: US20090251477P Applic. Date: 2009-10-14

Inventor: LUO GUANGLIN [US]; DUBOWCHIK GENE M [US]; MACOR JOHN E [US]


Publication No.: WO2011047227A2  Published: 21/Apr/2011

Title: WATER SOLUBLE DRUG-SOLUBILIZER POWDERS AND THEIR USES

Applicant/Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

Application No.: US2010/052786   Filing Date: 15/Oct/2010

Abstract:Enhanced methods have been discovered, using either sonication or homogenization followed by increased temperature and pressure, to solubilize compounds using diterpene glycosides and to produce a powder form of the compound-solubilizer complex than can be reconstituted in water. Without the diterpene glycoside, the compounds were insoluble or sparingly soluble in water, including some fat-insoluble vitamins. Water solutions of these compounds were made using a diterpene glycoside solubilizer, for example, rubusoside. The compound-solubilizer complex was then dehydrated to a stable powder that could then be reconstituted with water. A reconstituted drug-solubilizer complex (curcumin-rubusoside) was shown to be effective on reconstitution.

In addition, the diterpene glycoside, rubusoside, was shown to be an inhibitor of permeability glycoprotein (P-gp), and will thus increase gastrointestinal absorption of certain drugs administered with rubusoside.

Priority: US20090251768P Applic. Date: 2009-10-15; US20100314800P Applic. Date: 2010-03-17

Inventor: LIU ZHIJUN [US]


Publication No.: WO2011047432A1  Published: 28/Apr/2011

Title: FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS

Applicant/Assignee: FIBROTECH THERAPEUTICS PTY LTD

Application No.: AU2010/001398   Filing Date: 21/Oct/2010

Abstract:The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.

Priority: US20090253889P Applic. Date: 2009-10-22

Inventor: WILLIAMS SPENCER JOHN [AU]; ZAMMIT STEVEN [AU]; KELLY DARREN JAMES [AU]


Publication No.: WO2011047770A2  Published: 28/Apr/2011

Title: PYRAZOLOPYRIMIDINE DERIVATIVES

Applicant/Assignee: MERCK PATENT GMBH

Application No.: EP2010/005858   Filing Date: 24/Sep/2010

Abstract:The invention relates to compounds of the formula (I), where X, R1, and R2 have the meanings specified in claim 1, are PI3K inhibitors, and can be used, inter alia, to treat autoimmune diseases, inflammations, cardiovascular diseases, neurodegenerative diseases, and tumors.

Priority: DE200910049679 Applic. Date: 2009-10-19

Inventor: BUCHSTALLER HANS-PETER [DE]; EMDE ULRICH [DE]; KLEIN MARKUS [DE]; ESDAR CHRISTINA [DE]; BOMKE JOERG [DE]


Publication No.: WO2011048004A1  Published: 28/Apr/2011

Title: INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: EP2010/065414   Filing Date: 14/Oct/2010

Abstract:This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions such as inflammatory/nociceptive pain. A, M, R1, R2, R7' Ra, Rb, Q3, Q4, Q6, Z2, Z4, Z5, Z6 and W have meanings given in the description.

Priority: EP20090173872 Applic. Date: 2009-10-23

Inventor: PRIEPKE HENNING [DE]; DOODS HENRI [DE]; KUELZER RAIMUND [DE]; PFAU ROLAND [DE]; STENKAMP DIRK [DE]; ROENN ROBERT [SE]; PELCMAN BENJAMIN [SE]


Publication No.: WO2011048111A1  Published: 28/Apr/2011

Title: COMPOUNDS

Applicant/Assignee: RESPIVERT LIMITED

Application No.: EP2010/065746   Filing Date: 19/Oct/2010

Abstract:The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their 10 compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

Priority: GB20090018249 Applic. Date: 2009-10-19

Inventor: KING-UNDERWOOD JOHN [GB]; ITO KAZUHIRO [GB]; MURRAY PETER JOHN [GB]; HARDY GEORGE [GB]; BROOKFIELD FREDERICK ARTHUR [GB]; BROWN CHRISTOPHER JOHN [GB]


Publication No.: WO2011048350A1  Published: 28/Apr/2011

Title: TREATMENT USING REPROGRAMMED MATURE ADULT CELLS

Applicant/Assignee: TRISTEM TRADING (CYPRUS) LIMITED

Application No.: GB2009/051396   Filing Date: 19/Oct/2009

Abstract:A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

Priority:

Inventor: ABULJADAYEL ILHAM MOHAMMED SALEH SAEED [GB]


Publication No.: WO2011048409A1  Published: 28/Apr/2011

Title: CYCLIC AMINE DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Applicant/Assignee: ASTRAZENECA AB, PULMAGEN THERAPEUTICS (SYNERGY) LIMITED

Application No.: GB2010/051751   Filing Date: 18/Oct/2010

Abstract:Compounds of formula (I) having activities at muscarinic and ss2-receptors (MABAs) for use in therapy.

Priority: GB20090018322 Applic. Date: 2009-10-20; GB20100009803 Applic. Date: 2010-06-11

Inventor: DONALD DAVID KEITH [GB]; JENNINGS ANDREW STEPHEN ROBERT [GB]; RAY NICHOLAS CHARLES [GB]; ROUSSEL FABIEN [GB]; SUTTON JONATHAN MARK [GB]; TISSELLI PATRIZIA [GB]; WILSON MICHELLE [GB]


Publication No.: WO2011048936A1  Published: 28/Apr/2011

Title: AMINOTHIAZOLE DERIVATIVE

Applicant/Assignee: TAISHO PHARMACEUTICAL CO., LTD

Application No.: JP2010/067383   Filing Date: 04/Oct/2010

Abstract:A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase ? inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Priority: JP20090240008 Applic. Date: 2009-10-19

Inventor: YABUUCHI TETSUYA [JP]; OKA YUSUKE [JP]; KURODA SHOICHI [JP]; OI TAKAHIRO [JP]; SEKIGUCHI YOSHINORI [JP]


Publication No.: WO2011049053A1  Published: 28/Apr/2011

Title: INTESTINAL MUCOSA-INHERENT MYELOID CELLS INHIBITING T CELL ACTIVATION AND UTILIZATION OF SAME

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: JP2010/068305   Filing Date: 19/Oct/2010

Abstract:It was discovered that myeloid cells, which occurs in the lamina propria of healthy animals and are highly positive to Gr-1, positive to CD11b and positive to CD11c, can induce T cell apoptosis and, in its turn, inhibit T cell activation. These myeloid cells are highly useful as the active ingredient of an immunomodulator that is applicable to the prevention or treatment of inflammatory bowel disease and so on.

Priority: JP20090241034 Applic. Date: 2009-10-20

Inventor: TAKEDA KIYOSHI [JP]; KAYAMA HISAKO [JP]


Publication No.: WO2011049539A1  Published: 28/Apr/2011

Title: COMPOSITIONS COMPRISING A CORTICOSTEROID, A BETA2 AGONIST AS WELL AS CROMOGLICIC ACID OR NDEOCROMIL

Applicant/Assignee:

Application No.: TR2010/000208   Filing Date: 20/Oct/2010

Abstract:The present invention relates to a pharmaceutical composition for use in the treatment of respiratory diseases, characterized in that said composition comprises a pharmaceutically effective amount of cromoglicic acid and/or nedocromil salts besides ss2-agonists and corticosteroid drugs.

Priority: TR20090007914 Applic. Date: 2009-10-20

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2011050220A1  Published: 28/Apr/2011

Title: SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: US2010/053633   Filing Date: 21/Oct/2010

Abstract:The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith.

Priority: US20090254614P Applic. Date: 2009-10-23

Inventor: ZHANG BEILI [US]; KRAWIEC MARIUSZ [US]; LUISI BRIAN [US]; MEDEK ALES [US]


Publication No.: WO2011050325A1  Published: 28/Apr/2011

Title: COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: US2010/053852   Filing Date: 22/Oct/2010

Abstract:The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one compound of Formula I, Formula II, or Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Priority: US20090254180P Applic. Date: 2009-10-22

Inventor: VAN GOOR FREDRICK F [US]; BURTON WILLIAM LAWRENCE [US]


Publication No.: WO2011050590A1  Published: 05/May/2011

Title: POLYMORPH OF 3-(SUBSTITUTEDDIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND PHARMACEUTICAL COMPOSITIONS THEREOF

Applicant/Assignee: NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO.,LTD

Application No.: CN2010/001751   Filing Date: 02/Nov/2010

Abstract:The present invention provides polymorph of 3-(4-amino-1-oxo-1,3- dihydro-2H-isoindole-2-yl)-piperidine-2,6-dione, and also the preparing methods and pharmaceutical compositions thereof.

Priority: CN20091210392 Applic. Date: 2009-11-02

Inventor: YAN RONG [CN]; YANG HAO [CN]; XU YONGXIANG [CN]


Publication No.: WO2011051375A1  Published: 05/May/2011

Title: 2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Applicant/Assignee: DOMPE S.P.A

Application No.: EP2010/066324   Filing Date: 28/Oct/2010

Abstract:(R,S) 2-aryl-propionamide derivatives, or their single enantiomers (R) and (S) are disclosed useful in the treatment or prevention of symptoms and disorders such as pain and inflammation associated with the bradykinin B1 pathway.

Priority: EP20090174390 Applic. Date: 2009-10-28

Inventor: BECCARI ANDREA [IT]; ARAMINI ANDREA [IT]; BIANCHINI GIANLUCA [IT]; MORICONI ALESSIO [IT]


Publication No.: WO2011051671A1  Published: 05/May/2011

Title: AMINOPYRIDINE DERIVATIVES AS KALLIKREIN INHIBITORS

Applicant/Assignee: VANTIA LIMITED

Application No.: GB2010/001996   Filing Date: 27/Oct/2010

Abstract:The present invention provides compounds of formula (I): compositions comprising such compounds

the use of such compounds in therapy (such as asthma or COPD)

and methods of treating patients with such compounds

wherein R1 - R10 and A1 are as defined herein.

Priority: GB20090018922 Applic. Date: 2009-10-28; US20090255606P Applic. Date: 2009-10-28

Inventor: EVANS DAVID MICHAEL [GB]; ALLAN CHRISTINE ELIZABETH [GB]


Publication No.: WO2011051672A1  Published: 05/May/2011

Title: AZAINDOLE DERIVATIVES

Applicant/Assignee: VANTIA LIMITED

Application No.: GB2010/001997   Filing Date: 27/Oct/2010

Abstract:The present invention provides compounds of formula (I): compositions comprising such compounds

the use of such compounds in therapy (such as asthma or COPD)

and methods of treating patients with such compounds

wherein R1 to R20 and A1 are as defined herein.

Priority: GB20090018924 Applic. Date: 2009-10-28; US20090255610P Applic. Date: 2009-10-28

Inventor: EVANS DAVID MICHAEL [GB]; ALLAN CHRISTINE ELIZABETH [GB]


Publication No.: WO2011051673A1  Published: 05/May/2011

Title: AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS

Applicant/Assignee: VANTIA LIMITED

Application No.: GB2010/001998   Filing Date: 27/Oct/2010

Abstract:The present invention provides compounds of formula (I): compositions comprising such compounds

the use of such compounds in therapy (such as asthma or COPD)

and methods of treating patients which such compounds

wherein R1 to R17 and A1 are as defined herein.

Priority: GB20090018923 Applic. Date: 2009-10-28; US20090255614P Applic. Date: 2009-10-28

Inventor: EVANS DAVID MICHAEL [GB]


Publication No.: WO2011052706A1  Published: 05/May/2011

Title: DRY POWDER INHALER OF TRANILAST HAVING HIGH SOLUBILITY

Applicant/Assignee: KISSEI PHARMACEUTICAL CO., LTD, SHIZUOKA PREFECTURE PUBLIC UNIVERSITIES CORPORATION

Application No.: JP2010/069250   Filing Date: 29/Oct/2010

Abstract:Provided is a dry powder inhaler of tranilast. Specifically disclosed are a dry powder inhaler comprising a solid dispersion, which is obtained by grinding tranilast crystals together with a dispersant and freeze-drying a suspension thereof, and an inhalation carrier, and so on. The aforesaid dry powder inhaler has an improved solubility and such properties as desired for an inhaler, i.e., a high uniformity and a high photostability. Moreover, the dry powder inhaler shows a high lung reaching proportion and, therefore, can exert an excellent effect even in a small dose.

Priority: JP20090249949 Applic. Date: 2009-10-30

Inventor: ONOUE SATOMI [JP]; YAMADA SHIZUO [JP]


Publication No.: WO2011053130A1  Published: 05/May/2011

Title: BOLUS SYSTEM

Applicant/Assignee: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST - NATUURWETENSCHAPPELIJK ONDERZOEK TNO

Application No.: NL2010/050708   Filing Date: 25/Oct/2010

Abstract:Method for installing a bolus system into a stomach or other organ of an animal, comprising the steps of (a) providing at least two boluses (1, 5) comprising magnetic attraction means (4, 6) for mutual attracting each other when present in each other's proximity, (b) administering at least one of the boluses (1) to the animal at a first moment and (c) administering always at least one of the boluses (5) to the animal at later moments. At least one of the boluses administered to the animal at the first moment may include data exchange means (3) and possibly data collection means related to the health of the animal.

Priority: EP20090174031 Applic. Date: 2009-10-26

Inventor: SEWALT KARL EVERHARDUS [NL]; VAN TILBURG MARK WILHELMUS THERESIA [NL]


Publication No.: WO2011053273A1  Published: 05/May/2011

Title: ORAL COMPOSITION FOR TREATING ORAL MALODOR

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2009/062017   Filing Date: 26/Oct/2009

Abstract:Disclosed are oral care compositions and the use of such oral care compositions for treating or preventing oral malodor. Also disclosed are methods for treatment or prevention of oral malodor. The oral care compositions include serine in an amount effective to reduce oral malodor caused by hydrogen sulfide and/or indole.

Priority:

Inventor: PILCH SHIRA [US]; MASTERS JIM [US]; WON BETTY [US]


Publication No.: WO2011053291A1  Published: 05/May/2011

Title: DENTIFRICE COMPRISING STANNOUS FLUORIDE PLUS ZINC CITRATE AND LOW LEVELS OF WATER

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2009/062452   Filing Date: 29/Oct/2009

Abstract:A dentifrice composition having a low water phase comprising effective amounts of polyphosphate and ionic active ingredients.

Priority:

Inventor: FRUGE LINH [US]; FISHER STEVEN WADE [US]; PRENCIPE MICHAEL [US]


Publication No.: WO2011054301A1  Published: 12/May/2011

Title: USE OF DANSHENSU, NOTOGINSENOSIDE R1 OR THEIR COMBINATION IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING DISEASES CAUSED BY MICROCIRCULATION DISORDER

Applicant/Assignee: TIANJIN TASLY PHARMACEUTICAL CO., LTD

Application No.: CN2010/078411   Filing Date: 04/Nov/2010

Abstract:Use of danshensu, notoginsenoside R1 or their combination in the preparation of medicaments for preventing and treating diseases caused by microcirculation disorder.

Priority: CN20091071163 Applic. Date: 2009-11-05

Inventor: HAN JINGYAN [CN]; GUO JUN [CN]; YANG JIYING [CN]; SUN KAI [CN]; WANG MINGXIA [CN]; ZHANG YU [CN]; LIU YUYING [CN]


Publication No.: WO2011054399A1  Published: 12/May/2011

Title: IMPROVEMENT OF THE GLUCOCORTICOID RECEPTOR FUNCTION IN ASTHMA

Applicant/Assignee: AVAIL GMBH

Application No.: EP2009/064784   Filing Date: 06/Nov/2009

Abstract:The impaired function of the glucocorticoid receptor in the bronchial epithelial cells of some asthmatic patients and agents that restore an efficient glucocorticoid receptor signalling in these cells, resulting in an efficient inhibition of the expression of pro-inflammatory chemokines and cytokines, as well as corresponding methods of using said agents and the use of said agents for manufacturing corresponding medicaments are described. In particular, agents that reduce the intracellular availability of functionally active FKBP51 and, respectively, a method for using said agents and, respectively, the use of said agents for manufacturing corresponding medicaments are described, said agents and, respectively, methods and, respectively, medicaments increase the responsiveness to anti-inflammatory treatment with glucocorticoids in patients with glucocorticoid-hyporesponsive or resistant asthma.

Priority:

Inventor: MATTOLI SABRINA [CH]


Publication No.: WO2011054631A1  Published: 12/May/2011

Title: METHOD FOR PRODUCING A CARNOSIC ACID-RICH PLANT EXTRACT

Applicant/Assignee: EVONIK DEGUSSA GMBH

Application No.: EP2010/065268   Filing Date: 12/Oct/2010

Abstract:A carnosic acid-rich plant extract can be produced by extracting a dried and comminuted plant material containing carnosic acid with supercritical CO2 at a pressure of at least 200 bar and at a temperature of at most 100 DEG C. In a first step, supercritical CO2 in a quantity of 10 to 50 kg of CO2 per kg of plant material is passed through the plant material to obtain a first CO2 extract. In a second step, additional supercritical CO2 is passed through the plant material to obtain a second CO2 extract, and a carnosic acid-rich plant extract is separated from the second CO2 extract by lowering the pressure.

Priority: DE200910045994 Applic. Date: 2009-10-26

Inventor: WIESMUELLER JOHANN [DE]; MICHLBAUER FRANZ [DE]; KAHLEYSS RALF [DE]; HAUSNER HELMUT [DE]


Publication No.: WO2011055270A1  Published: 12/May/2011

Title: INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS

Applicant/Assignee: WYETH LLC

Application No.: IB2010/054845   Filing Date: 26/Oct/2010

Abstract:Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.

Priority: US20090257975P Applic. Date: 2009-11-04

Inventor: FOLLOWS BRUCE CHRISTOPHER [US]; HUANG ADRIAN [US]; JANZ KRISTIN MARIE [US]; KAILA NEELU [US]; LOWE MICHAEL DENNIS [US]; MANSOUR TAREK SUHAYL [US]; MORETTO ALESSANDRO FABIO [US]; SAIAH EDDINE [US]; THOMASON JENNIFER ROMANIC [US]; WILLIAMS CARA MARGARET MAY [US]


Publication No.: WO2011055391A1  Published: 12/May/2011

Title: SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF

Applicant/Assignee: ADVINUS THERAPEUTICS PRIVATE LIMITED

Application No.: IN2010/000732   Filing Date: 09/Nov/2010

Abstract:The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides process of preparation of formula (I).

Priority: IN2009CH02720 Applic. Date: 2009-11-09

Inventor: RAMDAS VIDYA [IN]; KOUL SUMMON [IN]; BASU SUJAY [IN]; WAMAN YOGESH [IN]; SHEJUL YOGESH [IN]; BARAWKAR DINESH [IN]; PALLE VENKATA POORNAPRAGNACHARYULU [IN]


Publication No.: WO2011055706A1  Published: 12/May/2011

Title: DENTIFRICE COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/069422   Filing Date: 01/Nov/2010

Abstract:Disclosed is a dentifrice composition which has an excellent bactericidal effect on biofilms and free-floating bacteria in the oral cavity and is capable of effectively destroying pathogenic bacteria in the oral cavity. The dentifrice composition is reduced in the unpleasant taste peculiar to isopropyl methyl phenol, while producing less irritation to the oral mucosa and providing excellent feeling of use. Specifically disclosed is a dentifrice composition which is characterized by containing (A) isopropyl methyl phenol, (B) triclosan, (C) a pyrophosphate and/or a tripolyphosphate and (D) at least one fragrance material selected from among 3-octanol, 3-octyl acetate, 3-octanone and fenchone. The dentifrice composition is also characterized in that the amount of the component (C) contained therein is within the range of 0.10-2.0% by mass. The dentifrice composition additionally contains (E) anisaldehyde.

Priority: JP20090255173 Applic. Date: 2009-11-06

Inventor: CHIKAZAWA TAKASHI [JP]; AMANO AYUMI [JP]; HIRAYAMA TAKASHI [JP]


Publication No.: WO2011055707A1  Published: 12/May/2011

Title: DENTIFRICE COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/069428   Filing Date: 01/Nov/2010

Abstract:Disclosed is a dentifrice composition which exhibits high local retention properties for a preparation in the oral cavity, while having an excellent bactericidal effect on oral biofilms. The dentifrice composition has a flavor that is almost free from unpleasant taste and excellent feeling of use, while being suppressed in stickiness. Specifically disclosed is a dentifrice composition which is characterized by containing (A) isopropyl methyl phenol, (B) at least one fragrance material selected from among 3-octanol, 3-octyl acetate, 3-octanone and fenchone, (C) sorbit, (D) glycerin and (E) a polyethylene glycol that has an average molecular weight of 280-9,300. The dentifrice composition additionally contains (F) anisaldehyde.

Priority: JP20090255181 Applic. Date: 2009-11-06

Inventor: YAMAMOTO KOJI [JP]; HIRAYAMA TAKASHI [JP]; AMANO AYUMI [JP]


Publication No.: WO2011055708A1  Published: 12/May/2011

Title: ISOPROPYL METHYL PHENOL-CONTAINING LIQUID COMPOSITION FOR ORAL CAVITY

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/069429   Filing Date: 01/Nov/2010

Abstract:Disclosed is a liquid composition for the oral cavity which contains isopropyl methyl phenol. The isopropyl methyl phenol-containing liquid composition for the oral cavity is contains (A) a nonionic surfactant, (B) a wetting agent selected from among glycerin, propylene glycol, polyethylene glycols and sorbitol, (C) 1-menthol, (D) a para-hydroxybenzoate and (E) a fragrance material selected from among 3-octanol, 3-octyl acetate, 3-octanone and fenchone. The total amount of component (B) contained in the composition is 5-20% by mass of the total mass of the composition, and substantially no ethanol is contained in the composition. The composition exhibits high penetration and high bactericidal effect on periodontal disease-causing biofilms, is free from the unpleasant taste caused by isopropyl methyl phenol, and has excellent feeling of use and good appearance stability.

Priority: JP20090255191 Applic. Date: 2009-11-06

Inventor: ISHIGURO KEIJI [JP]; HIRAYAMA TAKASHI [JP]; IKENISHI TAKAKI [JP]


Publication No.: WO2011055709A1  Published: 12/May/2011

Title: DENTIFRICE COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/069431   Filing Date: 01/Nov/2010

Abstract:Disclosed is a dentifrice composition which exhibits excellent bactericidal effect on biofilms, while having excellent hyperesthesia suppressing activity. The dentifrice composition is free from unpleasant taste and provides excellent feeling of use. Specifically disclosed is a dentifrice composition which is characterized by containing (A) isopropyl methyl phenol, (B) one or more substances selected from among potassium nitrate, aluminum lactate and strontium chloride, (C) one or more fragrance material components selected from among 3-octanol, 3-octyl acetate, 3-octanone and fenchone, and (D) an anionic surfactant and/or a nonionic surfactant. The dentifrice composition additionally contains (E) anisaldehyde.

Priority: JP20090255195 Applic. Date: 2009-11-06

Inventor: NAKAMURA AKIRA [JP]; AMANO AYUMI [JP]; HIRAYAMA TAKASHI [JP]


Publication No.: WO2011056234A1  Published: 12/May/2011

Title: TREATMENT FOR RADIATION-INDUCED DISORDERS

Applicant/Assignee: FIBROGEN, INC

Application No.: US2010/002922   Filing Date: 08/Nov/2010

Abstract:The present invention relates to methods and medicaments useful for treatment of radiation-induced disorders by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments for pre-treating individuals having or at risk for having exposure to ionizing radiation to prevent or reduce radiation-induced disorders are also provided.

Priority: US20090280634P Applic. Date: 2009-11-06

Inventor: LIPSON KENNETH E [US]


Publication No.: WO2011056327A1  Published: 12/May/2011

Title: OMEGA POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF ORAL DISEASES

Applicant/Assignee:

Application No.: US2010/050891   Filing Date: 30/Sep/2010

Abstract:The invention discloses a novel discovery of anti-microbial activity against oral bacteria, which can be applied for controlling and preventing oral diseases, of omega-3, omega-6, and omega-9 fatty acids, but not limited to omega-3, omega-6, and omega-9 fatty acids

omega-3, omega-6, and omega-9 fatty acid methyl esters, and omega-3, omega-6, omega-9 fatty acid ethyl esters and their application method. The application of this discovery includes the preparation of drugs, dietary supplements, food and daily necessities with oral health care and therapeutic effects.

Priority: US2009-606257 Applic. Date: 2009-10-27

Inventor: HUANG CHIFU [US]


Publication No.: WO2011056477A2  Published: 12/May/2011

Title: METHODS FOR TREATING INFLAMMATION AND OXIDATIVE STRESS RELATED DISEASES

Applicant/Assignee:

Application No.: US2010/053777   Filing Date: 22/Oct/2010

Abstract:This invention provides compositions and methods for treating inflammation related diseases. Particularly, the present invention provides methods and compositions of administering thiocyanate to treat inflammation related diseases, such as cystic fibrosis, lung disease, lung cancer, asthma, bronchitis, pancreatic disease, digestive track disease, diabetes, neurological disorder, cardio-vascular disease, atherosclerosis, arthritis, nephritis, or stroke, and neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or autism. The invention provides the use of thiocyanate to diagnose inflammation related diseases.

Priority: US20090255030P Applic. Date: 2009-10-26

Inventor: LU ZHE [US]


Publication No.: WO2011056511A2  Published: 12/May/2011

Title: 4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2010/053969   Filing Date: 25/Oct/2010

Abstract:The present invention relates to new 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090254812P Applic. Date: 2009-10-26

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Publication No.: WO2011056748A2  Published: 12/May/2011

Title: ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/054956   Filing Date: 01/Nov/2010

Abstract:An oral care composition for the treatment of dry mouth comprising a polyethylene oxide with a molecular weight from about 200,000 to about 7,000,000, an anti-bacterial agent, and a sensate.

Priority: US20090257677P Applic. Date: 2009-11-03; US2010-914669 Applic. Date: 2010-10-28

Inventor: SCOTT DOUGLAS CRAIG [US]; SALLOUM DAVID S [US]; SNIDER ANN GILLIGAN [US]; JOHNSON CHRISTINE LULA [US]


Publication No.: WO2011056759A2  Published: 12/May/2011

Title: ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/055027   Filing Date: 02/Nov/2010

Abstract:An oral care composition for the treatment of dry mouth comprising a polyethylene oxide with a molecular weight from about 200,000 to about 7,000,000, an anti-bacterial agent, and a sensate.

Priority: US20090257672P Applic. Date: 2009-11-03; US2010-914609 Applic. Date: 2010-10-28

Inventor: SALLOUM DAVID S [US]; SCOTT DOUGLAS CRAIG [US]; WHITE DONALD JAMES JR [US]; HAUGHT JOHN CHRISTIAN [US]; HO BEGONIA Y [US]; KLUKOWSKA MALGORZATA [US]


Publication No.: WO2011057336A1  Published: 19/May/2011

Title: ANTIBIOFILM GLYCOPEPTIDES

Applicant/Assignee: ORAL HEALTH AUSTRALIA PTY LTD

Application No.: AU2010/001506   Filing Date: 11/Nov/2010

Abstract:The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia.

Priority: AU20090905526 Applic. Date: 2009-11-11

Inventor: REYNOLDS ERIC CHARLES [AU]; DASHPER STUART GEOFFREY [AU]


Publication No.: WO2011057872A1  Published: 19/May/2011

Title: HEALTH-BENEFICIAL PREPARATION AND PRODUCTION METHOD

Applicant/Assignee: BASF SE

Application No.: EP2010/065180   Filing Date: 11/Oct/2010

Abstract:The invention relates to the area of health-beneficial preparations and the production methods thereof, in particular to the use of thermally pre-treated lactobacillus preparations having specific bonding capacity for streptococcus mutans for caries prophylaxis. Independent claims according to the invention are directed to the lactobacillus preparations and thermal pasteurization.

Priority: EP20090014070 Applic. Date: 2009-11-10

Inventor: BRYAN COOPER [DE]


Publication No.: WO2011058346A1  Published: 19/May/2011

Title: TREATMENT OF MICROBIAL INFECTIONS

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: GB2010/051858   Filing Date: 09/Nov/2010

Abstract:The invention provides compositions, medicaments and methods of treating microbial infections, and especially respiratory disorders caused by microbial infections. In particular, the invention relates to the treatment of respiratory diseases caused by pathogenic infections using certain either alkyl substituted or un-substituted 2-aryl acetic acid, or 2-aryl, N-hydroxyacetamide derivatives, or pentoxifylline, and to the use of these compounds in methods of treatment.

Priority: GB20090019711 Applic. Date: 2009-11-11; GB20100001837 Applic. Date: 2010-02-04

Inventor: BANNISTER ROBIN MARK [GB]; WANDERLAY WILSON CAPARROS [GB]; BREW JOHN [GB]


Publication No.: WO2011058373A2  Published: 19/May/2011

Title: DRUG COMBINATION WITH THEOBROMINE AND ITS USE IN THERAPY

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: GB2010/051895   Filing Date: 12/Nov/2010

Abstract:An agent comprises theobromine and another non-opiate antitussive, for simultaneous, sequential or separate use in therapy. Preferably, the therapy is of cough.

Priority: GB20090019889 Applic. Date: 2009-11-13

Inventor: BREW JOHN [GB]; BANNISTER ROBIN MARK [GB]


Publication No.: WO2011058374A1  Published: 19/May/2011

Title: DRUG COMBINATION WITH THEOBROMINE AND ITS USE IN THERAPY

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: GB2010/051896   Filing Date: 12/Nov/2010

Abstract:An agent comprises theobromine and an opiate, for simultaneous, sequential or separate use in therapy. Preferably, the therapy is of cough.

Priority: GB20090019893 Applic. Date: 2009-11-13

Inventor: BREW JOHN [GB]; BANNISTER ROBIN MARK [GB]


Publication No.: WO2011058423A2  Published: 19/May/2011

Title: IDENTIFICATION AND CHARACTERIZATION OF NATURAL CHEMICAL ENTITIES BY LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY LC-MS/MS AND USES THEREOF

Applicant/Assignee: AVESTHAGEN LIMITED

Application No.: IB2010/002886   Filing Date: 12/Nov/2010

Abstract:The present invention further relates to extracts which are isolated from Deschampsia antarctica plant, the preparation of such extracts, the medicaments containing said extracts, and the use of these extracts and constituents for the preparation of a medicament.

Priority: IN2009CH02800 Applic. Date: 2009-11-13

Inventor: PATELL VILLOO MORAWALA [IN]; JAIN RENUKA [IN]; SHINDE MANOHAR [IN]; SETTU LAKSMI [IN]


Publication No.: WO2011058764A1  Published: 19/May/2011

Title: GARGLE PREPARATION, AND PROCESS AND APPARATUS FOR PRODUCTION OF SAME

Applicant/Assignee: PERFECT PERIO CO., LTD

Application No.: JP2010/006682   Filing Date: 13/Nov/2010

Abstract:Disclosed is a gargle preparation which can remove viruses that are present adjacent to the pharynx without damaging mucosal cells in the pharynx. Specifically disclosed is a gargle preparation (63) which comprises hypochlorous acid (HClO) and sodium hydrogen carbonate (NaHCO3), has an effective chlorine concentration of 50 to 300 ppm, desirably 50 to 250 ppm, more desirably 50 to 200 ppm, has a pH value of 6.3 to 8 inclusive, desirably 7 to 8 inclusive. The pH value of the gargle preparation (63) can be kept as a whole within a range from 6.3 to 8 in which hypochlorous acid (HClO) can be present at a high concentration, by the action of sodium hydrogen carbonate (NaHCO3). Therefore, when the gargle preparation (63) is put in the oral cavity and the throat is gargled with the gargle preparation (63) for a few seconds to several tens of seconds, viruses present in the pharynx can be removed rapidly by the germicidal action of hypochlorous acid (HClO) contained in the gargle preparation (63) and the safety of the gargle preparation for the human body can be ensured by the buffering action of sodium hydrogen carbonate (NaHCO3).

Priority: JP20090260554 Applic. Date: 2009-11-16

Inventor: NOGUCHI MUNENORI [JP]


Publication No.: WO2011058881A1  Published: 19/May/2011

Title: APPARATUS FOR PRODUCING ULTRAFINE LIQUID DROPLETS

Applicant/Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY

Application No.: JP2010/069104   Filing Date: 27/Oct/2010

Abstract:A disperse phase is micronized steadily into liquid droplets of a uniform droplet size. The apparatus therefor comprises a micro-flow channel unit for joining a first fluid for forming a continuous phase and a second fluid for forming a disperse phase together to flow into a single microflow channel having a fine sectional area, and an ultrasonic vibration-applying unit for applying ultrasonic vibration to a microflow channel of the microflow channel unit. With this apparatus, the driving frequency of the ultrasonic vibration-applying unit is made equl to the resonance frequency of the vibration field formed in the microflow channel to enable formation of an emulsion containing ultrafine liquid droplets of the disperse phase. Thereby, the driving frequency of the ultrasonic vibration-applying unit made equal to the resonance frequency of the microflow channel direction enables generation of a powerful ultrasonic wave by a resonance phenomenon, and application of the powerful ultrasonic wave to the microflow channel enables uniform (homogeneous) mixing of the fluid as the continuous phase and the fluid as the disperse phase of the fluid flowing through the micro flow channel to form an emulsion. The disperse phase can be prepared as ultrafine liquid droplets.

Priority: JP20090260180 Applic. Date: 2009-11-13; JP20100209620 Applic. Date: 2010-09-17

Inventor: KANDA TAKEFUMI [JP]; SUZUMORI KOICHI [JP]; ONO TSUTOMU [JP]; HIGAKI KAZUTAKA [JP]; OGAWARA KENICHI [JP]


Publication No.: WO2011058943A1  Published: 19/May/2011

Title: PHARMACEUTICAL COMPOSITION FORMED FROM COMBINING COMPOUND HAVING MCH R1 ANTAGONIST ACTIVITY AND COMPOUND HAVING NPY Y5 ANTAGONIST ACTIVITY

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/069812   Filing Date: 08/Nov/2010

Abstract:Disclosed is a pharmaceutical composition formed from combining a compound having an MCH receptor antagonist activity or the pharmaceutically acceptable salt thereof or a solvate of said compound and salt with a compound having an NPY Y5 receptor antagonist activity or a pharmaceutically acceptable salt thereof or a solvate of said composition and salt, which exhibits an effect of significantly reducing body weight. Said pharmaceutical composition is useful for treatment or prevention of obesity or obesity related disorders, and for weight management for obese patients.

Priority: JP20090257880 Applic. Date: 2009-11-11

Inventor: YUKIOKA HIDEO [JP]


Publication No.: WO2011059021A1  Published: 19/May/2011

Title: 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/070095   Filing Date: 11/Nov/2010

Abstract:Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1)

R1a and R1b may be the same or different and each independently represents a C1-6 alkyl group which may be substituted by one to three halogen atoms

m and n each independently represents an integer of 0-5

X1 represents a hydroxyl group or an aminocarbonyl group

Z1 represents a single bond or the like

and R2 represents an optionally substituted C1-6 alkyl group, an optionally substituted C6-10 aryl group or the like.)

Priority: JP20090258451 Applic. Date: 2009-11-11; JP20100156263 Applic. Date: 2010-07-08

Inventor: HORIUCHI YOSHIHIRO [JP]; SAWAMURA KIYOTO [JP]; FUJIWARA HIROAKI [JP]


Publication No.: WO2011059080A1  Published: 19/May/2011

Title: ISOTOPE-SUBSTITUTED DIAMINE DERIVATIVE

Applicant/Assignee: DAIICHI SANKYO COMPANY,LIMITED

Application No.: JP2010/070261   Filing Date: 15/Nov/2010

Abstract:Disclosed is an isotope-substituted compound which has an inhibitory activity on activated blood coagulation factor X, is useful as an prophylactic and/or therapeutic agent for thrombotic diseases or as a test substance to be used in a test for examining the in vivo pharmacokinetics of a compound represented by formula (II) or the like, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt. Specifically disclosed is N1-(5-chloropyridin-2-yl)-N2-(4- [(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7- tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}- cyclohexyl)ethanediamide substituted by an isotope.

Priority: JP20090260687 Applic. Date: 2009-11-16

Inventor: NAGATA TSUTOMU; YOSHINO TOSHIHARU


Publication No.: WO2011059731A1  Published: 19/May/2011

Title: ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: US2010/054445   Filing Date: 28/Oct/2010

Abstract:The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Priority: US20090256171P Applic. Date: 2009-10-29

Inventor: PARKER MICHAEL H [US]; HLASTA DENNIS J [US]; HUANG YIFANG [US]; REITZ ALLEN B [US]; LAWSON EDWARD C [US]; SHUBERT CARSTEN [US]; STROBEL ERIC [US]; TOUNGE BRETT [US]; WHITE KIMBERLY [US]; WINTERS MICHAEL P [US]; GHOSH SHYAMALI [US]


Publication No.: WO2011060390A2  Published: 19/May/2011

Title: ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR COMPRESSIBLE AND NON-COMPRESSIBLE ACUTE WOUNDS

Applicant/Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK

Application No.: US2010/056758   Filing Date: 15/Nov/2010

Abstract:A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.

Priority: US20090261194P Applic. Date: 2009-11-13

Inventor: DOWLING MATTHEW [US]; RAGHAVAN SRINIVASA R [US]


Publication No.: WO2011060544A1  Published: 26/May/2011

Title: NOVEL FORMULATION OF PHYSIOLOGICAL CHITOSAN-INORGANIC SALT SOLUTION/BLOOD MIXTURES FOR TISSUE REPAIR

Applicant/Assignee: CORPORATION DE L'ECOLE POLYTECHNIQUE DE MONTREAL

Application No.: CA2010/001842   Filing Date: 18/Nov/2010

Abstract:The present description relates to a polymer composition for use in repairing tissue of a patient comprising at least one blood component, a polymer, such as chitosan, and at least one inorganic salt, such as NaCl, method of using the composition and method of preparing the composition.

Priority: US20090262786P Applic. Date: 2009-11-19

Inventor: OUYANG WEI [CA]; BUSCHMANN MICHAEL [CA]; HOEMANN CAROLINE [CA]; LAVERTU MARC [CA]; CHEVRIER ANIK [CA]


Publication No.: WO2011060545A1  Published: 26/May/2011

Title: SPECIFIC BLOOD:CHITOSAN MIXING RATIOS PRODUCING A VISCOUS PASTE-LIKE IMPLANT WITH GOOD HANDLING PROPERTIES FOR TISSUE REPAIR

Applicant/Assignee: CORPORATION DE L'ECOLE POLYTECHNIQUE DE MONTREAL

Application No.: CA2010/001843   Filing Date: 18/Nov/2010

Abstract:The present invention relates to a paste-like polymer composition for use in repairing tissue of a patient which is prepared by combining at least one blood component, a chitosan solution having a chitosan concentration of between about 1.0% w/w to 10.0% w/w and at least one salt, the volume ratio between said blood component and said chitosan solution is between about 4:1 to 1:1.

Priority: US20090262758P Applic. Date: 2009-11-19

Inventor: OUYANG WEI [CA]; BUSCHMANN MICHAEL [CA]; CHEVRIER ANIK [CA]


Publication No.: WO2011060555A1  Published: 26/May/2011

Title: SOLUBLE PHYSIOLOGICAL CHITOSAN FORMULATIONS COMBINED WITH PLATELET-RICH PLASMA (PRP) FOR TISSUE REPAIR

Applicant/Assignee: CORPORATION DE L'ECOLE POLYTECHNIQUE DE MONTREAL

Application No.: CA2010/001858   Filing Date: 19/Nov/2010

Abstract:The present disclosure relates to an activated polymer composition for use in repairing tissue of a patient comprising platelet-rich plasma (PRP), a chitosan solution, a salt such as NaCI or glycerol phosphate, and an activator such as at least one of CaCI2 and a mixture of thrombin/CaCI2.

Priority: US20090262792P Applic. Date: 2009-11-19

Inventor: OUYANG WEI [CA]; BUSCHMANN MICHAEL [CA]; CHEVRIER ANIK [CA]


Publication No.: WO2011061498A2  Published: 26/May/2011

Title: INHALATION SOLUTIONS

Applicant/Assignee: CIPLA LIMITED, CURTIS, PHILIP ANTHONY

Application No.: GB2010/002126   Filing Date: 17/Nov/2010

Abstract:A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure

a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof

and an actuator for actuating discharge of the metered dose to the patient

wherein the actuator includes a discharge orifice having a diameter in the range 0.2 to 0.4 mm

and wherein the pharmaceutical composition comprises an anticholinergic agent and a pharmaceutically acceptable propellant.

Priority: IN2009MU02657 Applic. Date: 2009-11-17

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Publication No.: WO2011062253A1  Published: 26/May/2011

Title: NOVEL FUSED PYRIMIDINE DERIVATIVE

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/070651   Filing Date: 19/Nov/2010

Abstract:Disclosed is a prophylactic and/or therapeutic agent for diseases associated with autoimmunity, immune deficiency diseases or neurodegenerative diseases, said prophylactic and/or therapeutic agent containing a novel fused pyrimidine derivative. Particularly disclosed is a prophylactic and/or therapeutic agent for sepsis.

Priority: JP20090264612 Applic. Date: 2009-11-20

Inventor: ASANO SHIGEHIRO [JP]; KUBOTA KATSUMI [JP]; KASAI MAI [JP]; ISOBE YOSHIAKI [JP]


Publication No.: WO2011064395A2  Published: 03/Jun/2011

Title: INHIBITORS AND ANTAGONISTS OF CALCIUM CHANNELS IN THE TREATMENT OF ASTHMA

Applicant/Assignee: INSERM

Application No.: EP2010/068546   Filing Date: 30/Nov/2010

Abstract:The present invention relates to an inhibitor of CACNA1C and/or CACNA1D gene expression for the treatment and/or the prevention of inflammatory diseases, preferably allergic diseases, and most preferably respiratory allergic diseases. The present invention also relates to a specific antagonist of at least one of the Cav1.2 and Cav1.3 subunits of voltage- dependent L- type calcium channels for the prevention and/or treatment of such inflammatory diseases.

Priority: EP20090306160 Applic. Date: 2009-11-30

Inventor: PELLETIER LUCETTE [FR]; GUERY JEAN-CHARLES [FR]


Publication No.: WO2011064657A2  Published: 03/Jun/2011

Title: QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF

Applicant/Assignee: PROTEOLOGICS, LTD

Application No.: IB2010/003048   Filing Date: 26/Nov/2010

Abstract:Provided are quinazolin-4(3A)-one derivatives, which are inhibitors of the ubiquitin ligase activity of a human polypeptide, particularly to POSH inhibitors, and to compositions and methods for the treatment RING E3 ubiquitin ligase related diseases.

Priority: US20090264741P Applic. Date: 2009-11-27

Inventor: EREZ OMRI [IL]; NAKACHE PHILIPPE [IL]


Publication No.: WO2011064753A1  Published: 03/Jun/2011

Title: PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF A HYDROCORTISONE DERIVATIVE DESIGNATED AS DEINA

Applicant/Assignee:

Application No.: IB2010/055455   Filing Date: 26/Nov/2010

Abstract:The invention relates to the hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3, 5-Dihydroxy-3-(2-hydroxy-acetyl)-3a, 6-dimethyl- 7-oxo-dodecahydro-cyclo- penta[alpha]naphthalen-6-yl] -propionic acid, designated as Deina TM , for use in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.

Priority: IT2009PI00151 Applic. Date: 2009-11-27

Inventor: BARCO GIOVANNI [IT]


Publication No.: WO2011064755A1  Published: 03/Jun/2011

Title: COMPOSITIONS COMPRISING AMINO ACIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Applicant/Assignee: PROFESSIONAL DIETETICS S.R.L

Application No.: IB2010/055459   Filing Date: 26/Nov/2010

Abstract:A composition comprising leucine, isoleucine, valine, threonine and lysine for treating chronic obstructive pulmonary disease.

Priority: IT2009TO00932 Applic. Date: 2009-11-27

Inventor: CONTI FRANCO [IT]; DIOGUARDI FRANCESCO SAVERIO [IT]


Publication No.: WO2011065350A1  Published: 03/Jun/2011

Title: HYDROXYALKYLCELLULOSE MICROPARTICLES

Applicant/Assignee: NIPPON SODA CO., LTD, OHKAWARA KAKOHKI CO., LTD

Application No.: JP2010/070867   Filing Date: 24/Nov/2010

Abstract:Provided is a method for producing hydroxyalkylcellulose microparticles, which comprises generating a pulse shock wave and then supplying an aqueous hydroxyalkylcellulose solution to the pulse shock wave-generation area to thereby grind the aqueous hydroxyalkylcellulose solution and dry the same. According to this production method, hydroxyalkylcellulose microparticles having a volume-average particle diameter of 0.1 [mu]m or more but not more than 15 [mu]m are obtained. By mixing said hydroxyalkylcellulose microparticles with a principal drug and tabletting the mixture thus obtained, a solid preparation having high tensile strength and excellent disintegration properties can be obtained.

Priority: JP20090266821 Applic. Date: 2009-11-24; JP20100135622 Applic. Date: 2010-06-14

Inventor: TAKEUCHI HIROFUMI [JP]; ABE SATORU [JP]; SHIMOTORI TAKESHI [JP]; NEMOTO GENTARO [JP]


Publication No.: WO2011065444A1  Published: 03/Jun/2011

Title: ANTITHROMBOTIC AGENT

Applicant/Assignee: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TAIHO PHARMACEUTICAL CO., LTD

Application No.: JP2010/071058   Filing Date: 25/Nov/2010

Abstract:Disclosed is an antithrombotic agent having few adverse side effects and excellent efficacy. Specifically disclosed is an anti-thrombotic agent comprising, as an active ingredient, (+-)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by formula (1).

Priority: JP20090270185 Applic. Date: 2009-11-27; JP20100077899 Applic. Date: 2010-03-30

Inventor: ISHIDA HIDEYUKI [JP]; KINIWA MAMORU [JP]


Publication No.: WO2011066107A1  Published: 03/Jun/2011

Title: INHALED FOSFOMYCIN/TOBRAMYCIN FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Applicant/Assignee: GILEAD SCIENCES, INC

Application No.: US2010/056256   Filing Date: 10/Nov/2010

Abstract:The present invention provides the use of an aerosol formulation comprising fosfomycin and tobramycin in the treatment of patients with chronic obstructive pulmonary disease (COPD) who are experiencing or are at risk of experiencing acute exacerbations of COPD. Formulations for such use and methods of treating humans with COPD are also provided.

Priority: US20090264160P Applic. Date: 2009-11-24

Inventor: BHATT ELIZABETH PETERS [US]; MACLEOD DAVID LLOYD [US]; MCKEVITT MATTHEW THOMAS [US]; NEWCOMB TERRY GLENN [US]


Publication No.: WO2011066147A2  Published: 03/Jun/2011

Title: NOVEL SALT FORMS OF PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: US2010/056944   Filing Date: 17/Nov/2010

Abstract:Provided are crystalline N-methyl-glucamine and sodium salts of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acetic acid, processes for their preparation, pharmaceutical compositions comprising the salts, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

Priority: US20090263866P Applic. Date: 2009-11-24

Inventor: YANG BING-SHIOU [US]


Publication No.: WO2011066176A1  Published: 03/Jun/2011

Title: PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: US2010/057312   Filing Date: 19/Nov/2010

Abstract:Provided is a process for preparing a choline salt of [4,6-bis(dimethylamino)-2-(4-{ [4- (trifluoromethyl)benzoyl] amino }benzyl)pyrimidin-5-yl] acetic acid. The process of the invention is useful for preparing the salt in purer forms of the salt. Also disclosed is a more pure form of the of choline salt of [4,6-bis(dimethylamino)-2-(4-{ [4- (trifluoromethyl)benzoyl] amino }benzyl)pyrimidin-5-yl] acetic acid.

Priority: US20090263871P Applic. Date: 2009-11-24

Inventor: KRISHNAMURTHY DHILEEP [US]; RODRIGUEZ DEHLI JUAN MANUEL [DE]; SCHUL MICHAEL [DE]; WANG XIAO-JUN [US]; YANG BING-SHIOU [US]


Publication No.: WO2011066506A1  Published: 03/Jun/2011

Title: 2-METHYLENE-19,26-NOR-(20S)-1a-HYDROXYVITAMIN D3

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: US2010/058208   Filing Date: 29/Nov/2010

Abstract:Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

Priority: US20090264990P Applic. Date: 2009-11-30

Inventor: DELUCA HECTOR F [US]; GRZYWACZ PAWEL [US]; PLUM LORI A [US]; CLAGETT-DAME MARGARET [US]


Publication No.: WO2011066681A1  Published: 09/Jun/2011

Title: HUMAN HIGH METASTATIC NASOPHARYNGEAL CARCINOMA CELL STRAIN S18 STABLY EXPRESSING TET-OFF ADVANCED, CONSTRUCTION METHOD AND USES THEREOF

Applicant/Assignee: SUN YAT-SEN UNIVERSITY

Application No.: CN2009/075248   Filing Date: 01/Dec/2009

Abstract:A human high metastatic nasopharyngeal carcinoma cell strain S18 stably expressing Tet-Off Advanced, construction method and uses thereof are provided. Through introducing tet-off advanced gene into nasopharyngeal carcinoma cells, screening, amplifying and culturing positive clones and identifying, nasopharyngeal carcinoma cell strain having ability of regulating target gene expression induced by tetracycline is obtained. The nasopharyngeal carcinoma cell strain constructed by the method is named as Tet-Off Advanced nasopharyngeal carcinoma cell strain, and is deposited in China Center for Type Culture Collection as CCTCC C200959. The cell strain has stable and sensitive regulation effect on the expression of target genes. When researching a certain target gene, transfecting the said nasopharyngeal carcinoma cell strain with TRE-Tight plasmid comprising the target gene, screening, and identifying the positive clones obtained, nasopharyngeal carcinoma cell strain expressing the target gene induced by tetracycline is obtained, and the expression of the target gene can be timely and quantitatively regulated by simply regulating the content of tetracycline in environment.

Priority:

Inventor: LI LI [CN]; QIAN CHAONAN [CN]; FENG YUPENG [CN]


Publication No.: WO2011067104A1  Published: 09/Jun/2011

Title: FRAGRANCING PROCESS COMBINING A TOPICAL FRAGRANCE WITH A COMPOSITION FOR FRAGRANCING THE ORAL CAVITY AND/OR THE LIPS

Applicant/Assignee: L'OREAL

Application No.: EP2010/067543   Filing Date: 16/Nov/2010

Abstract:The invention relates to a fragrancing process that includes the following steps: (1) the direct application to human keratin materials or to clothing of a fragrancing composition (A) comprising, in a cosmetically acceptable medium, at least one fragrancing substance

the said composition producing a fragrance with a head note and/or a heart note and/or a base note

(2) the placing in the mouth and the placing in contact with the lips of at least one edible composition (B) comprising at least one edible fragrancing substance capable of producing a fragrance in the oral cavity and/or on the lips

the said edible fragrancing substance being chosen such that the composition (B) produces a fragrance having at least one note in common with those of the fragrance produced by composition (A)

the order of the steps not being critical, and the application of compositions (A) and (B) can be simultaneous or at different times. The invention also relates to a kit or device for fragrancing human keratin materials or an item of clothing, containing at least two conditionings, characterized in that it comprises: -a first conditioning comprising composition (A) as defined previously

-a second conditioning comprising composition (B) as defined previously.

Priority: FR20090058654 Applic. Date: 2009-12-04; US20090285800P Applic. Date: 2009-12-11

Inventor: BARA ISABELLE [FR]


Publication No.: WO2011067212A1  Published: 09/Jun/2011

Title: COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/068429   Filing Date: 29/Nov/2010

Abstract:Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Priority: GB20090021075 Applic. Date: 2009-12-01

Inventor: BAKER DARRELL [GB]; BRUCE MARK [GB]; CRATER GLENN [US]; NOGA BRIAN [US]; THOMAS MARIAN [GB]; WIRE PATRICK [US]


Publication No.: WO2011067364A1  Published: 09/Jun/2011

Title: NOVEL COMPOUNDS

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/068796   Filing Date: 03/Dec/2010

Abstract:The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Priority: US20090266334P Applic. Date: 2009-12-03

Inventor: BALDWIN IAN ROBERT [GB]; DOWN KENNETH DAVID [GB]; FAULDER PAUL [GB]; GAINES SIMON [GB]; HAMBLIN JULIE NICOLE [GB]; LE JOELLE [GB]; LUNNISS CHRISTOPHER JAMES [GB]; PARR NIGEL JAMES [GB]; RITCHIE TIMOTHY JOHN [GB]; ROBINSON JOHN EDWARD [GB]; SIMPSON JULIET KAY [GB]; SMETHURST CHRISTIAN ALAN PAUL [GB]


Publication No.: WO2011067365A1  Published: 09/Jun/2011

Title: BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/068797   Filing Date: 03/Dec/2010

Abstract:The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Priority: US20090266346P Applic. Date: 2009-12-03

Inventor: BALDWIN IAN ROBERT [GB]; DOWN KENNETH DAVID [GB]; FAULDER PAUL [GB]; GAINES SIMON [GB]; HAMBLIN JULIE NICOLE [GB]; JONES KATHERINE LOUISE [GB]; JONES PAUL SPENCER [GB]; LE JOELLE [GB]; LUNNISS CHRISTOPHER JAMES [GB]; PARR NIGEL JAMES [GB]; RITCHIE TIMOTHY JOHN [GB]; ROBINSON JOHN EDWARD [GB]; SIMPSON JULIET KAY [GB]; SMETHURST CHRISTIAN ALAN PAUL [GB]


Publication No.: WO2011067366A1  Published: 09/Jun/2011

Title: INDAZOLE DERIVATIVES AS PI 3 - KINASE INHIBITORS

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/068798   Filing Date: 03/Dec/2010

Abstract:The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Priority: US20090266349P Applic. Date: 2009-12-03

Inventor: BALDWIN IAN ROBERT [GB]; DOWN KENNETH DAVID [GB]; FAULDER PAUL [GB]; GAINES SIMON [GB]; HAMBLIN JULIE NICOLE [GB]; JONES KATHERINE LOUISE [GB]; LE JOELLE [GB]; LUNNISS CHRISTOPHER JAMES [GB]; PARR NIGEL JAMES [GB]; RITCHIE TIMOTHY JOHN [GB]; ROBINSON JOHN EDWARD [GB]; SMETHURST CHRISTIAN ALAN PAUL [GB]


Publication No.: WO2011067924A1  Published: 09/Jun/2011

Title: HYDROGEL PARTICLES

Applicant/Assignee: KAO CORPORATION

Application No.: JP2010/006985   Filing Date: 30/Nov/2010

Abstract:Hydrogel particles each comprising (A) a catechin-containing water-insoluble complex, (B) a compound capable of reacting with a bivalent or trivalent metal ion to form a chelate, (C) a bivalent or trivalent metal salt, (D) a gel-forming agent, and (E) water.

Priority: JP20090276727 Applic. Date: 2009-12-04

Inventor: SHIDAHARA YASUHIRO [JP]; TAKAGI MICHIYA [JP]; FUKUDA KIMIKAZU [JP]; NAKATSU SUSUMU [JP]; ICHIMURA IKUHISA [JP]; TOKUNAGA TADAYUKI [JP]


Publication No.: WO2011068171A1  Published: 09/Jun/2011

Title: BICYCLIC NITROGEN-CONTAINING SATURATED HETEROCYCLIC DERIVATIVES

Applicant/Assignee: DAIICHI SANKYO COMPANY,LIMITED

Application No.: JP2010/071608   Filing Date: 02/Dec/2010

Abstract:Provided are compounds having prophylactic and/or therapeutic effect on chronic rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn diseases and ulcerative colitis, autoimmune diseases typified by psoriasis, rejection of a transplanted organ, allergic diseases and so on

medicinal compositions comprising these compounds

and a method for preventing or treating an autoimmune disease characterized by comprising administering an effective amount of a medicinal composition to a mammal. A compound represented by general formula (I) or a pharmacologically acceptable salt of the same.

Priority: JP20090275880 Applic. Date: 2009-12-03

Inventor: HAYAKAWA ICHIRO; WATANABE JUN; MOMOSE TAKAYUKI; TOMISATO WATARU


Publication No.: WO2011068513A1  Published: 09/Jun/2011

Title: DISSOLVABLE FILMS CONTAINING HIGH CONCENTRATIONS OF NONIONIC SURFACTANTS SUCH AS POLYSORBATES TO ENHANCE HIGH SOLID LOADINGS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2009/066727   Filing Date: 04/Dec/2009

Abstract:An oral care composition and method are described in which the composition includes a film or a plurality of film fragments entrained in a carrier. The film or plurality of film fragments comprises a relatively high concentration of nonionic surfactants. The composition and methods provide benefits including higher active material loading in the film formula for improved efficacy, and a reduced amount of film needed in a product, which at the same time delivering comparable or improved efficacy with lower loading of the film in the composition

Priority:

Inventor: MARTINETTI MELISSA [US]; JABBAL RAJAN [US]


Publication No.: WO2011068514A1  Published: 09/Jun/2011

Title: NON-AQUEOUS, SINGLE TUBE DENTRIFICE WHITENING COMPOSITIONS, METHODS OF USE AND MANUFACTURE THEREOF

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2009/066737   Filing Date: 04/Dec/2009

Abstract:This invention relates to oral care composition, methods of use and methods of manufacture thereof including a single-tube, non-aqueous dentifrice whitening composition containing at least an enzyme and a substrate.

Priority:

Inventor: CHOPRA SUMAN K [US]; ZAIDEL LYNETTE [US]; IBRAHIM SAYED [US]; LEIGH LEONORA [US]; PRENCIPE MICHAEL [US]


Publication No.: WO2011068811A1  Published: 09/Jun/2011

Title: ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZINGIBER OFFICINALE AND RELATED METHODS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/058463   Filing Date: 01/Dec/2010

Abstract:Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.

Priority: US20090266685P Applic. Date: 2009-12-04

Inventor: TRIVEDI HARSH M [US]; GITTINS ELIZABETH K [US]


Publication No.: WO2011068812A1  Published: 09/Jun/2011

Title: ORAL COMPOSITIONS CONTAINING A COMBINATION OF NATURAL EXTRACTS AND RELATED METHODS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/058464   Filing Date: 01/Dec/2010

Abstract:Described herein are compositions comprising a combination of extracts comprising a mixture of extracts from at least three of Punica granatum, Myristica fragrans, Zingiber officinale, and Zizyphus joazeiro and a natural extract other than the extract from at least three of Punica granatum, Myristica fragrans, Zingiber officinale, and Zizyphus joazeiro

and an orally acceptable carrier, and methods of preparing and using the same.

Priority: US20090266700P Applic. Date: 2009-12-04

Inventor: TRIVEDI HARSH M [US]; GITTINS ELIZABETH K [US]


Publication No.: WO2011068813A1  Published: 09/Jun/2011

Title: ORAL COMPOSITIONS CONTAINING EXTRACTS OF MYRISTICA FRAGRANS AND RELATED METHODS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/058466   Filing Date: 01/Dec/2010

Abstract:Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.

Priority: US20090266570P Applic. Date: 2009-12-04

Inventor: TRIVEDI HARSH M [US]; GITTINS ELIZABETH K [US]


Publication No.: WO2011068814A1  Published: 09/Jun/2011

Title: ORAL COMPOSITIONS CONTAINING EXTRACTS OF GARCINIA MANGOSTANA L. AND RELATED METHODS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/058467   Filing Date: 01/Dec/2010

Abstract:Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.

Priority: US20090266563P Applic. Date: 2009-12-04

Inventor: TRIVEDI HARSH M [US]; GITTINS ELIZABETH K [US]


Publication No.: WO2011068815A1  Published: 09/Jun/2011

Title: ORAL COMPOSITIONS CONTAINING EXTRACTS OF ZIZYPHUS JOAZEIRO AND RELATED METHODS

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/058468   Filing Date: 01/Dec/2010

Abstract:Described herein are compositions comprising a combination of extracts, and methods of preparing and using the same.

Priority: US20090266558P Applic. Date: 2009-12-04

Inventor: TRIVEDI HARSH M [US]; GITTINS ELIZABETH K [US]


Publication No.: WO2011068821A1  Published: 09/Jun/2011

Title: BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: US2010/058479   Filing Date: 01/Dec/2010

Abstract:The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Priority: US20090266562P Applic. Date: 2009-12-04

Inventor: CHEN ZHIDONG [US]; HAO MING-HONG [US]; LIU WEIMIN [US]; LO HO-YIN [US]; LOKE PUI LENG [GB]; MAN CHUK CHUI [US]; MORWICK TINA MARIE [US]; NEMOTO PETER ALLEN [US]; TAKAHASHI HIDENORI [US]; TYE HEATHER [GB]; WU LIFEN [US]


Publication No.: WO2011069197A1  Published: 16/Jun/2011

Title: INHALABLE FORMULATIONS

Applicant/Assignee: THE UNIVERSITY OF SYDNEY

Application No.: AU2010/001656   Filing Date: 08/Dec/2010

Abstract:Respirable inhalable particles comprising active agent(s) and excipients in at least a partially crystalline form and their uses thereof.

Priority: AU20090905978 Applic. Date: 2009-12-08

Inventor: CHAN HAK-KIM [AU]; YOUNG PAUL [AU]; TRAINI DANIELA [AU]; KWOK PHILIP CHI LIP [AU]; ANADA MICHIKO [JP]


Publication No.: WO2011069921A1  Published: 16/Jun/2011

Title: SUCROSE OCTASULFATES OF ZINC, THE PREPARATION OF SAME AND THE PHARMACEUTICAL AND COSMETIC USES THEREOF

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: EP2010/068873   Filing Date: 03/Dec/2010

Abstract:The present invention relates to an sucrose octasulfate of zinc of general formula (I), to the method for the preparation of same and to the use thereof in the pharmaceutical and/or cosmetic field, where: 0 =n = 4, n is an integer, and Y is OH, CI, Br, I, NO3, C6H5O7, CH3CO2, CF3CO2 or -OCH3.

Priority: FR20090058689 Applic. Date: 2009-12-07

Inventor: FABRE PIERRE [FR]; JEULIN SEVERINE [FR]; KOPEC MARION [FR]


Publication No.: WO2011070415A1  Published: 16/Jun/2011

Title: NOVEL THERAPEUTIC METHODS FOR TREATING INFLAMMATION AND IMMUNE SYSTEM DISORDERS

Applicant/Assignee: PURAPHARM INTERNATIONAL (HK) LIMITED, VERSITECH LIMITED

Application No.: IB2010/003050   Filing Date: 08/Nov/2010

Abstract:A method for treating inflammatory and immune conditions by modulating TNF-a and nitric oxide production is provided. Said [method comprises administering a compound having the following formula (I):

Priority: US20090263517P Applic. Date: 2009-11-23

Inventor: LAU ALLAN SY [CN]; YANG LAI HUNG CINDY [CN]; OR CHO TSUN [CN]; LAW HING YEE [CN]


Publication No.: WO2011070539A1  Published: 16/Jun/2011

Title: CYSTEINE PROTEASE INHIBITORS

Applicant/Assignee: MEDIVIR UK LIMITED

Application No.: IB2010/055732   Filing Date: 10/Dec/2010

Abstract:Compounds of Formula (II) wherein R1a is H

and R1b is C1-C6alkyl, Carbocyclyl or Het

or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms

R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl

R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or -CH2C3-C7 cycloalkyl

R4' is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Priority: SE20090050951 Applic. Date: 2009-12-10; GB20100010084 Applic. Date: 2010-06-16

Inventor: AYESA SUSANA [SE]; ERSMARK KAROLINA [SE]; GRABOWSKA URSZULA [GB]; HEWITT ELLEN [GB]; JOENSSON DANIEL [SE]; KAHNBERG PIA [SE]; KLASSON BJOERN [SE]; LIND PETER [SE]; LUNDGREN STINA [SE]; ODEN LOURDES [SE]; PARKES KEVIN [GB]; WIKTELIUS DANIEL [SE]


Publication No.: WO2011070541A1  Published: 16/Jun/2011

Title: CYSTEINE PROTEASE INHIBITORS

Applicant/Assignee: MEDIVIR UK LIMITED

Application No.: IB2010/055738   Filing Date: 10/Dec/2010

Abstract:Compounds of the formula (I) wherein R1a is H

and R1b is C1-C6alkyl, Carbocyclyl or Het

or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms

R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl

R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or -CH2C3-C7 cycloalkyl

R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino

for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Priority: SE20090050951 Applic. Date: 2009-12-10; GB20100010084 Applic. Date: 2010-06-16

Inventor: AYESA SUSANA [SE]; CARLQUIST PETER [SE]; ERSMARK KAROLINA [SE]; GRABOWSKA URSZULA [GB]; HEWITT ELLEN [GB]; JOENSSON DANIEL [SE]; KAHNBERG PIA [SE]; KLASSON BJOERN [SE]; LIND PETER [SE]; ODEN LOURDES [SE]; PARKES KEVIN [GB]; WIKTELIUS DANIEL [SE]


Publication No.: WO2011070970A1  Published: 16/Jun/2011

Title: OVEREXPRESSION INHIBITOR OF THYMIC STROMAL LYMPHOPOIETIN

Applicant/Assignee: SAPPORO MEDICAL UNIVERSITY, SAPPORO BREWERIES LIMITED

Application No.: JP2010/071595   Filing Date: 02/Dec/2010

Abstract:Provided is an overexpression inhibitor of thymic stromal lymphopoietin (TSLP) which contains, as the active ingredient, a water extract of hop, a water-soluble fraction thereof, a water-soluble polymer fraction thereof or a water-soluble polymeric polyphenol fraction thereof. The aforesaid overexpression inhibitor of TSLP enables the fundamental prevention and/or treatment of allergic diseases and improvement of allergic predisposition. This overexpression inhibitor of TSLP can be taken daily and continuously and is usable not only as an ingredient of medicines but also as a starting material of foods, drinks and so on.

Priority: JP20090277906 Applic. Date: 2009-12-07

Inventor: SAWADA NORIMASA [JP]; KOJIMA TAKASHI [JP]; FUCHIMOTO JUN [JP]; KOBAYASHI NAOYUKI [JP]


Publication No.: WO2011071296A2  Published: 16/Jun/2011

Title: ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING EXTRACTS FROM BROUSSONETIA PAPYRIFERA AND LONICERA JAPONICA

Applicant/Assignee: PHARMAKING CO., LTD, KNU-INDUSTRY COOPERATION FOUNDATION

Application No.: KR2010/008710   Filing Date: 07/Dec/2010

Abstract:The present invention relates to a pharmaceutical composition for alleviating or treating inflammations and/or pains, the pharmaceutical composition comprising extracts from Broussonetia papyrifera and Lonicera japonica as an effective component. The present invention is based on a finding that when a prenylated flavonoid-enriched extract from Broussonetia papyrifera and an ethanol extract from Lonicera japonica are administered in combination, excellent and synergetic anti-inflammatory and analgesic effects are obtained in in vitro and in vivo tests, compared to when the extracts are separately administered.

Priority: KR20090120711 Applic. Date: 2009-12-07

Inventor: KIM SOON BAE [KR]; KIM GWANG SOON [KR]; KIM WAN BAE [KR]; KWAK WIE JONG [KR]; BANG SUNG HYE [KR]; KIM HYUN PYO [KR]; SON KUN HO [KR]


Publication No.: WO2011072241A1  Published: 16/Jun/2011

Title: 4 -OXO- IH -QUINOLINE- 3 - CARBOXAMIDES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: US2010/059920   Filing Date: 10/Dec/2010

Abstract:The present invention relates to 4 -oxo- lH-quinoline- 3 carboxamides as modulators of ATP -Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present Invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Priority: US2009-635927 Applic. Date: 2009-12-11

Inventor: SHETH URVI [US]; FANNING TEV T D [US]; NUMA MEHDI [US]; BINCH HAYLEY [US]; HURLEY DENNIS JAMES [US]; ZHOU JINGLAN [US]; HADIDA RUAH SARA S [US]; HAZLEWOOD ANNA R [US]; SILINA ALINA [US]; VAIRAGOUNDAR RAJENDRAN [US]; VAN GOOR FREDRICK F [US]; GROOTENHUIS PETER DIEDERIK JAN [US]; BOTFIELD MARTYN C [US]


Publication No.: WO2011073194A2  Published: 23/Jun/2011

Title: DEBRIDEMENT PASTE

Applicant/Assignee: STRAUMANN HOLDING AG

Application No.: EP2010/069638   Filing Date: 14/Dec/2010

Abstract:The present invention relates to a new and inventive composition for implant cleaning and/or debridement of hard surfaces in the oral cavity, which comprises optimally activated nanoparticles of TiO2, having a mean particle diameter (D50) of about 10-100 nm at a concentration between 0.5-500g/L, and H2O2, at a concentration of at the most 7.5% by volume, said composition being antibacterial, without causing microbial resistance, and anti-inflammatory, and wherein said composition further comprises solid microparticles, having a mean particle diameter (D50) of about 100-200 [mu]m at a concentration between 0.5-300 g/L, for improved mechanical debridement and/or cleaning of rough surfaces in the oral cavity and/or on an implant.

Priority: EP20090179258 Applic. Date: 2009-12-15

Inventor: LYNGSTADAAS S PETTER [NO]; HAUGEN HAAVARD J [NO]


Publication No.: WO2011073229A1  Published: 23/Jun/2011

Title: COMPOSITIONS COMPRISING ALGINATES WITH HIGH GULURONIC ACID/MANNURONIC ACID RATIO FOR USE IN THE TREATMENT OF DENTINE HYPERSENSITIVITY

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: EP2010/069699   Filing Date: 15/Dec/2010

Abstract:The present invention relates to oral care compositions comprising certain alginates for the treatment of dentine hypersensitivity and to their use.

Priority: GB20090022133 Applic. Date: 2009-12-17

Inventor: PARKINSON CHARLES RICHARD [GB]


Publication No.: WO2011073231A1  Published: 23/Jun/2011

Title: 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c] ISOQUINOLINE DERIVATIVES

Applicant/Assignee: NYCOMED GMBH

Application No.: EP2010/069704   Filing Date: 15/Dec/2010

Abstract:The compounds of formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

Priority: EP20090179982 Applic. Date: 2009-12-18; US20100315552P Applic. Date: 2010-03-19

Inventor: FLOCKERZI DIETER [DE]; STENGEL THOMAS [DE]; MANN ALEXANDER [DE]; OHMER HARALD [DE]; KAUTZ ULRICH [DE]; WEINBRENNER STEFFEN [DE]; FISCHER STEFAN [DE]; ZITT CHRISTOF [DE]; HATZELMANN ARMIN [DE]; DUNKERN TORSTEN [DE]; HESSLINGER CHRISTIAN [DE]; MAIER THOMAS [DE]; TENOR HERMANN [DE]; BRAUN CLEMENS [DE]; KUELZER RAIMUND [DE]; MARX DEGENHARD [DE]


Publication No.: WO2011073269A1  Published: 23/Jun/2011

Title: PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS

Applicant/Assignee: EVOTEC AG

Application No.: EP2010/069787   Filing Date: 15/Dec/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with potassium channel modulation.

Priority: US20090286910P Applic. Date: 2009-12-16

Inventor: GREENHOUSE ROBERT [US]; HOGG JOAN HEATHER [US]; LIN XIAO-FA [US]; O'YANG COUNDE [US]; RAPTOVA LUBICA [US]; TREJO-MARTIN TERESA ALEJANDRA [US]


Publication No.: WO2011073273A1  Published: 23/Jun/2011

Title: BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS

Applicant/Assignee: EVOTEC AG

Application No.: EP2010/069793   Filing Date: 15/Dec/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, p, E, X, R1, R2, R3, R4 R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with potassium channel modulation.

Priority: US20090286978P Applic. Date: 2009-12-16

Inventor: HAN XIAOCHUN [US]; HAWLEY RONALD CHARLES [US]; HOGG JOAN HEATHER [US]; LIN XIAO-FA [US]; TREJO-MARTIN TERESA ALEJANDRA [US]


Publication No.: WO2011073276A1  Published: 23/Jun/2011

Title: BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS

Applicant/Assignee: EVOTEC AG

Application No.: EP2010/069798   Filing Date: 15/Dec/2010

Abstract:Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein E, Z, m, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with potassium channel modulation.

Priority: US20090287002P Applic. Date: 2009-12-16

Inventor: HAN XIAOCHUN [US]; HAWLEY RONALD CHARLES [US]; HOGG JOAN HEATHER [US]; LIN XIAO-FA [US]; TREJO-MARTIN TERESA ALEJANDRA [US]


Publication No.: WO2011073277A1  Published: 23/Jun/2011

Title: PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS

Applicant/Assignee: EVOTEC AG

Application No.: EP2010/069801   Filing Date: 15/Dec/2010

Abstract:Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n, p, X, R1, R2, R3, R4 R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with potassium channel modulation.

Priority: US20090286934P Applic. Date: 2009-12-16

Inventor: GREENHOUSE ROBERT [US]; HOGG JOAN HEATHER [US]; LIN XIAO-FA [US]; O'YANG COUNDE [US]; RAPTOVA LUBICA [US]; TREJO-MARTIN TERESA ALEJANDRA [US]


Publication No.: WO2011073646A1  Published: 23/Jun/2011

Title: COMBINATION OF THEOBROMINE WITH A DECONGESTANT AND ITS USE FOR THE TREATMENT OF COUGH

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: GB2010/052085   Filing Date: 14/Dec/2010

Abstract:An agent comprises theobromine and a decongestant, as a combined preparation for simultaneous, sequential or separate use in therapy, particularly in the therapy of cough.

Priority: GB20090021805 Applic. Date: 2009-12-14

Inventor: BREW JOHN [GB]; BANNISTER ROBIN MARK [GB]


Publication No.: WO2011073647A1  Published: 23/Jun/2011

Title: THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: GB2010/052086   Filing Date: 14/Dec/2010

Abstract:An agent comprises theobromine and an antihistamine, as a combined preparation for simultaneous, sequential or separate use in therapy, particularly in the therapy of cough.

Priority: GB20090021803 Applic. Date: 2009-12-14

Inventor: BREW JOHN [GB]; BANNISTER ROBIN MARK [GB]


Publication No.: WO2011073662A1  Published: 23/Jun/2011

Title: COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES

Applicant/Assignee: ASTRAZENECA AB, ASTRAZENECA UK LIMITED

Application No.: GB2010/052103   Filing Date: 16/Dec/2010

Abstract:The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(3-(1-methyl-1H-pyrazol-4- yl)phenethoxy)propanamide or a pharmaceutically acceptable salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist

an antioxidant

a CCR1 antagonist

a chemokine antagonist (not CCR1)

a corticosteroid

a CRTh2 antagonist

a DP1 antagonist

an Histone Deacetylase Inducer

an IKK2 inhibitor

a COX inhibitor

a lipoxygenase inhibitor

a leukotriene receptor antagonist

an MPO inhibitor

a muscarinic antagonist

a p38 inhibitor

a PDE inhibitor

a PPAR? agonist

a protease inhibitor

a Statin

a thromboxane antagonist

a vasodilator

or, an ENAC blocker (Epithelial Sodium-channel blocker)

and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma).

Priority: US20090287457P Applic. Date: 2009-12-17

Inventor: BONNERT ROGER VICTOR [GB]; CONNOLLY STEPHEN [GB]


Publication No.: WO2011074526A1  Published: 23/Jun/2011

Title: DENTIFRICE COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/072350   Filing Date: 13/Dec/2010

Abstract:Provided is a dentifrice composition exerting an excellent antiinflammatory effect, having an ameliorated herb-derived undesirable taste, showing good foaming properties and imparting a good feel in using, wherein glycyrrhizinic acid and a salt thereof or glycyrrhetinic acid can be stably blended with a dentifrice composition containing a water and/or organic solvent extract of a plant selected from among rosemary, sage, scutellaria root, ginseng, peony root, soapberry and Angelica acutiloba. The dentifrice composition, which contains a water and/or organic solvent extract of a plant selected from among rosemary, sage, scutellaria root, ginseng, peony root, soapberry and Angelica acutiloba, is blended with: (A) one or more members selected from among glycyrrhizinic acid, a salt thereof and glycyrrhetinic acid

(B) sodium chloride

and (C) polyoxyethylene-hardened castor oil having an average molar number of added ethylene oxide units of 5-30, while controlling the mass ratio of component (B) to component (C) ((B)/(C)) to 0.3-20.

Priority: JP20090287159 Applic. Date: 2009-12-18

Inventor: KITAGAWA CHIHARU [JP]; ARAI MASATO [JP]; HIRASAWA AYAKA [JP]


Publication No.: WO2011074766A2  Published: 23/Jun/2011

Title: METHOD AND APPARATUS FOR SIMULTANEOUSLY MANUFACTURING ULTRA PURE BETULIN AND HIGHLY PURE BETULINIC ACID FROM BIRCH BARK

Applicant/Assignee: KOREA INSTITUTE OF ENERGY RESEARCH

Application No.: KR2010/006329   Filing Date: 16/Sep/2010

Abstract:The present invention relates to a method and apparatus for simultaneously manufacturing ultra pure betulin and highly pure betulinic acid from birch bark, which employ a technique of: using a polar organic solvent to obtain a crude extract containing a betulin content of 70 to 83% and a betulinic acid content of 4 to 8% from the outer bark and inner bark of birch trees that grow naturally in northern hemisphere regions at a northern latitude of 34 DEG or greater, such as in South Korea, China, North America, and Europe

and using a single or mixed polar solvent to obtain a crystallized highly pure betulin with a purity of 95% or greater, wherein ultra pure betulin with a purity of 99.5% or greater and highly pure betulinic acid with a purity of 95% or greater can be simultaneously produced from the crystallized product.

Priority: KR20090123831 Applic. Date: 2009-12-14

Inventor: CHUE KUCK-TACK [KR]; PARK JONG-KEE [KR]; KIM TAE-HWAN [KR]; YI CHANG-KEUN [KR]


Publication No.: WO2011075515A1  Published: 23/Jun/2011

Title: AMINOPYRIMIDINES AS SYK INHIBITORS

Applicant/Assignee: MERCK SHARP & DOHME CORP, MERCK CANADA INC

Application No.: US2010/060454   Filing Date: 15/Dec/2010

Abstract:The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Priority: US20090287267P Applic. Date: 2009-12-17

Inventor: ALTMAN MICHAEL D [US]; ANDRESEN BRIAN M [US]; ARRINGTON KENNETH L [US]; CHILDERS KALEEN KONRAD [US]; DI FRANCESCO MARIA EMILIA [US]; DONOFRIO ANTHONY [US]; ELLIS JOHN MICHAEL [US]; FISCHER CHRISTIAN [US]; GUERIN DAVID JOSEPH [US]; HAIDLE ANDREW M [US]; KATTAR SOLOMON [US]; KNOWLES SANDRA LEE [US]; LI CHAOMIN [US]; LIM JONGWON [US]; MACHACEK MICHELLE R [US]; NORTHRUP ALAN B [US]; O'BOYLE BRENDAN M [US]; OTTE RYAN D [US]; PETROCCHI ALESSIA [US]; REUTERSHAN MICHAEL H [US]; ROMEO ERIC [US]; SIU TONY [US]; TAOKA BRANDON M [US]; TROTTER B WESLEY [US]; ZHOU HUA [US]; BURCH JASON [CA]; COTE BERNARD [CA]; DUPONT-GAUDET KRISTINA [CA]; FOURNIER JEAN-FRANCOIS [CA]; GAUTHIER JACQUES YVES [CA]; GUAY DANIEL [CA]; ROBICHAUD JOEL S [CA]; GRIMM JONATHAN [US]; MADDESS MATTHEW L [US]; SCHELL ADAM J [US]; SPENCER KERRIE B [US]; WOO HYUN CHONG [US]; BHAT SATHESH [CA]


Publication No.: WO2011075517A1  Published: 23/Jun/2011

Title: AMINOPYRIMIDINES AS SYK INHIBITORS

Applicant/Assignee: MERCK SHARP & DOHME CORP, MERCK CANADA INC

Application No.: US2010/060463   Filing Date: 15/Dec/2010

Abstract:The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Priority: US20090287267P Applic. Date: 2009-12-17

Inventor: ALTMAN MICHAEL D [US]; ANDRESEN BRIAN M [US]; ARRINGTON KENNETH L [US]; CHILDERS KALEEN KONRAD [US]; DI FRANCESCO MARIA EMILIA [US]; DONOFRIO ANTHONY [US]; ELLIS JOHN MICHAEL [US]; FISCHER CHRISTIAN [US]; GUERIN DAVID JOSEPH [US]; HAIDLE ANDREW M [US]; KATTAR SOLOMON [US]; KNOWLES SANDRA LEE [US]; LI CHAOMIN [US]; LIM JONGWON [US]; MACHACEK MICHELLE R [US]; NORTHRUP ALAN B [US]; O'BOYLE BRENDAN M [US]; OTTE RYAN D [US]; PETROCCHI ALESSIA [US]; REUTERSHAN MICHAEL H [US]; ROMEO ERIC [US]; SIU TONY [US]; TAOKA BRANDON M [US]; TROTTER B WESLEY [US]; ZHOU HUA [US]; BURCH JASON [CA]; COTE BERNARD [CA]; DUPONT-GAUDET KRISTINA [CA]; FOURNIER JEAN-FRANCOIS [CA]; GAUTHIER JACQUES YVES [CA]; GUAY DANIEL [CA]; ROBICHAUD JOEL S [CA]


Publication No.: WO2011075596A1  Published: 23/Jun/2011

Title: CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Applicant/Assignee: ARENA PHARMACEUTICALS, INC

Application No.: US2010/060848   Filing Date: 16/Dec/2010

Abstract:Provided are certain solvates of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.

Priority: US20090288130P Applic. Date: 2009-12-18

Inventor: STIRN SCOTT [US]; LALLY EDWARD A [US]


Publication No.: WO2011075631A1  Published: 23/Jun/2011

Title: SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: US2010/060981   Filing Date: 17/Dec/2010

Abstract:The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.

Priority: US20090287878P Applic. Date: 2009-12-18

Inventor: JORDAN ALFONZO D [US]; DESJARLAIS RENEE L [US]; HLASTA DENNIS J [US]; PARKER MICHAEL H [US]; SCHUBERT CARSTEN [US]; WHITE KIMBERLY B [US]


Publication No.: WO2011075657A2  Published: 23/Jun/2011

Title: FOAM OXIDATIVE HAIR COLORANT COMPOSITION

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/061060   Filing Date: 17/Dec/2010

Abstract:An oxidative hair colorant composition to be dispensed from a manually-actuable, non-aerosol dispenser as a foam. The oxidative hair colorant composition contains a foam stabilizing agent and is essentially free of surfactant.

Priority: US20090287931P Applic. Date: 2009-12-18

Inventor: LANE BRANDON SCOTT [US]; VOHRA FIROJ [US]; GALAZKA SEBASTIAN KAROL [US]; NALLY KAREN MICHELLE [US]; AGOSTINO ELIZABETH H [US]; KERR GEORGE SCOTT [US]; LEWIS ROBERT DRENNAN [US]; LUND MARK THOMAS [US]; MCCONAUGHY SHAWN DAVID [US]; SMITH EDWARD DEWEY III [US]


Publication No.: WO2011075659A2  Published: 23/Jun/2011

Title: FOAM HAIR COLORANT COMPOSITION

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: US2010/061062   Filing Date: 17/Dec/2010

Abstract:A hair colorant composition being essentially free of surfactant and having a specific perfume system for the hair colorant composition, where the hair colorant composition is capable of forming a foamed hair colorant composition.

Priority: US20090287931P Applic. Date: 2009-12-18

Inventor: VELAZQUEZ JOSE MARIA [GB]; GALAZKA SEBASTIAN KAROL [US]; LANE BRANDON SCOTT [US]; VOHRA FIROJ [US]; AGOSTINO ELIZABETH H [US]; KERR GEORGE SCOTT [US]; LEWIS ROBERT DRENNAN [US]; LUND MARK THOMAS [US]


Publication No.: WO2011075662A2  Published: 23/Jun/2011

Title: BIGUANIDE PRESERVATION OF PRECIPITATED CALCIUM CARBONATE

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: US2010/061069   Filing Date: 17/Dec/2010

Abstract:Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.

Priority: US20090287847P Applic. Date: 2009-12-18

Inventor: SHIMOHIRAO NILZA [BR]; YAMANE ODETE TIEKO [BR]; CORREIA ABEL [BR]; COSTA KATRIN [BR]; UTIMA ENZO [BR]; DAVID ANDRE S [BR]


Publication No.: WO2011075848A1  Published: 30/Jun/2011

Title: EPSILON-POLY-LYSINE CAPSULES

Applicant/Assignee: MICROPHARMA LIMITED

Application No.: CA2010/002057   Filing Date: 22/Dec/2010

Abstract:The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.

Priority: US20090289727P Applic. Date: 2009-12-23; WO2010CA00660 Applic. Date: 2010-04-30

Inventor: MARTONI CHRISTOPHER JOHN [CA]; JONES MITCHELL LAWRENCE [CA]; PRAKASH SATYA [CA]


Publication No.: WO2011076391A1  Published: 30/Jun/2011

Title: CONJUGATE WITH TARGET-FINDING LIGAND AND USE THEREOF

Applicant/Assignee: LUDWIG-MAXIMILIANS-UNIVERSITAET

Application No.: EP2010/007846   Filing Date: 21/Dec/2010

Abstract:The invention relates to a conjugate comprising an agent complex and at least one target-finding ligand, wherein the agent complex encapsulates an agent with an encapsulating material, and wherein the target-finding ligand is a prostacyclin analog, and also to the use thereof.

Priority: EP20090015812 Applic. Date: 2009-12-21

Inventor: RUDOLPH CARSTEN [DE]; GEIGER JOHANNES-PETER [DE]


Publication No.: WO2011076781A1  Published: 30/Jun/2011

Title: TETRAVALENT CD47-ANTIBODY CONSTANT REGION FUSION PROTEIN FOR USE IN THERAPY

Applicant/Assignee: NOVARTIS AG

Application No.: EP2010/070355   Filing Date: 21/Dec/2010

Abstract:The present invention relates to soluble SIRPa binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRPa binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRPa binding domain fused at the N-terminal part of a heavy chain constant region of an antibody

and, (ii) a second monovalent single chain polypeptide comprising a second SIRPa binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRPa-binding antibody-like protein as shown in Figure 1.

Priority: US20090289007P Applic. Date: 2009-12-22

Inventor: HUBER THOMAS [CH]; KOLBINGER FRANK [CH]; SARFATI MARIE [CA]; WELZENBACH KARL [CH]


Publication No.: WO2011077587A1  Published: 30/Jun/2011

Title: COMPOSITION FOR INHIBITING ALLERGIC DISEASES

Applicant/Assignee: KINJIRUSHI CO., LTD

Application No.: JP2009/071824   Filing Date: 21/Dec/2009

Abstract:Disclosed is a composition for inhibiting allergic diseases, which is capable of inhibiting or ameliorating various symptoms of allergic diseases. Specifically disclosed is a composition for inhibiting allergic diseases, which contains an isothiocyanate and a fragrance material as active ingredients. The composition for inhibiting allergic diseases is characterized in that the isothiocyanate is composed of one or more substances selected from the group consisting of ?-methylthioalkyl isothiocyanate, ?-methylsulfinylalkyl isothiocyanate, ?-methylsulfonylalkyl isothiocyanate and ?-alkenyl isothiocyanate, and the fragrance material is composed of one or more substances selected from the group consisting of indoles, ethers, esters, ketones, fatty acids, aliphatic higher alcohols, aliphatic higher aldehydes, aliphatic higher hydrocarbons, thioethers, thiols, terpene hydrocarbons, phenol ethers, phenols, furfurals, aromatic aldehydes, aromatic alcohols, lactones, furans and natural fragrance materials.

Priority:

Inventor: NAGAI MASASHI [JP]; ICHIKAWA YOSHINOBU [JP]


Publication No.: WO2011077800A1  Published: 30/Jun/2011

Title: HYPERLIPEMIA-AMELIORATING AGENT, ANEMIA-AMELIORATING COMPOSITION, URIC-ACID-LEVEL-REDUCING COMPOSITION, AND FOODS AND BEVERAGES

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/067058   Filing Date: 30/Sep/2010

Abstract:A neutral fat level control agent, a cholesterol level control agent, a free fatty acid level control agent and an anti-obesity agent, each characterized by comprising at least one of protopanaxatriol, panaxatriol, protopanaxadiol and panaxadiol which are aglycons of dammrane-type saponins

and a hyperlipemia-ameliorating agent characterized by comprising at least one of the neutral fat level control agent, the cholesterol level control agent, the free fatty acid level control agent and the anti-obesity agent.

Priority: JP20090289798 Applic. Date: 2009-12-21; JP20100131169 Applic. Date: 2010-06-08

Inventor: KAMBAYASHI HIROAKI [JP]; KITAMURA KUMIKO [JP]; IWASAKI HIDEAKI [JP]


Publication No.: WO2011077847A1  Published: 30/Jun/2011

Title: EMULSION-TYPE LIQUID COMPOSITION FOR ORAL CAVITY, AND PROCESS FOR PRODUCTION THEREOF

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/070070   Filing Date: 11/Nov/2010

Abstract:Disclosed is an emulsion-type liquid composition for the oral cavity, which comprises (A) a liquid composition for the oral cavity that contains isopropyl methyl phenol and is substantially ethanol-free, (B) polyoxyethylene hydrogenated castor oil having an E.O. of 40 to 100 moles, (C) (C-1) a decaglycerin monofatty acid ester and (C-2) a trifatty acid glyceryl, and (D) a polyhydric alcohol selected from glycerin, propylene glycol and polyethylene glycol having an average molecular weight of 190 to 630, wherein the [(B)+(C-1)]/[(C-2)] ratio is 0.77 to 1.87 by mass, the component (D) is contained in an amount of 5 to 15 mass%, and glycerin is contained in an amount of 0.003 mass% or more. The emulsion-type liquid composition has a high infiltration/sterilization effect on a periodontopathic biofilm, enables high accumulation of isopropyl methyl phenol in the oral cavity, and has good appearance stability and mild irritating properties. Also disclosed is a process for producing the composition, which comprises mixing the components (A), (B) and (D) with one another and adding the component (C) in the form of an emulsion to the resulting mixture.

Priority: JP20090290242 Applic. Date: 2009-12-22

Inventor: YAMAGUCHI TSUBASA [JP]; NOMURA YASUO [JP]


Publication No.: WO2011077983A1  Published: 30/Jun/2011

Title: DENTRIFICE COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/072353   Filing Date: 13/Dec/2010

Abstract:Provided is a berberine-containing dentrifice composition. The berberine therein is highly stable, and the dentrifice composition is non-irritating and has improved astringency and no unpleasant tastes. When used, said dentrifice composition feels pleasant, foams well, and has excellent foam retention characteristics. The provided dentrifice composition contains: (a) berberine

(b) sodium chloride

(c) at least one plant extract selected from among rosemary extract, sage extract, Scutellaria baicalensis extract, carrot extract, Paeonia lactiflora extract, Lonicera japonica extract, and Betula platyphylla var. japonica extract

(d) and a non-ionic surfactant. The mass ratio of component (b) to component (d) is between 1.5 and 20. The dentrifice composition also contains (e) lauryl sulfate, and the mass ratio of component (d) to component (e) is between 0.25 and 2.5.

Priority: JP20090290751 Applic. Date: 2009-12-22

Inventor: HIRASAWA AYAKA [JP]; ARAI MASATO [JP]; KITAGAWA CHIHARU [JP]


Publication No.: WO2011078143A1  Published: 30/Jun/2011

Title: PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: SHIONOGI & CO. LTD

Application No.: JP2010/072951   Filing Date: 21/Dec/2010

Abstract:Disclosed is a novel compound which has histamine H4 receptor modulating activity. Specifically disclosed is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or salt. (In the formula, ring A represents an aromatic heterocyclic ring

-B1 represents a group represented by -X-(CR8aR8b)m-Y

X represents a group represented by N(R7c) or the like

R7c represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like

R8a and R8b each independently represents a hydrogen atom, a halogen atom or the like

m represents an integer of 0-5

Y represents a substituted or unsubstituted cycloalkylthio group or the like

and -B2 represents a group represented by formula (II) (wherein R10s each independently represents a substituted or unsubstituted alkyl group or the like

R11 represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like

and p represents an integer of 0-4) or the like.)

Priority: JP20090290033 Applic. Date: 2009-12-22; JP20100081490 Applic. Date: 2010-03-31

Inventor: MASUDA TSUTOMU [JP]; TACHIBANA YUKI [JP]; MIYAGAWA MASAYOSHI [JP]; HASEGAWA TSUYOSHI [JP]; TOBINAGA HIROYUKI [JP]


Publication No.: WO2011078221A1  Published: 30/Jun/2011

Title: IMIDAZOPYRIDAZINE COMPOUNDS

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: JP2010/073126   Filing Date: 22/Dec/2010

Abstract:By making a search for many various compounds having inhibitory activity against IL-12/IL-23 production, provided are medicinal compositions that contain the compounds and therapeutic or prophylactic agents that contain the compounds and that are efficacious against diseases associated with IL-12/IL-23 overproduction. Disclosed are: imidazopyridazine compounds represented by general formula (I), which have inhibitory activity against IL-12/IL-23 production

pharmaceutically acceptable salts thereof

and useful medicinal compositions and therapeutic or prophylactic agents for diseases associated with IL-12/IL-23 overproduction, characterized by containing the compounds or the pharmaceutically acceptable salts. In general formula (I), A and E are each an optionally substituted aryl group, or the like

U, V, X and Y are each a single bond or the like

T is N=C(Rd) (wherein Rd is a hydrogen atom or the like) or the like

m and n are each 0, 1 or 2

p and q are each 0 or 1

R1 is a hydrogen atom or the like

R2 is a hydrogen atom or the like

R3 is a hydrogen atom or the like

R4 is a hydrogen atom or the like

R5 is a hydrogen atom or the like

R6, R7, R8 and R9 are each a hydrogen atom or the like

and the W-containing group is a 4- to 6-membered cyclic amino group (wherein W is O or the like).

Priority: JP20090293145 Applic. Date: 2009-12-24; JP20100146436 Applic. Date: 2010-06-28

Inventor: YAMAMOTO TAKASHI [JP]; ANDOU AYATOSHI [JP]; HAYAKAWA NOBUHIKO [JP]; NOGUCHI MASATSUGU [JP]; NISHIO HIKARU [JP]; EVIRYANTI AGUNG [JP]; YOKOYAMA RYOHEI [JP]; KAGEYAMA SHUNSUKE [JP]; KURIBAYASHI KANNA [JP]


Publication No.: WO2011078230A1  Published: 30/Jun/2011

Title: 3,5-DIHYDROXY-2-MENTHENYL STILBENE, PLANT EXTRACT CONTAINING SAME, METHOD FOR COLLECTING SAME, AND APPLICATION FOR SAME

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/073153   Filing Date: 22/Dec/2010

Abstract:Provided are: a 3,5-dihydroxy-2-menthenyl stilbene represented by structural formula (1)

an extract from a plant in the Lindera genus, said extract containing at least 1% by mass of the 3,5-dihydroxy-2-menthenyl stilbene

applications for the 3,5-dihydroxy-2-menthenyl stilbene, such as an antimicrobial agent using same as an active ingredient

and a method for collecting the active ingredient from Lindera sp. Also provided are: a mixture comprising the substance represented by formula (1) and the 3,5-dihydroxy stilbene represented by formula (2)

an extract from Lindera sp., said extract containing at least 1% by mass of the aforementioned mixture

and applications for said mixture, such as an odor-production inhibitor using same as an active ingredient.

Priority: JP20090295558 Applic. Date: 2009-12-25

Inventor: MORISHIMA SEIJI [JP]; KAZUNO KEIKO [JP]; HIRAYAMA TOMOKO [JP]; IGARASHI AKINORI [JP]; HISANAGA KOJI [JP]; OISHI MASAYOSHI [JP]; HIGASHINO MASAYUKI [JP]


Publication No.: WO2011078303A1  Published: 30/Jun/2011

Title: AMINOPYRIDINE COMPOUND

Applicant/Assignee: UBE INDUSTRIES, LTD

Application No.: JP2010/073274   Filing Date: 24/Dec/2010

Abstract:A compound represented by general formula (I) or a pharmacologically acceptable salt thereof, a medicinal composition comprising the same, and a medicinal composition for the treatment or prevention of respiratory diseases or glaucoma.

Priority: JP20090294744 Applic. Date: 2009-12-25; JP20090294745 Applic. Date: 2009-12-25; JP20100242885 Applic. Date: 2010-10-29

Inventor: IWAMURA RYO; TANAKA MASAYUKI; KATSUBE TETSUSHI; SHIBAKAWA NOBUHIKO; SHIGETOMI MANABU; OKANARI EIJI; KANDA TOMOKO; TOKUNAGA YASUNORI; FUJIWARA HIROSHI


Publication No.: WO2011078413A1  Published: 30/Jun/2011

Title: SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: JP2010/073879   Filing Date: 24/Dec/2010

Abstract:Provided is a compound that has a nitrogen-containing seven-membered ring skeleton represented by formula (I) and is useful in the prevention or treatment of pathological conditions in which chymase is involved. Also provided is a drug, containing the aforementioned compound, for prevention or treatment of disorders in which chymase is involved.

Priority: JP20090296113 Applic. Date: 2009-12-25

Inventor: MUTO TSUYOSHI [JP]; TANAKA TAISAKU [JP]; FUTAMURA JUNKO [JP]; IMAJO SEICHI [JP]; SUGAWARA HAJIME [JP]


Publication No.: WO2011078815A1  Published: 30/Jun/2011

Title: DRY POWDER COMBINATION OF TIOTROPIUM, BUDESONIDE AND A CROMOGLICIC ACID DERIVATIVE

Applicant/Assignee:

Application No.: TR2010/000185   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a pharmaceutical composition containing tiotropium combined with a corticosteroid and an effective amount of a cromolyn derivative which is used for the treatment of respiratory disorder by inhalation route.

Priority: TR20090009789 Applic. Date: 2009-12-25

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2011078816A1  Published: 30/Jun/2011

Title: DRY POWDER COMBINATION OF TIOTROPIUM, FORMOTEROL AND A CROMOGLICIC ACID DERIVATIVE

Applicant/Assignee:

Application No.: TR2010/000187   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a pharmaceutical composition wherein tiotropium combined with formoterol which is a ss-2 adrenergic receptor antagonist and an effective amount of a cromolyn derivative are formulated together and are used for the treatment of respiratory disorders by inhalation route.

Priority: TR20090009790 Applic. Date: 2009-12-25

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2011078817A1  Published: 30/Jun/2011

Title: COMBINATION OF TIOTROPIUM, MOMETASONE AND A CROMOGLICIC ACID DERIVATIVE IN DRY POWDER FORM

Applicant/Assignee:

Application No.: TR2010/000188   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a medicament formulation containing tiotropium formulated with a corticosteroid and an effective amount of a cromolyn derivative for use in the treatment of respiratory diseases by inhalation route.

Priority: TR20090009793 Applic. Date: 2009-12-25

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2011078818A1  Published: 30/Jun/2011

Title: DRY POWDER COMBINATION OF TIOTROPIUM, A CORTICOSTEROID AND A CROMOGLICIC ACID DERIVATIVE

Applicant/Assignee:

Application No.: TR2010/000189   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a pharmaceutical composition wherein tiotropium combined with corticosteroid and effective amounts of a cromolyn derivative formulated together and used for the treatment of respiratory disorders by inhalation route.

Priority: TR20090009792 Applic. Date: 2009-12-25

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2011078823A1  Published: 30/Jun/2011

Title: COMPOSITIONS CONTAINING SALMETEROL, FLUTICASONE AND CROMOGLICIC ACID

Applicant/Assignee:

Application No.: TR2010/000250   Filing Date: 20/Dec/2010

Abstract:The present invention relates to the use of cromoglicic acid and/or nedocromil salts in pharmaceutically effective amounts in a pharmaceutical composition containing salmeterol or a pharmaceutically acceptable salt thereof as a ss2-agonisti combined with fluticasone or a pharmaceutically acceptable salt thereof as a corticosteroid for the treatment of the respiratory diseases.

Priority: TR20090009791 Applic. Date: 2009-12-25

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2011078984A1  Published: 30/Jun/2011

Title: [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF

Applicant/Assignee: SANOFI

Application No.: US2010/060006   Filing Date: 13/Dec/2010

Abstract:The present invention relates herein to compounds and compositions for the treatment and amelioration of inflammatory disease. Specifically the present invention relates to compounds that having a tryptase inhibition activity and the intermediates thereof, pharmaceutical compositions comprising such compounds, and a method of treating subjects suffering from a condition disease or disorder that can be ameliorated by the administration of an inhibitor of tryptase including but not limited to for example asthma and other inflammatory diseases including age-related macular degeneration.

Priority: US20090289565P Applic. Date: 2009-12-23; FR20100057606 Applic. Date: 2010-09-22

Inventor: CHOI-SLEDESKI YONG MI [US]; NIEDUZAK THADDEUS R [US]; POLI GREGORY B [US]; SHUM PATRICK WAI-KWOK [US]; STOKLOSA GREGORY T [US]; ZHAO ZHICHENG [US]


Publication No.: WO2011079051A1  Published: 30/Jun/2011

Title: FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: US2010/061146   Filing Date: 17/Dec/2010

Abstract:Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Priority: US20090289969P Applic. Date: 2009-12-23; US20100386964P Applic. Date: 2010-09-27

Inventor: ARIKAWA YASUYOSHI [US]; JONES BENJAMIN [US]; LAM BETTY [US]; NIE ZHE [US]; SMITH CHRISTOPHER [US]; TAKAHASHI MASASHI [US]; DONG QING [US]; FEHER VICTORIA [US]


Publication No.: WO2011079103A1  Published: 30/Jun/2011

Title: SPIROPIPERIDINE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS

Applicant/Assignee: SANOFI

Application No.: US2010/061464   Filing Date: 21/Dec/2010

Abstract:The present invention discloses and claims a series of substituted spiropiperidine benzylamines of formula (I) wherein R is as described herein. More specifically, the compounds of this invention are inhibitors of ss-tryptase and are, therefore, useful as pharmaceutical agents for treating joint inflammation, including arthritis, rheumatoid arthritisand other arthritic condition such as rheumatoid spondylitis, gouty arthptis, traumatic arthritis, rubella arthritis, psoriatic arthritis, osteoarthritis or other chronic inflammatory joint disease, or diseases of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina or other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, macular degeneration, acute macular degeneration, wet macular degeneration, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcers, or a syncytial viral infection.

Priority: US20090289611P Applic. Date: 2009-12-23; FR20100057200 Applic. Date: 2010-09-10

Inventor: CHOI-SLEDESKI YONG MI [US]; LIANG GUYAN [US]; POLI GREGORY B [US]

Clck to enlarge and view details
World  Patents Published  in 2012
World  Patents Published  in 2011 -Page 2
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..